Tabak, C.
Tabakov, D.
Tabanelli, V.
Tabares, P.
Tabata, M.
Tabata, R.
366 - Soluble B-Cell Maturation Antigen Levels for Disease Monitoring in Oligo- and Non-Secretory Relapsed Multiple Myeloma
491 - Total Diffusion Volume Evaluated By Whole-Body Diffusion Weighted Magnetic Resonance Image for the Assessment of Tumor Burden in Multiple Myeloma; Relations with Measurable Residual Disease Evaluated By Next-Generation Flow Cytometry and Bone Marrow CD138 Staining Assessed By Qupath
741 - Spatially Resolved Single-Cell Transcriptomics of T Cells in Follicular Lymphoma Reveals Distinct Immune Ecosystems
1931 - Prognostic Value of t(11;14)(q13;32) in Newly Diagnosed Myeloma Patients in Novel Agent Era; Matched-Pair Analysis
3035 - Serum BCMA Is a Better Reflector of Tumor Volume Than IgM in the Induction Period of Waldenström Macroglobulinemia
3042 - Simultaneous Assessment of Total Metabolic Tumor Volume and Intratumoral CD4+ T-Cell Infiltration Identifies Early Progression of Follicular Lymphoma on Watch-and-Wait Approach
3313 - Soluble BCMA As a Surrogate Biomarker for Tumor Burden in Multiple Myeloma: Correlations with Various Biomarkers and Treatment Responses
4682 - Different Patterns of Antigen Expression in Bone Marrow and Circulating Tumor Plasma Cells in Patients with MGUS and Smoldering Multiple Myeloma
491 - Total Diffusion Volume Evaluated By Whole-Body Diffusion Weighted Magnetic Resonance Image for the Assessment of Tumor Burden in Multiple Myeloma; Relations with Measurable Residual Disease Evaluated By Next-Generation Flow Cytometry and Bone Marrow CD138 Staining Assessed By Qupath
741 - Spatially Resolved Single-Cell Transcriptomics of T Cells in Follicular Lymphoma Reveals Distinct Immune Ecosystems
1931 - Prognostic Value of t(11;14)(q13;32) in Newly Diagnosed Myeloma Patients in Novel Agent Era; Matched-Pair Analysis
3035 - Serum BCMA Is a Better Reflector of Tumor Volume Than IgM in the Induction Period of Waldenström Macroglobulinemia
3042 - Simultaneous Assessment of Total Metabolic Tumor Volume and Intratumoral CD4+ T-Cell Infiltration Identifies Early Progression of Follicular Lymphoma on Watch-and-Wait Approach
3313 - Soluble BCMA As a Surrogate Biomarker for Tumor Burden in Multiple Myeloma: Correlations with Various Biomarkers and Treatment Responses
4682 - Different Patterns of Antigen Expression in Bone Marrow and Circulating Tumor Plasma Cells in Patients with MGUS and Smoldering Multiple Myeloma
Tabata, Y.
Tabatabai, A.
Tabayashi, T.
338 - Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study
1310 - Long-Term Follow-up of Patients with Aplastic Anemia Enrolled in Phase 2/3 Trials of Immunosuppressive Therapy Plus Romiplostim As a First-Line Treatment: Two-Year Interim Analysis
1310 - Long-Term Follow-up of Patients with Aplastic Anemia Enrolled in Phase 2/3 Trials of Immunosuppressive Therapy Plus Romiplostim As a First-Line Treatment: Two-Year Interim Analysis
Tabe, Y.
Tabiti, B. F.
1134 - Differences in the in-Hospital Outcomes of Sickle Cell Crisis Among Patients with and without Liver Cirrhosis: A Nationwide in-Patient Analysis
2423 - Association of Neighborhood Crime with AML Molecular Subtypes and Survival
2887 - Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
3630 - Do Jehovah’s Witnesses with Sickle Cell Disease Avoid the Healthcare System?
2423 - Association of Neighborhood Crime with AML Molecular Subtypes and Survival
2887 - Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
3630 - Do Jehovah’s Witnesses with Sickle Cell Disease Avoid the Healthcare System?
Taborda, C.
Tabrizi, R.
Tabuchi, K.
Tacchetti, P.
Tacher, V.
Tachibana, T.
Tadese, A.
750 - Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease
1722 - Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis
1724 - A Pilot Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (VIPOR) for Diffuse Large B-Cell Lymphoma Involving the Central Nervous System
2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study
1722 - Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis
1724 - A Pilot Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (VIPOR) for Diffuse Large B-Cell Lymphoma Involving the Central Nervous System
2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study
Tadmor, T.
883 - Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1
1862 - Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter's Syndrome-Givers Regimen
2975 - Dissecting Diffuse Large B Cell Lymphoma Heterogeneity: New Insights from a State-Specific Molecular Characterization
3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial
3239 - Development of a Machine Learning–Based Risk Score for Predicting Atrial Fibrillation in Treatment-Naive CLL Patients Initiating BTK Inhibitor Therapy
4504 - CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia
4626 - Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study
5124 - Epcoritamab for Relapsed/Refractory B Cell Lymphoma – the Israeli Real-World Experience of a Compassionate Use Program
1875.2 - Nemtabrutinib Versus Ibrutinib or Acalabrutinib for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The Phase 3, Open-Label, Randomized Bellwave-011 Study
1862 - Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter's Syndrome-Givers Regimen
2975 - Dissecting Diffuse Large B Cell Lymphoma Heterogeneity: New Insights from a State-Specific Molecular Characterization
3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial
3239 - Development of a Machine Learning–Based Risk Score for Predicting Atrial Fibrillation in Treatment-Naive CLL Patients Initiating BTK Inhibitor Therapy
4504 - CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia
4626 - Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study
5124 - Epcoritamab for Relapsed/Refractory B Cell Lymphoma – the Israeli Real-World Experience of a Compassionate Use Program
1875.2 - Nemtabrutinib Versus Ibrutinib or Acalabrutinib for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The Phase 3, Open-Label, Randomized Bellwave-011 Study
Tadros, N. G.
Tafjord, O.
Taft, J.
Tafur, A.
Taggi Pinto, A.
Taghon, T.
Tagliaferri, E.
Tagliaferri, M.
Taguchi, A.
Taguchi, S.
1682 - Comparison of Clinical Characteristics and Prognosis between Aggressive NK-Cell Leukemia and Advanced-Stage Extranodal NK/T-Cell Lymphoma
3026 - Clinical Features and Outcomes of Localized Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma: A Dual-Center Retrospective Observational Study with a Long-Term Follow-up
3058 - Number of Sites of Involvement Predicts Central Nervous System Relapse in Patients with Localized Extranodal Natural Killer/T-Cell Lymphoma
3026 - Clinical Features and Outcomes of Localized Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma: A Dual-Center Retrospective Observational Study with a Long-Term Follow-up
3058 - Number of Sites of Involvement Predicts Central Nervous System Relapse in Patients with Localized Extranodal Natural Killer/T-Cell Lymphoma
Tahara, Y.
Taher, A. T.
409 - ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia
2475 - Improvement of Iron Overload Parameters in Patients with Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Data from the Phase 3b Long-Term Rollover Study Following the BELIEVE Trial
3857 - Luspatercept Improves Fatigue-Related Quality of Life through 5 Years of Treatment in Non-Transfusion Dependent Beta-Thalassemia
- Luspatercept: A Treatment for Ineffective Erythropoiesis in Thalassemia
2475 - Improvement of Iron Overload Parameters in Patients with Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Data from the Phase 3b Long-Term Rollover Study Following the BELIEVE Trial
3857 - Luspatercept Improves Fatigue-Related Quality of Life through 5 Years of Treatment in Non-Transfusion Dependent Beta-Thalassemia
- Luspatercept: A Treatment for Ineffective Erythropoiesis in Thalassemia
Taheri, M.
Tahir, M.
Tahir, R.
Tahira, Y.
Tai, C. H.
Tai, S. T.
Taib, N. A. M.
Taibo Salorio, J. A.
3593 - Automated Image Analysis Pipeline for Standardized Processing, Segmentation, and Feature Extraction in Diffuse Large B-Cell Lymphoma Histological Slides: Towards Enhanced Prediction of Immunotherapy Response and Risk Stratification
3606 - Smartcytoflow: A Machine Learning Decision Support System for Flow Cytometry Analysis in Non-Hodgkin Lymphoma Diagnosis and Screening
3606 - Smartcytoflow: A Machine Learning Decision Support System for Flow Cytometry Analysis in Non-Hodgkin Lymphoma Diagnosis and Screening
Taiclet, S.
Taillon, A.
205 - Posttranslational Changes in Histone Modification Driven By USP48 Loss Increase Sensitivity to Hypomethylating Agents in Acute Myeloid Leukemia
626 - Riboflavin Drives Nucleotide Biosynthesis and Iron-Sulfur Metabolism to Promote Acute Myeloid Leukemia
2717 - ADAR1 Is a Vulnerability in TP53-Mutant Acute Myeloid Leukemia
626 - Riboflavin Drives Nucleotide Biosynthesis and Iron-Sulfur Metabolism to Promote Acute Myeloid Leukemia
2717 - ADAR1 Is a Vulnerability in TP53-Mutant Acute Myeloid Leukemia
Tailor, P.
Taka, K.
Takacs, I.
Takacs, N.
Takada, S.
2819 - JALSG Ph (-) B-ALL213 Study: Pediatric-Type Chemotherapy Improves Prognosis in Adult Ph-Negative Acute Lymphoblastic Leukemia Patients, Including Older Adults
3541 - Treatment Outcomes of Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed after Allogeneic Stem Cell Transplant in the Era of Novel Immunochemotherapeutic Agents
3541 - Treatment Outcomes of Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed after Allogeneic Stem Cell Transplant in the Era of Novel Immunochemotherapeutic Agents
Takada, T.
Takagi, S.
1453 - Combined Targeting Patient-Specific Anti-Apoptotic Molecules and CXCR4-Expressing CAR-T Cells Eliminated High-Inflammation State Leukemia with Poor-Prognostic Mutations
2162 - Novel Insights into Predictors, Optimized Treatments, and Prognosis Factors for Virus-Induced Hemorrhagic Cystitis Post-Hematopoietic Stem Cell Transplantation: A Single-Institution Study of 427 Japanese Patients
2189 - Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL
3485 - What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes
3508 - Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation
4920 - Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status
4926 - Single Cord Blood Transplantation with Fludarabine, Busulfan and Melphalan Is Crucial Therapeutic Strategy for AML Not in Remission: A Single-Center Retrospective Study of 286 Patients Including Prognostic Factor Analysis
4933 - Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms
2162 - Novel Insights into Predictors, Optimized Treatments, and Prognosis Factors for Virus-Induced Hemorrhagic Cystitis Post-Hematopoietic Stem Cell Transplantation: A Single-Institution Study of 427 Japanese Patients
2189 - Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL
3485 - What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes
3508 - Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation
4920 - Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status
4926 - Single Cord Blood Transplantation with Fludarabine, Busulfan and Melphalan Is Crucial Therapeutic Strategy for AML Not in Remission: A Single-Center Retrospective Study of 286 Patients Including Prognostic Factor Analysis
4933 - Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms
Takahashi, H.
Takahashi, K.
56 - Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia
61 - Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones
219 - A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update
346 - Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant
446 - Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine
642 - Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1-Mutated Myeloid Malignancies
726 - Mitigating Therapy-Related Myeloid Neoplasia in p53-Mutant Clones through Targeted DNA Repair Pathway Inhibition with PARP Inhibitors
728 - Older Age and TP53 Mutations Are Predictors for the Development of Therapy-Related Myeloid Neoplasms in Adults Undergoing Frontline Therapy for Acute Lymphoblastic Leukemia
734 - A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
837 - Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse
841 - Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3-Tyrosine Kinase Domain (TKD) Mutations
882 - Novel p53 Mutant Mouse Model Recapitulates the Biology of Human Therapy-Related Myeloid Neoplasms
1011 - Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
1441 - Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update
1442 - Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia
1461 - Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens
1816 - Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms
1837 - Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies
1855 - Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL
2438 - Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds
2883 - Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials
2896 - Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy
3212 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome
3817 - Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods
4263 - Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
4272 - Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
4293 - Patterns of Relapse Following Venetoclax-Based Therapies of Differing Intensity in Acute Myeloid Leukemia
4601 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome
1527.2 - Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation
61 - Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones
219 - A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update
346 - Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant
446 - Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine
642 - Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1-Mutated Myeloid Malignancies
726 - Mitigating Therapy-Related Myeloid Neoplasia in p53-Mutant Clones through Targeted DNA Repair Pathway Inhibition with PARP Inhibitors
728 - Older Age and TP53 Mutations Are Predictors for the Development of Therapy-Related Myeloid Neoplasms in Adults Undergoing Frontline Therapy for Acute Lymphoblastic Leukemia
734 - A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
837 - Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse
841 - Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3-Tyrosine Kinase Domain (TKD) Mutations
882 - Novel p53 Mutant Mouse Model Recapitulates the Biology of Human Therapy-Related Myeloid Neoplasms
1011 - Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
1441 - Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update
1442 - Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia
1461 - Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens
1816 - Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms
1837 - Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies
1855 - Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL
2438 - Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds
2883 - Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials
2896 - Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy
3212 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome
3817 - Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods
4263 - Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
4272 - Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
4293 - Patterns of Relapse Following Venetoclax-Based Therapies of Differing Intensity in Acute Myeloid Leukemia
4601 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome
1527.2 - Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation
Takahashi, M.
Takahashi, N.
338 - Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study
3030 - Treatment and Outcomes of Stage I-II Pulmonary MALT Lymphoma: A Multi-Institutional Observational Study in Japan
3030 - Treatment and Outcomes of Stage I-II Pulmonary MALT Lymphoma: A Multi-Institutional Observational Study in Japan
Takahashi, N.
Takahashi, N.
331 - Identification of a Novel Function of B2M Involving T-Cell Exhaustion Via P-Selectin Ligand Upregulation in Diffuse Large B-Cell Lymphoma
475 - Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study
475 - Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study
Takahashi, R.
Takahashi, S.
Takahashi, S.
Takahashi, T.
2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
2689 - Efficacy and Safety of Eltrombopag Added to Rabbit Anti-Human Thymocyte Globulin+Cyclosporine in Aplastic Anemia: Results from a Prospective Multicenter Phase II Study
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
2689 - Efficacy and Safety of Eltrombopag Added to Rabbit Anti-Human Thymocyte Globulin+Cyclosporine in Aplastic Anemia: Results from a Prospective Multicenter Phase II Study
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
Takahashi, T.
Takahashi, T.
Takahashi, Y.
Takahashi, Y.
Takaki, E. O.
Takaku, T.
Takaku, T.
Takakuwa, T.
Takamatsu, H.
362 - Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial
1038 - HLA-Pan-DP CAR-T Demonstrates Cytotoxicity Against Multiple Hematological Malignancies
1307 - HLA Class I Allele-Deficient Clones Regenerate in Immune Aplastic Anemia without Anti-Thymocyte Globulin
2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study
1038 - HLA-Pan-DP CAR-T Demonstrates Cytotoxicity Against Multiple Hematological Malignancies
1307 - HLA Class I Allele-Deficient Clones Regenerate in Immune Aplastic Anemia without Anti-Thymocyte Globulin
2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study
Takami, A.
3179 - Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor
3917 - Activation of mTOR Signal Bolster Natural Killer Cell Immunity Against EBV-Infected B Lymphocytes
4345 - Impact of a Functional NKG2D Genetic Variant on Lymphoma Susceptibility and NK Cell Immune Response to Epstein Barr Virus
3917 - Activation of mTOR Signal Bolster Natural Killer Cell Immunity Against EBV-Infected B Lymphocytes
4345 - Impact of a Functional NKG2D Genetic Variant on Lymphoma Susceptibility and NK Cell Immune Response to Epstein Barr Virus
Takanari, H.
Takano, K.
Takao, M.
Takao, S.
Takaoka, K.
Takaoka, K.
Takaori-Kondo, A.
Takasaki, K.
Takasugi, N.
Takata, K.
Takayama, S.
Takeda, Y.
Takei, H. N.
Takei, T.
3292 - Single-Center Retrospective Analysis of Autologous Stem Cell Transplantation for Patients with Systemic Light Chain Amyloidosis
4925 - The Outcome of Fertility Preservation Strategy in Female Hematopoietic Stem Cell Transplant Recipients of Reproductive Age. Retrospective Study from the Kanto Study Group for Cell Therapy
4925 - The Outcome of Fertility Preservation Strategy in Female Hematopoietic Stem Cell Transplant Recipients of Reproductive Age. Retrospective Study from the Kanto Study Group for Cell Therapy
Takeishi, Y.
Takemoto, C. M.
698 - Late Venous Thromboembolic Events in Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort Study
1065 - Sickle Cell Disease-Related Worry and Associations with Healthcare Utilization in Youth with Sickle Cell Disease
1129 - Impact of Duffy-Null Phenotype on Neutrophil Counts and Clinical Outcomes in Patients with Sickle Cell Disease and without Hydroxyurea
1257 - Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
2633 - Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
2704 - Prospective Genomic Study for Optimizing Clonal Hematopoiesis Surveillance in Bone Marrow Failure Syndromes and Related Cytopenia
3688 - Health-Related Communication in Adolescents and Young Adults with Sickle Cell Disease
5063 - Vaso-Occlusive Crisis in Patients with Sickle Cell Anemia with Elevated Fetal Hemoglobin
1065 - Sickle Cell Disease-Related Worry and Associations with Healthcare Utilization in Youth with Sickle Cell Disease
1129 - Impact of Duffy-Null Phenotype on Neutrophil Counts and Clinical Outcomes in Patients with Sickle Cell Disease and without Hydroxyurea
1257 - Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
2633 - Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
2704 - Prospective Genomic Study for Optimizing Clonal Hematopoiesis Surveillance in Bone Marrow Failure Syndromes and Related Cytopenia
3688 - Health-Related Communication in Adolescents and Young Adults with Sickle Cell Disease
5063 - Vaso-Occlusive Crisis in Patients with Sickle Cell Anemia with Elevated Fetal Hemoglobin
Takenaka, K.
Takenaka, K.
Takeshita, J.
Taketo, M. M.
Takeuchi, K.
Takeuchi, M.
Takeuchi, M.
366 - Soluble B-Cell Maturation Antigen Levels for Disease Monitoring in Oligo- and Non-Secretory Relapsed Multiple Myeloma
491 - Total Diffusion Volume Evaluated By Whole-Body Diffusion Weighted Magnetic Resonance Image for the Assessment of Tumor Burden in Multiple Myeloma; Relations with Measurable Residual Disease Evaluated By Next-Generation Flow Cytometry and Bone Marrow CD138 Staining Assessed By Qupath
1805 - Impact of Cooperating Myeloid Gene Mutations on Disease Progression and Survival in Japanese MPN Patients: A Multicenter Study
1931 - Prognostic Value of t(11;14)(q13;32) in Newly Diagnosed Myeloma Patients in Novel Agent Era; Matched-Pair Analysis
3035 - Serum BCMA Is a Better Reflector of Tumor Volume Than IgM in the Induction Period of Waldenström Macroglobulinemia
3042 - Simultaneous Assessment of Total Metabolic Tumor Volume and Intratumoral CD4+ T-Cell Infiltration Identifies Early Progression of Follicular Lymphoma on Watch-and-Wait Approach
3313 - Soluble BCMA As a Surrogate Biomarker for Tumor Burden in Multiple Myeloma: Correlations with Various Biomarkers and Treatment Responses
4682 - Different Patterns of Antigen Expression in Bone Marrow and Circulating Tumor Plasma Cells in Patients with MGUS and Smoldering Multiple Myeloma
491 - Total Diffusion Volume Evaluated By Whole-Body Diffusion Weighted Magnetic Resonance Image for the Assessment of Tumor Burden in Multiple Myeloma; Relations with Measurable Residual Disease Evaluated By Next-Generation Flow Cytometry and Bone Marrow CD138 Staining Assessed By Qupath
1805 - Impact of Cooperating Myeloid Gene Mutations on Disease Progression and Survival in Japanese MPN Patients: A Multicenter Study
1931 - Prognostic Value of t(11;14)(q13;32) in Newly Diagnosed Myeloma Patients in Novel Agent Era; Matched-Pair Analysis
3035 - Serum BCMA Is a Better Reflector of Tumor Volume Than IgM in the Induction Period of Waldenström Macroglobulinemia
3042 - Simultaneous Assessment of Total Metabolic Tumor Volume and Intratumoral CD4+ T-Cell Infiltration Identifies Early Progression of Follicular Lymphoma on Watch-and-Wait Approach
3313 - Soluble BCMA As a Surrogate Biomarker for Tumor Burden in Multiple Myeloma: Correlations with Various Biomarkers and Treatment Responses
4682 - Different Patterns of Antigen Expression in Bone Marrow and Circulating Tumor Plasma Cells in Patients with MGUS and Smoldering Multiple Myeloma
Takeuchi, S.
Takhar, M.
Takizawa, J.
Takizawa, M.
Taksin, A. L.
Takvorian, R. W.
Talab, Y.
2277 - Characteristics and Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A 14-Year Experience in a Limited Resource Setting
3797 - Genetic Profiling and Risk Stratification of Acute Myeloid Leukemia (AML): Comparative Analysis of the Jordanian AML Cohort (JAMLC) to the German-Austrian AML Study Group (AMLSG)
3797 - Genetic Profiling and Risk Stratification of Acute Myeloid Leukemia (AML): Comparative Analysis of the Jordanian AML Cohort (JAMLC) to the German-Austrian AML Study Group (AMLSG)
Talackine, J. R.
Talal, U.
Talami, A.
Talarico, G.
Talati, C.
1994 - Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
4270 - Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
4270 - Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
Talati, C.
496 - ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study
1985 - A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
1985 - A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
Talaulikar, D.
3006 - Multiomics Analysis of Paired Diagnosis and Relapse DLBCL Biopsies Shows a Reduction in T Cell Infiltration and Function at Relapse
3007 - Frontline R-CHOP and BR Have Similar Outcomes By SUVmax in Follicular Lymphoma
4652 - Defining Therapeutic Epitranscriptome of Multiple Myeloma for Accurate Subtyping and Personalized Prognostics
3007 - Frontline R-CHOP and BR Have Similar Outcomes By SUVmax in Follicular Lymphoma
4652 - Defining Therapeutic Epitranscriptome of Multiple Myeloma for Accurate Subtyping and Personalized Prognostics
Talavera Yagüez, M.
Talbot, A.
Talbot, A.
1980 - Effect of Daratumumab on Renal Outcome in Newly Diagnosed Multiple Myeloma with Light Chain CAST Nephropathy
4765 - Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)
4765 - Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)
Talbot, D.
Talleur, A. C.
383 - Memory T-Cell Add Back and Prophylactic blinatumomab Post Tcrαβ Depleted Haploidentical Transplantation Results in Promising Outcomes in Pediatric Patients with High-Risk Acute Leukemia
2076 - CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia
2076 - CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia
Tallman, M. S.
218 - 10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years
445 - Outpatient Vs Inpatient Hidac Consolidation for AML: The MSKCC Experience
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
2847 - Patients with AML and an IDH2-R172 Mutation Exhibit a Unique Response to Intensive Induction Chemotherapy, Suggesting Futility of Mid-Cycle Bone Marrow Biopsy and Caution When Considering Re-Induction
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
445 - Outpatient Vs Inpatient Hidac Consolidation for AML: The MSKCC Experience
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
2847 - Patients with AML and an IDH2-R172 Mutation Exhibit a Unique Response to Intensive Induction Chemotherapy, Suggesting Futility of Mid-Cycle Bone Marrow Biopsy and Caution When Considering Re-Induction
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
Talluri, S.
Talotta, D.
Talpaz, M.
482 - Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial
657 - A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia
1765 - Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial
3178 - Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis
3264 - Inhibition of Endoplasmic Reticulum Associated Degradation Is Cytotoxic to Relapsed Refractory Multiple Myeloma through Altered Proapoptotic Signaling
3379 - Phase 2 Study Using Minimal Residual Disease-Driven Adaptive Strategy in Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy – First Report from the Maestro Trial
657 - A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia
1765 - Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial
3178 - Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis
3264 - Inhibition of Endoplasmic Reticulum Associated Degradation Is Cytotoxic to Relapsed Refractory Multiple Myeloma through Altered Proapoptotic Signaling
3379 - Phase 2 Study Using Minimal Residual Disease-Driven Adaptive Strategy in Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy – First Report from the Maestro Trial
Tam, C. S.
341 - Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma
860 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study
868 - Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T–Naive and CAR-T–Exposed Patients
885 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study
1012 - Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101
1649 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study
3031 - Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study
3255 - Deep and Sustained Responses in Patients with CLL Treated with Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report from the Zanubrutinib Extension Study
4384 - Marginal Zone Lymphoma Is Associated with Dysregulated Peripheral Blood Immunity Which Is Not Changed By Ibrutinib-Venetoclax Treatment
4412 - Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)
860 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study
868 - Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T–Naive and CAR-T–Exposed Patients
885 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study
1012 - Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101
1649 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study
3031 - Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study
3255 - Deep and Sustained Responses in Patients with CLL Treated with Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report from the Zanubrutinib Extension Study
4384 - Marginal Zone Lymphoma Is Associated with Dysregulated Peripheral Blood Immunity Which Is Not Changed By Ibrutinib-Venetoclax Treatment
4412 - Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)
Tam, C. S.
1869 - Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study
3248 - Phase 1/2 Studies of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia (CLL) and Other B-Cell Non-Hodgkin Lymphoma (B-NHL)
3249 - Sustained Superiority of Zanubrutinib vs Bendamustine + Rituximab in Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN CLL): 5-Year Follow-Up of Cohort 1 from the SEQUOIA Study
4416 - Practices and Outcomes during a Watch and Wait Approach for Follicular Lymphoma: A Study from the Australasian Lymphoma Alliance
4501 - Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
4829 - CTX112, a Next-Generation Allogeneic CRISPR-Cas9 Engineered CD19 CAR T Cell with Novel Potency Edits: Data from Phase 1 Dose Escalation Study in Patients with Relapsed or Refractory B-Cell Malignancies
3248 - Phase 1/2 Studies of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia (CLL) and Other B-Cell Non-Hodgkin Lymphoma (B-NHL)
3249 - Sustained Superiority of Zanubrutinib vs Bendamustine + Rituximab in Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN CLL): 5-Year Follow-Up of Cohort 1 from the SEQUOIA Study
4416 - Practices and Outcomes during a Watch and Wait Approach for Follicular Lymphoma: A Study from the Australasian Lymphoma Alliance
4501 - Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
4829 - CTX112, a Next-Generation Allogeneic CRISPR-Cas9 Engineered CD19 CAR T Cell with Novel Potency Edits: Data from Phase 1 Dose Escalation Study in Patients with Relapsed or Refractory B-Cell Malignancies
Tam, E. L.
2892 - Optimizing Venetoclax Duration in Combination with Hypomethylating Agents for Newly Diagnosed AML: Impact on Treatment Response and Survival Outcomes
3566 - Clinical Impact of Pretransplant Blinatumomab in Predominantly Hispanic Adults with B-Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
3566 - Clinical Impact of Pretransplant Blinatumomab in Predominantly Hispanic Adults with B-Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Tam, K. H.
Tam, P.
Tam, W. L.
Tam, Y. K.
Tamada, R.
149 - Prolonged Persistence and Functional Activity of Anti-BCMA CAR-T Durcabtagene Autoleucel (PHE885) Manufactured Using the T-Charge™ Platform
1041 - Effects of GvHD Prophylaxis with Post-Transplant Cyclophosphamide on Immune Reconstitution and TCR Repertoire after Haploidentical and HLA-Matched Transplantation Compared to Prophylaxis with Calcineurin Inhibitor Plus Methotrexate in HLA-Matched Transplantation
1041 - Effects of GvHD Prophylaxis with Post-Transplant Cyclophosphamide on Immune Reconstitution and TCR Repertoire after Haploidentical and HLA-Matched Transplantation Compared to Prophylaxis with Calcineurin Inhibitor Plus Methotrexate in HLA-Matched Transplantation
Tamamyan, G.
Tamana, S.
794 - uRADAR: European Patients Referral Frame to Improve Access to New Drugs and Therapies in Ultra-Rare Anemia Disorders and Severe Hereditary Spherocytosis
1138 - Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease
1138 - Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease
Tamang, H. K.
Tamari, R.
267 - Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies
686 - Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies
694 - Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients
777 - Prediction of Post-Transplant Relapse of the Myelodysplastic Syndromes Via Evaluation of Stem Cells
2873 - A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)
686 - Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies
694 - Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients
777 - Prediction of Post-Transplant Relapse of the Myelodysplastic Syndromes Via Evaluation of Stem Cells
2873 - A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)
Tamariz-Amador, L. E.
1934 - Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)
4798 - Molecular Mechanisms Promoting Long-Term Cytopenia after BCMA CAR-T Therapy in Multiple Myeloma
4798 - Molecular Mechanisms Promoting Long-Term Cytopenia after BCMA CAR-T Therapy in Multiple Myeloma
Tamary, H.
Tamayo, I.
Tambaro, F. P.
1423 - Qol-Blina Protocol: Preliminary Data of a Paediatric Italian Multicentric Study
1855 - Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL
2095 - Gelofusine As Alternative to Dextran40 for Washing Cryopreserved Hematopoietic Stem Cell Products Prior to Infusion: Validation and Application to Clinical Practice
1855 - Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL
2095 - Gelofusine As Alternative to Dextran40 for Washing Cryopreserved Hematopoietic Stem Cell Products Prior to Infusion: Validation and Application to Clinical Practice
Tambe, M. B.
Tamdin, T.
Tamellini, E.
Tamim, S.
Tamò, G.
Tamura, H.
Tamura, M.
Tamura, T.
Tan, B. S.
Tan, B.
Tan, C. S.
Tan, C. R.
248 - Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease
671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
672 - Immune-MRD Status Informs Tumor-MRD Outcome Prognostication in Multiple Myeloma Patients on Lenalidomide Maintenance
704 - Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis
1944 - Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)
3343 - Evaluation of the Safety and Efficacy of Denosumab in Patients with Multiple Myeloma and Severe Renal Impairment; Results from an IMWG Bone Subcommittee Study
3362 - Daratumumab Versus Lenalidomide As Maintenance Therapy in Newly Diagnosed Multiple Myeloma – Interim Efficacy Results of a Randomized Clinical Trial
3368 - Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium
3760 - Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study
4735 - Frailty and Outcomes after Bispecific T-Cell Engager Therapy for Patients with Relapsed/Refractory Multiple Myeloma
4850 - Manufacture of Anti-BCMA CAR T Cell Is Feasible after Salvage Autologous or Allogeneic Hematopoietic Stem Cell Transplantation
5166 - Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee
671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
672 - Immune-MRD Status Informs Tumor-MRD Outcome Prognostication in Multiple Myeloma Patients on Lenalidomide Maintenance
704 - Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis
1944 - Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)
3343 - Evaluation of the Safety and Efficacy of Denosumab in Patients with Multiple Myeloma and Severe Renal Impairment; Results from an IMWG Bone Subcommittee Study
3362 - Daratumumab Versus Lenalidomide As Maintenance Therapy in Newly Diagnosed Multiple Myeloma – Interim Efficacy Results of a Randomized Clinical Trial
3368 - Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium
3760 - Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study
4735 - Frailty and Outcomes after Bispecific T-Cell Engager Therapy for Patients with Relapsed/Refractory Multiple Myeloma
4850 - Manufacture of Anti-BCMA CAR T Cell Is Feasible after Salvage Autologous or Allogeneic Hematopoietic Stem Cell Transplantation
5166 - Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee
Tan, C. L.
Tan, C. K.
Tan, C. W.
5 - Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)
2612 - Dilute Russel Viper Venom Time (DRVVT) Ratio Predicts the Identification of Triple Positive Antiphospholipid Antibody Profile
2612 - Dilute Russel Viper Venom Time (DRVVT) Ratio Predicts the Identification of Triple Positive Antiphospholipid Antibody Profile
Tan, F.
Tan, H.
Tan, J. Y.
Tan, J.
Tan, J. Y.
Tan, J.
Tan, K.
313 - Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma
316 - Multimodal Single-Cell Profiling of Minimal Residual Disease in B Acute Lymphoblastic Leukemia Reveals Genetic and Non-Genetic Factors of Early Drug Resistance
725 - Aberrant Stemness Transcription Signature Unveils a Mechanism of Chemotherapy Resistance through Blunting p53-Mediated Response in Acute Myeloid Leukemia
1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL
2989 - Lymph Node Stromal Cells Underlie the Clinicopathologic Features of Castleman Disease
316 - Multimodal Single-Cell Profiling of Minimal Residual Disease in B Acute Lymphoblastic Leukemia Reveals Genetic and Non-Genetic Factors of Early Drug Resistance
725 - Aberrant Stemness Transcription Signature Unveils a Mechanism of Chemotherapy Resistance through Blunting p53-Mediated Response in Acute Myeloid Leukemia
1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL
2989 - Lymph Node Stromal Cells Underlie the Clinicopathologic Features of Castleman Disease
Tan, K. W.
1484 - Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study
1507 - Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML
1527 - Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification
1507 - Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML
1527 - Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification
Tan, M. M.
Tan, P. T.
212 - Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
498 - A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma
1001 - Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis
1500 - EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Final Results of Dose Escalation and Optimization Cohorts from a Phase I/IIa Study in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) or Myelodysplastic Syndrome (MDS)
3364 - Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma
4257 - WUN101-01: First in Human Human (FIH) Phase 1 Study of WU-NK-101 (W-NK1) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
498 - A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma
1001 - Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis
1500 - EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Final Results of Dose Escalation and Optimization Cohorts from a Phase I/IIa Study in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) or Myelodysplastic Syndrome (MDS)
3364 - Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma
4257 - WUN101-01: First in Human Human (FIH) Phase 1 Study of WU-NK-101 (W-NK1) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
Tan, S. K.
2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study
Tan, S.
216 - Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML
2903 - Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
2903 - Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
Tan, S.
Tan, S.
217 - A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial
997 - Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial
1001 - Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis
1825 - Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)
4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML
4591 - Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial
997 - Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial
1001 - Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis
1825 - Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)
4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML
4591 - Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial
Tan, S. Y.
Tan, T. K.
Tan, W.
767 - Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects
3272 - Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma
4640 - Elucidation of Molecular Mechanisms of Iberdomide and Mezigdomide Resistance in Cell Line Models of Multiple Myeloma
3272 - Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma
4640 - Elucidation of Molecular Mechanisms of Iberdomide and Mezigdomide Resistance in Cell Line Models of Multiple Myeloma
Tan, X.
1449 - Combination of Olverembatinib and VP Regimen for Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2902 - Venetoclax, Azacitidine, Combined with Low-Dose Cytarabine in Older Newly Diagnosed Acute Myeloid Leukemia:the Result of a Prospective, Multicenter, Open, Randomized Controlled Trials
2902 - Venetoclax, Azacitidine, Combined with Low-Dose Cytarabine in Older Newly Diagnosed Acute Myeloid Leukemia:the Result of a Prospective, Multicenter, Open, Randomized Controlled Trials
Tan, Y.
2171 - Easix Score Predicts Overall Survival and Non-Relapse Mortality in Elderly Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation
4391 - A Prospective, Multicenter, Single-Arm Study on the Combination of Orelabrutinib and Rituximab in the Second-Line Treatment of Relapsed/Refractory Marginal Zone Lymphoma
4391 - A Prospective, Multicenter, Single-Arm Study on the Combination of Orelabrutinib and Rituximab in the Second-Line Treatment of Relapsed/Refractory Marginal Zone Lymphoma
Tan, Y.
1485 - Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML
1505 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia
2885 - 7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia
4279 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia
1505 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia
2885 - 7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia
4279 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia
Tan, Y.
Tanabe, A.
Tanabe, M.
Tanaka, H.
Tanaka, H.
Tanaka, M.
Tanaka, M.
Tanaka, M.
384 - Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC
1311 - Frequent Loss of HLA-B*40:02 from Leukocytes in Male Patients with Hepatitis-Associated Aplastic Anemia
2121 - Kinetics of Recipients with Thrombocytopenia and Its Impact on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study
3569 - To What Extent Have Post-Transplant Outcomes Improved Following the Introduction of Tyrosine Kinase Inhibitors in Elderly Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia? a Retrospective Nationwide Survey in Japan
4925 - The Outcome of Fertility Preservation Strategy in Female Hematopoietic Stem Cell Transplant Recipients of Reproductive Age. Retrospective Study from the Kanto Study Group for Cell Therapy
1311 - Frequent Loss of HLA-B*40:02 from Leukocytes in Male Patients with Hepatitis-Associated Aplastic Anemia
2121 - Kinetics of Recipients with Thrombocytopenia and Its Impact on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study
3569 - To What Extent Have Post-Transplant Outcomes Improved Following the Introduction of Tyrosine Kinase Inhibitors in Elderly Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia? a Retrospective Nationwide Survey in Japan
4925 - The Outcome of Fertility Preservation Strategy in Female Hematopoietic Stem Cell Transplant Recipients of Reproductive Age. Retrospective Study from the Kanto Study Group for Cell Therapy
Tanaka, S.
Tanaka, S.
Tanaka, T.
Tanaka, T.
Tanaka, Y.
Tanariyakul, M.
1240 - Characteristics of Patients with Inflammatory Bowel Disease and Impact on Outcomes Following Heparin-Induced Thrombocytopenia: A 5-Year Nationwide Analysis
4389 - Incidence and Time to Diagnosis of Secondary Malignancies in Patients with Hairy Cell Leukemia: A Systematic Review and Meta-Analysis
4389 - Incidence and Time to Diagnosis of Secondary Malignancies in Patients with Hairy Cell Leukemia: A Systematic Review and Meta-Analysis
Tanase, A. D.
Tanasi, I.
Taneja, S.
Tang, A.
Tang, A.
Tang, B.
1305 - Deciphering Transcriptome Alterations in Bone Marrow Hematopoiesis at Single-Cell Resolution in Prolonged Thrombocytopenia after Umbilical Cord Blood Transplantation
2138 - Effective Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease with Human Induced Pluripotent Stem Cell Derived Mesenchymal Stromal Cells (iMSC) in a Clinical Setting
3504 - Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment after Allogeneic Stem Cell Transplantation: A Prospective, Single-Arm Clinical Trail
2138 - Effective Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease with Human Induced Pluripotent Stem Cell Derived Mesenchymal Stromal Cells (iMSC) in a Clinical Setting
3504 - Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment after Allogeneic Stem Cell Transplantation: A Prospective, Single-Arm Clinical Trail
Tang, C. H. A.
Tang, F.
1537 - Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World
1834 - Myelodysplastic Syndrome Stem Cells Evaluated By Multiparameter Flow Cytometry Are Associated with Posttreatment Relapse: A Prospective Study
4235 - The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia
1834 - Myelodysplastic Syndrome Stem Cells Evaluated By Multiparameter Flow Cytometry Are Associated with Posttreatment Relapse: A Prospective Study
4235 - The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia
Tang Girdwood, S.
Tang, G.
Tang, G.
735 - Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse
1461 - Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens
1971 - Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma
3038 - Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma
3246 - Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53-Mutated Chronic Lymphocytic Leukemia
3344 - Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant
4224 - Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory
4263 - Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
4306 - Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy
4336 - Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1-mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease
1461 - Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens
1971 - Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma
3038 - Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma
3246 - Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53-Mutated Chronic Lymphocytic Leukemia
3344 - Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant
4224 - Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory
4263 - Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
4306 - Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy
4336 - Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1-mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease
Tang, H.
Tang, H.
249 - Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
4635 - The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
4635 - The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma
Tang, J.
Tang, J.
2135 - Lymphocyte Dynamics during the Treatment of SR-aGVHD with Mesenchymal Stem Cells Derived from Human Umbilical Cord Blood - a Phase III, Multi-Center, Prospective, Single-Arm Pivotal Study
3462 - CMV-Specific TCR-T Cells for the Treatment of CMV Reactivation after Allogeneic Hematopoietic Stem-Cell Transplantation
3462 - CMV-Specific TCR-T Cells for the Treatment of CMV Reactivation after Allogeneic Hematopoietic Stem-Cell Transplantation
Tang, K.
Tang, L.
92 - IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies
2074 - 1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust In Vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients
2074 - 1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust In Vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients
Tang, L.
Tang, L.
Tang, L.
Tang, S.
4391 - A Prospective, Multicenter, Single-Arm Study on the Combination of Orelabrutinib and Rituximab in the Second-Line Treatment of Relapsed/Refractory Marginal Zone Lymphoma
4500 - Preliminary Data on the Efficacy and Safety of Orelabrutinib Combined with Rituximab and Methotrexate (ORM Regimen) As First-Line Treatment for Primary Central Nervous System Lymphoma, and the Exploration of Cerebrospinal Fluid Ctdna Dynamic Monitoring
4500 - Preliminary Data on the Efficacy and Safety of Orelabrutinib Combined with Rituximab and Methotrexate (ORM Regimen) As First-Line Treatment for Primary Central Nervous System Lymphoma, and the Exploration of Cerebrospinal Fluid Ctdna Dynamic Monitoring
Tang, S.
Tang, T.
Tang, T. H.
Tang, W.
Tang, X.
1507 - Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML
3535 - Autologous Fecal Microbiota Transplantation As a Gvhd Prophylaxis in Patients with Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Trial
4287 - Hypomethylating Agent and Venetoclax in Newly Diagnosed and Relapsed CBFβ::MYH11(+) Acute Myeloid Leukemia
3535 - Autologous Fecal Microbiota Transplantation As a Gvhd Prophylaxis in Patients with Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Trial
4287 - Hypomethylating Agent and Venetoclax in Newly Diagnosed and Relapsed CBFβ::MYH11(+) Acute Myeloid Leukemia
Tang, X.
270 - Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial
683 - Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness
3384 - Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial
3493 - VA Combined with Mbucy Conditioning Regimen Followed By Allo-HSCT Can Improve Survival of High-Risk AML Patients: A Prospective, Single-Center, Single-Arm Clinical Trial
4197 - Chemotherapy-Free Induction with Venetoclax and Azacitidine, Followed By Tandem CD19/CD22 CAR-T Cell Therapy As First-Line Treatment in Newly Diagnosed High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Prospective, Single-Center, Single-Arm, Phase 2 Trial
4284 - How to Improve the Efficacy of Venetoclax and Azacitidine(VA)for Newly Diagnosed Acute Myeloid Leukemia?a Prospective, Single-Center, Single-Arm, Phase 2 Trial for New Diagnosed AML
4836 - Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial
683 - Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness
3384 - Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial
3493 - VA Combined with Mbucy Conditioning Regimen Followed By Allo-HSCT Can Improve Survival of High-Risk AML Patients: A Prospective, Single-Center, Single-Arm Clinical Trial
4197 - Chemotherapy-Free Induction with Venetoclax and Azacitidine, Followed By Tandem CD19/CD22 CAR-T Cell Therapy As First-Line Treatment in Newly Diagnosed High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Prospective, Single-Center, Single-Arm, Phase 2 Trial
4284 - How to Improve the Efficacy of Venetoclax and Azacitidine(VA)for Newly Diagnosed Acute Myeloid Leukemia?a Prospective, Single-Center, Single-Arm, Phase 2 Trial for New Diagnosed AML
4836 - Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial
Tang, X. J.
Tang, Y.
Tang, Y.
Tang, Y.
Tang, Z.
683 - Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness
971 - Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial
971 - Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial
Tani, M.
577 - Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma
1577 - TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial
1631 - Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study
4411 - Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study
4501 - Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
1577 - TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial
1631 - Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study
4411 - Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study
4501 - Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
Tanigawa, T.
Taniguchi, K.
Taniguchi, S.
Tanimoto, K.
Tanizawa, A.
Tanner, M. R.
Tannu, S.
Tanoue, S.
1939 - Gnri (Geriatric Nutritional Risk Index) in Multiple Myeloma
3090 - Short Diagnosis to Treatment Interval Is Associated with Poor Outcomes in Relapse or Refractory Diffuse Large B-Cell Lymphoma
4459 - Low Immunoglobulin G and Low Lymphocyte-Monocyte Ratio at the End of Treatment Predict Early Progression in Diffuse Large B-Cell Lymphoma
3090 - Short Diagnosis to Treatment Interval Is Associated with Poor Outcomes in Relapse or Refractory Diffuse Large B-Cell Lymphoma
4459 - Low Immunoglobulin G and Low Lymphocyte-Monocyte Ratio at the End of Treatment Predict Early Progression in Diffuse Large B-Cell Lymphoma
Tantawy, S. I.
Tantiworawit, A.
1776 - Vitamin D Deficiency Negatively Affects Responses in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
2331 - Clinical Characteristic Outcomes and Mortality Among Cancer and Non-Cancer Patients Presented with Incidental Pulmonary Embolism
2568 - Dexamethasone Versus Prednisolone in Adults with Newly Diagnosed Immune Thrombocytopenia: A Systematic Review and Meta-Analysis
2331 - Clinical Characteristic Outcomes and Mortality Among Cancer and Non-Cancer Patients Presented with Incidental Pulmonary Embolism
2568 - Dexamethasone Versus Prednisolone in Adults with Newly Diagnosed Immune Thrombocytopenia: A Systematic Review and Meta-Analysis
Tantravahi, S. K.
479 - Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)
655 - Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients
658 - Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
2334 - Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Real-World Outcomes and Disparities in the Era of Novel Therapies, 2010-2021
2420 - Mixed Phenotype Acute Leukemias: Real-World Outcomes By Who Classifications 2010-2021
2426 - Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium
3179 - Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor
5026 - Evaluation of Pharmacist-Managed Thiopurine-Based Leukemia Maintenance Service Via a Collaborative Practice Agreement
5052 - U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)
655 - Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients
658 - Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
2334 - Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Real-World Outcomes and Disparities in the Era of Novel Therapies, 2010-2021
2420 - Mixed Phenotype Acute Leukemias: Real-World Outcomes By Who Classifications 2010-2021
2426 - Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium
3179 - Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor
5026 - Evaluation of Pharmacist-Managed Thiopurine-Based Leukemia Maintenance Service Via a Collaborative Practice Agreement
5052 - U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)
Tanturli, M.
Tantyo, N. A.
Tanweer, M.
Tanzer, J. R.
Tanzi, E.
Tao, M.
Tao, Q.
2754 - Vincristine Overcomes Cytarabine Resistance in Acute Myeloid Leukemia By Suppression of ARHGAP18-Mediated Cellular Senescence
4301 - Elevated Circulating CD10¯ G-MDSC-like Neutrophils of Acute Myeloid Leukemia Patients in Complete Remission Status Are Correlated with Relapse and Poor Prognosis
4301 - Elevated Circulating CD10¯ G-MDSC-like Neutrophils of Acute Myeloid Leukemia Patients in Complete Remission Status Are Correlated with Relapse and Poor Prognosis
Tao, R.
Tao, R.
4448 - Selinexor Combined with Tislelizumab in Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL): Preliminary Results of Arm C, from a Multicenter, Single-Arm, Phase I/II Study, Touch
1718.1 - SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)
1718.1 - SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)
Tao, Y.
Tao, Y.
Tao, Y.
Tao, Y.
Taouxi, K.
1020 - Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
1600 - Genomic Characterization of Ibrutinib-Resistant Waldenström’s Macroglobulinemia
1603 - The Combined Treatment of Btkis with Venetoclax Exhibits an Enhanced Therapeutic Effect on Waldenström Macroglobulinemia Cells Bearing CXCR4 Mutations
1600 - Genomic Characterization of Ibrutinib-Resistant Waldenström’s Macroglobulinemia
1603 - The Combined Treatment of Btkis with Venetoclax Exhibits an Enhanced Therapeutic Effect on Waldenström Macroglobulinemia Cells Bearing CXCR4 Mutations
Taparia, M. S.
Tapia Torres, M.
Tarabarova, A. G.
Taranets, L.
Tarango, C.
Tarannum, M.
915 - One-Step Construction of Allogeneic CAR-NK Cells Preventing Rejection and Mediating Enhanced Anti-Tumor Responses
917 - Mesothelin Targeting IL12-Engineered CAR Memory-like NK Cells Demonstrate Promising Efficacy in Acute Myeloid Leukemia
4800 - A TCR-like CAR T Cell Therapy for the Treatment of MZB1 Positive Multiple Myeloma and Other B-Cell Malignancies
917 - Mesothelin Targeting IL12-Engineered CAR Memory-like NK Cells Demonstrate Promising Efficacy in Acute Myeloid Leukemia
4800 - A TCR-like CAR T Cell Therapy for the Treatment of MZB1 Positive Multiple Myeloma and Other B-Cell Malignancies
Tarantelli, C.
Tarantino, D.
Tarantino, M. D.
2559 - Enhanced Patient Satisfaction and Stability of Platelet Counts Following a Switch from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA) in Adult Idiopathic Thrombocytopenic Purpura (ITP): Post-Hoc Analyses from a Prospective Phase 4 Study
2560 - Results of a Prospective, Open-Label, Phase 4 Study Evaluating the Safety, Efficacy, and Treatment Satisfaction in Adult Immune Thrombocytopenia (ITP) Subjects after Switching to Avatrombopag from Eltrombopag or Romiplostim
2592 - Indirect Comparison of the Efficacy and Therapy-Related Costs of a Pharmacokinetic and Individualized Prophylaxis Regimen with Simoctocog Alfa Versus Other Extended-Half Life Factor VIII Concentrates
2560 - Results of a Prospective, Open-Label, Phase 4 Study Evaluating the Safety, Efficacy, and Treatment Satisfaction in Adult Immune Thrombocytopenia (ITP) Subjects after Switching to Avatrombopag from Eltrombopag or Romiplostim
2592 - Indirect Comparison of the Efficacy and Therapy-Related Costs of a Pharmacokinetic and Individualized Prophylaxis Regimen with Simoctocog Alfa Versus Other Extended-Half Life Factor VIII Concentrates
Tarantino, V.
Taranto, S.
Tarantolo, S. R.
737 - Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients
3225 - Preliminary Safety, Efficacy and Molecular Characterization in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Single Agent Emavusertib (CA-4948)
3225 - Preliminary Safety, Efficacy and Molecular Characterization in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Single Agent Emavusertib (CA-4948)
Tarasenko, E.
Tardif-Samson, A.
Tardy, A. L.
131 - Real-World Experience of Switching to Prophylactic Efanesoctocog Alfa in Patients with Moderate and Severe Hemophilia a: An Analysis of the Adelphi Hemophilia Wave III Disease Specific Programme
3967 - Real-World Patterns of Additional Factor Treatment Use Among Hemophilia a Patients on Regular Prophylaxis in the United States: Results from the Picnichealth Database
3973 - Unmet Needs, Factor Consumption, and Healthcare Resource Use Among People with Hemophilia a: Real-World Analysis of the Adelphi Hemophilia Disease Specific ProgrammeTM
3967 - Real-World Patterns of Additional Factor Treatment Use Among Hemophilia a Patients on Regular Prophylaxis in the United States: Results from the Picnichealth Database
3973 - Unmet Needs, Factor Consumption, and Healthcare Resource Use Among People with Hemophilia a: Real-World Analysis of the Adelphi Hemophilia Disease Specific ProgrammeTM
Tareen, S.
Tarella, C.
1541 - Genomic Landscape and Clonal Hematopoiesis Dynamics in Patients with Ovarian Cancer during PARP Inhibitors Treatment: Preliminary Results of a Prospective Longitudinal Study
1620 - Impaired rRNA Synthesis Contributes to BCL-2 Induced Chemoresistance in Diffuse Large B-Cell Lymphoma
2186 - Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Retrospective Multicenter Analysis on 285 Procedures Performed between 2000 and 2020
1620 - Impaired rRNA Synthesis Contributes to BCL-2 Induced Chemoresistance in Diffuse Large B-Cell Lymphoma
2186 - Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Retrospective Multicenter Analysis on 285 Procedures Performed between 2000 and 2020
Targonski, L.
Tarin-Arzaga, L.
376 - Lowering Conditioning Intensity in Fit Adolescents and Adults with Lymphoblastic Leukemia without Residual Disease Undergoing Transplantation: A Proof of Concept
1665 - Low-Dose Nivolumab Plus AVD As Front-Line Therapy for Classical Hodgkin's Lymphoma: Preliminary Results of a Phase 2 Trial
2364 - Identifying Barriers to Sexual Health in Patients with Hematological Malignancies and Underprivileged Circumstances
4873 - Optimizing Conditioning Intensity to Disease Burden in Adults with Acute Myeloid Leukemia Undergoing Transplantation: Results of a Prospective Multicenter Study
1665 - Low-Dose Nivolumab Plus AVD As Front-Line Therapy for Classical Hodgkin's Lymphoma: Preliminary Results of a Phase 2 Trial
2364 - Identifying Barriers to Sexual Health in Patients with Hematological Malignancies and Underprivileged Circumstances
4873 - Optimizing Conditioning Intensity to Disease Burden in Adults with Acute Myeloid Leukemia Undergoing Transplantation: Results of a Prospective Multicenter Study
Tario Jr, J. D.
Tariq, M. J.
Tariq, M. J.
Tarlock, K.
369 - Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro, In Vivo, and Ex Vivo Anti-Leukemia Activity
967 - A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group
967 - A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group
Tarquinio, K.
Tartaglione, I.
Tartari, C. J.
Tarte, K.
Tarumoto, S.
Tarver, M.
Tarver, III, T. C.
Tashbook, S. E.
Tashi, T.
659 - Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)
1791 - Quality of Life Evaluation for Patients on Ropeginterferon Alpha-2b Versus Other Best Available Therapies
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
4569.2 - A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm
1791 - Quality of Life Evaluation for Patients on Ropeginterferon Alpha-2b Versus Other Best Available Therapies
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
4569.2 - A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm
Tashi, T.
Tashkandi, H.
Tasian, S. K.
369 - Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro, In Vivo, and Ex Vivo Anti-Leukemia Activity
370 - Gilteritinib Augments Preclinical FLT3 and CD19 CAR T Cell Immunotherapy in High-Risk Pediatric Leukemias
1361 - Targeting HMGA1 Epigenetic Regulators and Downstream ETV5 Pathways with Histone Deacetylase Inhibitors in Combination Therapy for Relapsed, Pediatric B-ALL
1407 - A Novel Antibody-Drug Conjugate Targeting the CD179a Component of the Surrogate Light Chain for the Treatment of B-Cell Acute Lymphoblastic Leukemia/Lymphoma
1455 - KMT2A-Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation
2789 - A Novel Approach Combining Type II JAK Inhibitor Chz-868 with Nutrient Restriction to Augment Cell Death in Philadelphia like Acute Lymphoblastic Leukemia
3424 - Co-Targeting of the Thymic Stromal Lymphopoietin Receptor to Decrease Immunotherapeutic Resistance in CRLF2-Rearranged Ph-like and Down Syndrome ALL
4233 - Molecular Features, Treatments and Outcomes for Pediatric AML Patients from APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial
2828.1 - Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2)
4265.3 - APAL2020K/ITCC-101: A Phase I Trial of the Menin Inhibitor Ziftomenib in Combination with Chemotherapy in Children with Relapsed/Refractory KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant Acute Leukemias
4265.4 - PEPN2312: A Pediatric Early Phase Clinical Trials Network (PEP-CTN) Phase 1 Trial of Imetelstat with Fludarabine/Cytarabine in Pediatric Patients with Relapsed/Refractory AML, MDS, or JMML
370 - Gilteritinib Augments Preclinical FLT3 and CD19 CAR T Cell Immunotherapy in High-Risk Pediatric Leukemias
1361 - Targeting HMGA1 Epigenetic Regulators and Downstream ETV5 Pathways with Histone Deacetylase Inhibitors in Combination Therapy for Relapsed, Pediatric B-ALL
1407 - A Novel Antibody-Drug Conjugate Targeting the CD179a Component of the Surrogate Light Chain for the Treatment of B-Cell Acute Lymphoblastic Leukemia/Lymphoma
1455 - KMT2A-Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation
2789 - A Novel Approach Combining Type II JAK Inhibitor Chz-868 with Nutrient Restriction to Augment Cell Death in Philadelphia like Acute Lymphoblastic Leukemia
3424 - Co-Targeting of the Thymic Stromal Lymphopoietin Receptor to Decrease Immunotherapeutic Resistance in CRLF2-Rearranged Ph-like and Down Syndrome ALL
4233 - Molecular Features, Treatments and Outcomes for Pediatric AML Patients from APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial
2828.1 - Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2)
4265.3 - APAL2020K/ITCC-101: A Phase I Trial of the Menin Inhibitor Ziftomenib in Combination with Chemotherapy in Children with Relapsed/Refractory KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant Acute Leukemias
4265.4 - PEPN2312: A Pediatric Early Phase Clinical Trials Network (PEP-CTN) Phase 1 Trial of Imetelstat with Fludarabine/Cytarabine in Pediatric Patients with Relapsed/Refractory AML, MDS, or JMML
Taszner, M.
Tatake, I. J.
Tatarata, Q. Z.
207 - Enhancing Macrophage Mediated Phagocytosis in AML: The Complementary Mechanisms of Venetoclax and Azacitidine Combination Therapy
2749 - Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML
2760 - Anti-Leukemia Combinatorial Efficacy of ABBV155, a B7H3-BCL-XL Inhibitor Antibody-Drug Conjugate, in Combination with Venetoclax through BCL-XL/BIM and BCL-2/BIM Complex Dissociations
2777 - Safety and Efficacy of a Novel Mammalian-Derived Asparaginase without Glutaminase Activity in Combination with Venetoclax for Acute Myeloid Leukemia
2749 - Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML
2760 - Anti-Leukemia Combinatorial Efficacy of ABBV155, a B7H3-BCL-XL Inhibitor Antibody-Drug Conjugate, in Combination with Venetoclax through BCL-XL/BIM and BCL-2/BIM Complex Dissociations
2777 - Safety and Efficacy of a Novel Mammalian-Derived Asparaginase without Glutaminase Activity in Combination with Venetoclax for Acute Myeloid Leukemia
Tatarczuch, M.
Tatetsu, H.
Tatsuno, S.
Tatun, M.
1780 - Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML
4320 - Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML
4320 - Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML
Taub, J. W.
1376 - Loss of Cystathionine-β-Synthase Activity Results in Increased Oxidative Phosphorylation and Cytarabine Resistance in Myeloid Leukemia Associated with Down Syndrome
2731 - Multi-Pronged Effects of Cohesin Mutations in the Myeloid Leukemia of Down Syndrome
2949 - Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children’s Oncology Group
2731 - Multi-Pronged Effects of Cohesin Mutations in the Myeloid Leukemia of Down Syndrome
2949 - Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children’s Oncology Group
Taubmann, J.
Tauchmann, S.
Taur, Y.
Taurino, A.
2168 - HLA-DQ8 Haplotype Increases the Risk of Relapse after Allogeneic Stem Cell Transplantation Possibly Affecting Graft-Versus-Leukemia: A Single-Center Study on 400 Patients
3520 - Endothelial Dysfunction and Risk of Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation: END-GAME Prospective Study Final Results
3520 - Endothelial Dysfunction and Risk of Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation: END-GAME Prospective Study Final Results
Tausch, E.
1846 - In-Depth Immune and Metabolic Profiling of GAIA/CLL13 Patients to Uncover Treatment-Specific Changes to the T-Cell Compartment
1859 - Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial
3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial
4608 - Biallelic Deletion 13q in Chronic Lymphocytic Leukemia Treated with Targeted Agents
4613 - Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial
4618 - Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) – Primary Endpoint Analysis of the Phase II CLL-Frail Trial
4626 - Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study
1859 - Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial
3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial
4608 - Biallelic Deletion 13q in Chronic Lymphocytic Leukemia Treated with Targeted Agents
4613 - Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial
4618 - Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) – Primary Endpoint Analysis of the Phase II CLL-Frail Trial
4626 - Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study
Taussig, D.
Taussig, D.
1500 - EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Final Results of Dose Escalation and Optimization Cohorts from a Phase I/IIa Study in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) or Myelodysplastic Syndrome (MDS)
1535 - Bone Marrow Failure in AML: Residual Neutrophils and Erythroblasts Are Derived By Differentiation from the AML
1535 - Bone Marrow Failure in AML: Residual Neutrophils and Erythroblasts Are Derived By Differentiation from the AML
Tauveron-Jalenques, U.
846 - Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group
1475 - Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group
1518 - Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group
3564 - Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group
4335 - Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group
1475 - Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group
1518 - Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group
3564 - Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group
4335 - Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group
Tavakkoli, M.
398 - Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies
2344 - Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study
2344 - Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study
Tavakoli, P.
Tavana, O.
Tavares, E.
Tavarez, J. V.
983 - Refining Prognostication in Peripheral T Cell Lymphoma (PTCL): A Risk-Adapted Prognostic Model for Patients with Limited-Stage PTCL
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
1692 - The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
1692 - The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)
Tavarozzi, R.
Tavassoli, S.
Tavenner, M.
Taveras, A. G.
Tavernier, E.
846 - Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group
2905 - Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission
4335 - Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group
2905 - Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission
4335 - Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group
Tavernier, E.
58 - Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study
1475 - Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group
1518 - Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group
3564 - Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group
4275 - Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study
1475 - Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group
1518 - Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group
3564 - Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group
4275 - Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study
Tavitian, S.
302 - Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study
3133 - Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)
3167 - Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination – a FIM Study
4275 - Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study
3133 - Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)
3167 - Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination – a FIM Study
4275 - Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study
Tavori, G.
Tawara, I.
1789 - A Simple Diagnostic Algorithm for the Prediction of JAK2 Mutation Status in Erythrocytosis Based on Complete Blood Count Data: A Multi-Center Retrospective Analysis
3030 - Treatment and Outcomes of Stage I-II Pulmonary MALT Lymphoma: A Multi-Institutional Observational Study in Japan
3058 - Number of Sites of Involvement Predicts Central Nervous System Relapse in Patients with Localized Extranodal Natural Killer/T-Cell Lymphoma
4523 - A JAK2 Germline Variant Modulates Cytokine Release from Stromal Niche Cells and Induces Remodeling of the Bone Marrow Niche
3030 - Treatment and Outcomes of Stage I-II Pulmonary MALT Lymphoma: A Multi-Institutional Observational Study in Japan
3058 - Number of Sites of Involvement Predicts Central Nervous System Relapse in Patients with Localized Extranodal Natural Killer/T-Cell Lymphoma
4523 - A JAK2 Germline Variant Modulates Cytokine Release from Stromal Niche Cells and Induces Remodeling of the Bone Marrow Niche
Tawde, S.
Tawfiq, R. K.
1637 - Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study
3206 - Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis
3206 - Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis
Tawk, A.
Taya, Y.
2162 - Novel Insights into Predictors, Optimized Treatments, and Prognosis Factors for Virus-Induced Hemorrhagic Cystitis Post-Hematopoietic Stem Cell Transplantation: A Single-Institution Study of 427 Japanese Patients
2189 - Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL
3485 - What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes
3508 - Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation
4920 - Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status
4926 - Single Cord Blood Transplantation with Fludarabine, Busulfan and Melphalan Is Crucial Therapeutic Strategy for AML Not in Remission: A Single-Center Retrospective Study of 286 Patients Including Prognostic Factor Analysis
4933 - Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms
2189 - Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL
3485 - What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes
3508 - Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation
4920 - Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status
4926 - Single Cord Blood Transplantation with Fludarabine, Busulfan and Melphalan Is Crucial Therapeutic Strategy for AML Not in Remission: A Single-Center Retrospective Study of 286 Patients Including Prognostic Factor Analysis
4933 - Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms
Tayeh, M.
Taylor, A.
Taylor, A. O.
2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
2422 - Treatment Experience of Patients with Acute Myeloid Leukemia in the Era of Novel Therapies: A Longitudinal Electronic Patient-Reported Outcomes Study
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
2422 - Treatment Experience of Patients with Acute Myeloid Leukemia in the Era of Novel Therapies: A Longitudinal Electronic Patient-Reported Outcomes Study
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
Taylor, C. T.
716 - Descriptive Characterization of Bleeding Events in Participants with Severe Hemophilia Α or B without Inhibitors, Receiving Prophylactic Marstacimab Treatment
1210 - Safety Biomarkers in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B Without Inhibitors Receiving Prophylactic Marstacimab Treatment: Results From the Phase 3 BASIS Trial
1210 - Safety Biomarkers in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B Without Inhibitors Receiving Prophylactic Marstacimab Treatment: Results From the Phase 3 BASIS Trial
Taylor, D. M.
Taylor, I.
Taylor, J.
1821 - A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results
2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results
3679 - Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey
4333 - Clinical Application of Single-Cell MRD By Genotype and Phenotype in AML
2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results
3679 - Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey
4333 - Clinical Application of Single-Cell MRD By Genotype and Phenotype in AML
Taylor, K.
Taylor, L. J.
Taylor, L.
Taylor, M.
Taylor, N.
195 - Hematopoietic Stem Cells Supporting Fetal Erythropoiesis Are Differentially Regulated By Small and Large Ribosomal Subunits
680 - Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies
- Metabolism and Erythropoiesis (including metabolism, IDH mutations and relevance to MDS, sideroblastic anemia)
680 - Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies
- Metabolism and Erythropoiesis (including metabolism, IDH mutations and relevance to MDS, sideroblastic anemia)
Taylor, O. A.
4190 - Evaluation of Methotrexate Pharmacogenomic Variants to Predict Acute Neurotoxicity in Children with Acute Lymphoblastic Leukemia
2808.1 - A Children’s Oncology Group Clinical Trial of Long-Term Outcomes in Survivors of Down Syndrome-Associated Acute Leukemia (ALTE22C1): Clinical Trial in Progress
2808.1 - A Children’s Oncology Group Clinical Trial of Long-Term Outcomes in Survivors of Down Syndrome-Associated Acute Leukemia (ALTE22C1): Clinical Trial in Progress
Taylor, R.
Tazon, B.
Tazón-Vega, B.
Tbakhi, A.
Tchernonog, E.
1657 - 5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial
1856 - Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study
1856 - Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study
Tchinda, J.
Te, H. S.
403 - Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Myeloid Malignancies: A BMTSS Report
2338 - Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Lymphoid Malignancies: A BMTSS Report
5036 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Lymphoid Malignancies – a BMT Survivor Study (BMTSS)
5053 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Myeloid Malignancies – a BMT Survivor Study (BMTSS)
5146 - Self-Rated Health Is an Independent Predictor of Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Plasma Cell Disorders: A BMTSS Report
2338 - Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Lymphoid Malignancies: A BMTSS Report
5036 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Lymphoid Malignancies – a BMT Survivor Study (BMTSS)
5053 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Myeloid Malignancies – a BMT Survivor Study (BMTSS)
5146 - Self-Rated Health Is an Independent Predictor of Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Plasma Cell Disorders: A BMTSS Report
te Pas, B. M.
Te Vrugt, M.
Teachey, D. T.
1 - Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731
313 - Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma
315 - Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children’s Oncology Group (COG) Protocols
633 - The Role of an Inflammatory Phenotype in Driving Clonal Evolution in B-Acute Lymphoblastic Leukemia
634 - TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL
725 - Aberrant Stemness Transcription Signature Unveils a Mechanism of Chemotherapy Resistance through Blunting p53-Mediated Response in Acute Myeloid Leukemia
1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL
2813 - Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
2830 - A Non-Canonical Lymphoblast in Refractory Childhood T-Cell Acute Lymphoblastic Leukemia
2838 - Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages
3454 - Preinfusion Risk Factors for the Development of Severe Immune Effector Cell Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Infusion in Pediatric Patients
4195 - Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children's Oncology Group Protocols AALL0932 and AALL1131
313 - Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma
315 - Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children’s Oncology Group (COG) Protocols
633 - The Role of an Inflammatory Phenotype in Driving Clonal Evolution in B-Acute Lymphoblastic Leukemia
634 - TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL
725 - Aberrant Stemness Transcription Signature Unveils a Mechanism of Chemotherapy Resistance through Blunting p53-Mediated Response in Acute Myeloid Leukemia
1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL
2813 - Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
2830 - A Non-Canonical Lymphoblast in Refractory Childhood T-Cell Acute Lymphoblastic Leukemia
2838 - Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages
3454 - Preinfusion Risk Factors for the Development of Severe Immune Effector Cell Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Infusion in Pediatric Patients
4195 - Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children's Oncology Group Protocols AALL0932 and AALL1131
Teague, R.
Tebaldi, T.
Tedeschi, A.
73 - Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway
1009 - Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial
1869 - Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study
3013 - Ibrutinib or Chemo-Immunotherapy As Second Line Treatment in Waldenstrom Macroglobulinaemia? a Real-Life Multicentre Study
3254 - Initiating First-Line (1L) Fixed-Duration (FD) Ibrutinib and Venetoclax (Ibr+Ven) in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched General European Population
4412 - Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)
4621 - Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control Study
1009 - Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial
1869 - Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study
3013 - Ibrutinib or Chemo-Immunotherapy As Second Line Treatment in Waldenstrom Macroglobulinaemia? a Real-Life Multicentre Study
3254 - Initiating First-Line (1L) Fixed-Duration (FD) Ibrutinib and Venetoclax (Ibr+Ven) in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched General European Population
4412 - Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)
4621 - Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control Study
Tedeschi, J. G.
Tedone, E.
1471 - Real World Evidence of Efficacy of CPX-351 in Secondary Acute Myeloid Leukemia Defined According to Who 2022 Classification
1478 - High Risk Mutations in Critical Genes Do Not Significantly Affect Remission Rates and Minimal Residual Disease Clearance in Acute Myeloid Leukemia Patients Receiving CPX-351 Induction
1482 - Comparing Outcomes between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease
1574 - Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML
2891 - Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
1478 - High Risk Mutations in Critical Genes Do Not Significantly Affect Remission Rates and Minimal Residual Disease Clearance in Acute Myeloid Leukemia Patients Receiving CPX-351 Induction
1482 - Comparing Outcomes between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease
1574 - Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML
2891 - Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
Teegavarapu, P. S.
Tees, M. T.
467 - Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDACTM Degrader, in Patients with Non-Hodgkin’s Lymphoma
526 - Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2300 - Comparison of 15- Vs. 30-Day Remote Patient Monitoring for Outpatient Chimeric Antigen Receptor T-Cell Therapy (CAR-T) across a Large Health System
3734 - The Patient Journey and Treatment Outcomes Comparing Inpatient Versus Outpatient Axicabtagene Ciloleucel in Non-Hodgkin’s Lymphoma (NHL) - a Large, Multicenter Study
4398 - Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry
4422.1 - A Phase 1 Study of AC676, a Novel BTK Chimeric Degrader, in Patients with B-Cell Malignancies
526 - Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2300 - Comparison of 15- Vs. 30-Day Remote Patient Monitoring for Outpatient Chimeric Antigen Receptor T-Cell Therapy (CAR-T) across a Large Health System
3734 - The Patient Journey and Treatment Outcomes Comparing Inpatient Versus Outpatient Axicabtagene Ciloleucel in Non-Hodgkin’s Lymphoma (NHL) - a Large, Multicenter Study
4398 - Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry
4422.1 - A Phase 1 Study of AC676, a Novel BTK Chimeric Degrader, in Patients with B-Cell Malignancies
Teesink, S.
Teeter, J.
716 - Descriptive Characterization of Bleeding Events in Participants with Severe Hemophilia Α or B without Inhibitors, Receiving Prophylactic Marstacimab Treatment
1210 - Safety Biomarkers in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B Without Inhibitors Receiving Prophylactic Marstacimab Treatment: Results From the Phase 3 BASIS Trial
1210 - Safety Biomarkers in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B Without Inhibitors Receiving Prophylactic Marstacimab Treatment: Results From the Phase 3 BASIS Trial
Teferra, A.
2377 - Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers
3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
Tefferi, A.
244 - TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance
657 - A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia
1785 - Revised International Working Group Risk Model for Survival in Polycythemia Vera
1795 - Homozygosity of the JAK2 46/1 or GGCC Haplotype Contributes to Phenotype and Outcome Diversity Among Patients with Polycythemia Vera
1797 - The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates
1798 - Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials
1820 - Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)
1827 - Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
3169 - Monocytosis Is an Independent Risk Factor for Survival in Essential Thrombocythemia - a Revised Triple-a Prognostic Score (AAA+A) Based on Age and Absolute Monocyte, Neutrophil, and Lymphocyte Counts
3171 - Autoimmune or Inflammatory Diseases in 1,968 Consecutive Patients with Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcome and Co-Morbidities
3176 - Cytogenetic Abnormalities in Polycythemia Vera: Phenotypic Correlates and Prognostic Relevance in 669 Informative Cases
3183 - Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41MT Germline Predisposition Syndrome
3185 - Thrombosis Risk Assessment in Polycythemia Vera (TRAP): A 4,636-Patient-Year Analysis of Arterial and Venous Thrombosis in Low-Risk Patients
3204 - Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
3218 - PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
4552 - Cancers in Polycythemia Vera and Essential Thrombocythemia: A before and after Diagnosis Survey and Analysis of Risk Factors
4586 - PHF6 Mutation in Chronic Myelomonocytic Leukemia Is Associated with Chronic Thrombocytopenia and Predicts Superior Overall and Leukemia-Free Survival
4593 - Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)
4594 - TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
657 - A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia
1785 - Revised International Working Group Risk Model for Survival in Polycythemia Vera
1795 - Homozygosity of the JAK2 46/1 or GGCC Haplotype Contributes to Phenotype and Outcome Diversity Among Patients with Polycythemia Vera
1797 - The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates
1798 - Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials
1820 - Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)
1827 - Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
3169 - Monocytosis Is an Independent Risk Factor for Survival in Essential Thrombocythemia - a Revised Triple-a Prognostic Score (AAA+A) Based on Age and Absolute Monocyte, Neutrophil, and Lymphocyte Counts
3171 - Autoimmune or Inflammatory Diseases in 1,968 Consecutive Patients with Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcome and Co-Morbidities
3176 - Cytogenetic Abnormalities in Polycythemia Vera: Phenotypic Correlates and Prognostic Relevance in 669 Informative Cases
3183 - Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41MT Germline Predisposition Syndrome
3185 - Thrombosis Risk Assessment in Polycythemia Vera (TRAP): A 4,636-Patient-Year Analysis of Arterial and Venous Thrombosis in Low-Risk Patients
3204 - Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
3218 - PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
4552 - Cancers in Polycythemia Vera and Essential Thrombocythemia: A before and after Diagnosis Survey and Analysis of Risk Factors
4586 - PHF6 Mutation in Chronic Myelomonocytic Leukemia Is Associated with Chronic Thrombocytopenia and Predicts Superior Overall and Leukemia-Free Survival
4593 - Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)
4594 - TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
Tegels, S.
Tegnér, J.
Teh, B. S.
Teh, B. T.
Teh, C. H.
Teh, E.
Teichert, M.
2003 - Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma
4857 - Analysis of Early Apheresis Immunophenotype, Batch Data Variables and Clinical Outcomes for Optimization of CAR-T-Cell Therapy in Aggressive B-Cell Lymphomas
4857 - Analysis of Early Apheresis Immunophenotype, Batch Data Variables and Clinical Outcomes for Optimization of CAR-T-Cell Therapy in Aggressive B-Cell Lymphomas
Teichman, J.
Teichmann, L. L.
840 - Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation
961 - Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013
1766 - Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) – an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
961 - Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013
1766 - Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) – an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
Teipel, R.
493 - Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
2007 - Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis
2007 - Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis
Teitel, J. M.
1053 - Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial
3577 - Use of Fidanacogene Elaparvovec, a Gene Therapy Vector, to Deliver a Stable, Fully Functional Human Factor IX Transgene for the Treatment of Hemophilia B: A Combined Analysis of Safety
3634 - From Theory to Therapy: Evaluating Canadian Hemophilia Treatment Centres' Readiness for Gene Therapy Implementation
3577 - Use of Fidanacogene Elaparvovec, a Gene Therapy Vector, to Deliver a Stable, Fully Functional Human Factor IX Transgene for the Treatment of Hemophilia B: A Combined Analysis of Safety
3634 - From Theory to Therapy: Evaluating Canadian Hemophilia Treatment Centres' Readiness for Gene Therapy Implementation
Teixeira, D. E.
Tejada Vasquez, A. C.
Tejedor, A.
Tekkesin, F.
Tekle, C.
770 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study
2411e - Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis
3761 - Understanding Frontline Therapy Pattern, Attrition Rates and Survival Outcomes in Patients with Newly Diagnosed Multiple Myeloma Who Underwent Transplant
5138 - Frontline Treatment Patterns and Outcomes in Patients with Newly Diagnosed Multiple Myeloma Who Did Not Undergo Transplant: A US Electronic Health Records Database Analysis
2411e - Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis
3761 - Understanding Frontline Therapy Pattern, Attrition Rates and Survival Outcomes in Patients with Newly Diagnosed Multiple Myeloma Who Underwent Transplant
5138 - Frontline Treatment Patterns and Outcomes in Patients with Newly Diagnosed Multiple Myeloma Who Did Not Undergo Transplant: A US Electronic Health Records Database Analysis
Tekrane, R.
Telange, R.
Telen, M. J.
174 - Molecular Mechanism Underlying Excessive Phosphatidylserine Exposure in Sickle Red Blood Cells and Potential Therapeutics
179 - Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks
1110 - Novel Loci Associated with Acute Chest Syndrome in Sickle Cell Disease Patients
2512 - A Phase 2 Prospective Randomized Trial of Topical Sodium Nitrite in Patients with Sickle Cell Disease and Leg Ulcers
179 - Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks
1110 - Novel Loci Associated with Acute Chest Syndrome in Sickle Cell Disease Patients
2512 - A Phase 2 Prospective Randomized Trial of Topical Sodium Nitrite in Patients with Sickle Cell Disease and Leg Ulcers
Telenius, A.
Telfer, P.
522 - Enhanced Artificial Intelligence (AI)-Driven Prediction of Vaso-Occlusive Crises in Sickle Cell Disease: Precision through Advanced Machine-Learning Frameworks and Digital Remote Monitoring
4954 - Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease
5071 - Comparison of Sickle Cell Disease Patient Experiences in Developed and Developing Countries: Insights from UK and India Patient Cohorts
5072 - A Virtual Hospital Approach in Sickle Cell Disease | Remote Biometric, Quality of Life, and Hospitalisations Monitoring
4954 - Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease
5071 - Comparison of Sickle Cell Disease Patient Experiences in Developed and Developing Countries: Insights from UK and India Patient Cohorts
5072 - A Virtual Hospital Approach in Sickle Cell Disease | Remote Biometric, Quality of Life, and Hospitalisations Monitoring
Tella, K.
Tellechea, M. F.
Téllez, A.
Telpoukhovskaia, M. A.
Tembhare, P.
852 - Machine Learning Identifies Gene Mutations and Variant Allele Fractions That Refine the 2022 European Leukemianet Risk Stratification for Acute Myeloid Leukemia
1550 - Prognostic Significance of Wilms’ Tumor 1 Gene Mutations in Acute Myeloid Leukemia: Risk Stratification and Survival Outcomes
2931 - Double Trouble: Composite Mutations in Driver Genes in Acute Myeloid Leukemia (AML)
2953 - Leukemic Stem Cell Measurable Residual Disease (LSC MRD) Status Is a Better Predictor of Relapse Than Multiparametric Flowcytometric Analysis in Acute Myeloid Leukemia Patients
4290 - Mutational Landscape and Factors Affecting Prognosis in Acute Myeloid Leukaemia (AML) with RUNX1::RUNX1T1
4310 - Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia (AML)
1550 - Prognostic Significance of Wilms’ Tumor 1 Gene Mutations in Acute Myeloid Leukemia: Risk Stratification and Survival Outcomes
2931 - Double Trouble: Composite Mutations in Driver Genes in Acute Myeloid Leukemia (AML)
2953 - Leukemic Stem Cell Measurable Residual Disease (LSC MRD) Status Is a Better Predictor of Relapse Than Multiparametric Flowcytometric Analysis in Acute Myeloid Leukemia Patients
4290 - Mutational Landscape and Factors Affecting Prognosis in Acute Myeloid Leukaemia (AML) with RUNX1::RUNX1T1
4310 - Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia (AML)
Temel, J. S.
117 - Multi-Site Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Receiving Non-Intensive Therapy
5056 - Factors Associated with Early Quality of Life Response to Palliative Care during Hematopoietic Cell Transplantation
5056 - Factors Associated with Early Quality of Life Response to Palliative Care during Hematopoietic Cell Transplantation
Temple, M.
Templé, M.
Templin, M.
Ten Cate, H.
1235 - Markers of Activated Coagulation Factor XII Are Inversely Associated with Progression of Atrial Fibrillation in the Race V Study
1246 - Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation
2602 - Interpreting High Levels of Unfolded Von Willebrand Factor in Patients with the Antiphospholipid Syndrome
1246 - Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation
2602 - Interpreting High Levels of Unfolded Von Willebrand Factor in Patients with the Antiphospholipid Syndrome
Ten Hacken, E.
758 - Impaired Response to Oxidative DNA Damage Underlies Genomic Instability in B-Cell Leukemia Driven By RPS15 Mutation
761 - Polyfunctional Effector PD-1+ CD8+ T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models
4610 - Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTKC481S-Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia
761 - Polyfunctional Effector PD-1+ CD8+ T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models
4610 - Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTKC481S-Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia
ten Hoeve, J.
Tendler, C.
Tenen, D. G.
Teng, G.
Teng, Z.
Tentori, C. A.
105 - Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)
665 - Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
2221 - A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
3597 - The “David Vs Goliath” Study: Application of Large Language Models (LLM) for Automatic Medical Information Retrieval from Multiple Data Sources to Accelerate Clinical and Translational Research in Hematology
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
4981 - Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
665 - Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
2221 - A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
3597 - The “David Vs Goliath” Study: Application of Large Language Models (LLM) for Automatic Medical Information Retrieval from Multiple Data Sources to Accelerate Clinical and Translational Research in Hematology
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
4981 - Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
Teodorescu, P.
Teofili, L.
Teoh, J.
Teoh, P. J.
Ter Borg, M.
Teramachi, J.
Teramo, A.
Terashima, M.
Terauchi, T.
Tercero-Mora Rodriguez, M. T.
Terenteva, A.
Terhune, S.
Terlizzi, S.
82 - Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score
4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials
5153 - Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study
4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials
5153 - Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study
Termanini, A.
Termini, R.
Terol, M. J.
988 - Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study
1642 - Zanubrutinib Is Effective in the Treatment of Patients with Waldenström's Macroglobulinemia and Bing-Neel Syndrome: A Retrospective Multicenter Study
1642 - Zanubrutinib Is Effective in the Treatment of Patients with Waldenström's Macroglobulinemia and Bing-Neel Syndrome: A Retrospective Multicenter Study
Terpos, E.
361 - Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study
487 - Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study
490 - A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma
1020 - Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
1600 - Genomic Characterization of Ibrutinib-Resistant Waldenström’s Macroglobulinemia
1603 - The Combined Treatment of Btkis with Venetoclax Exhibits an Enhanced Therapeutic Effect on Waldenström Macroglobulinemia Cells Bearing CXCR4 Mutations
1948 - Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients
1991 - Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group
3285 - Circular RNA Profiling Using High-Accuracy Long-Read Nanopore Sequencing of Multiple Myeloma Cell Lines Reveals the Wide Diversity of the Circular Transcriptome
3343 - Evaluation of the Safety and Efficacy of Denosumab in Patients with Multiple Myeloma and Severe Renal Impairment; Results from an IMWG Bone Subcommittee Study
3361 - Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group
3380 - Less Is More: Deciphering the Association between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma
4397 - Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom’s Macroglobulinemia Treated with Different Regimens in the Real-World Setting
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
4674 - Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis
4675 - Risk and Patterns of Progression Among Smoldering Myeloma Patients after the Implementation of New Criteria and Modern Imaging
4694 - Measurable Residual Disease and Peripheral Residual Disease to Assess Treatment Response in Real-World Patients with Newly Diagnosed Multiple Myeloma
4696 - Evaluating Minimal Residual Disease Negativity As a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
4715 - Sequential Whole Body Low Dose CTs in Patients with Smoldering Multiple Myeloma Identify Early Progression and May Improve Patient Outcomes
4724 - Early Treatment Response Assessment with Sequential Whole Body Magnetic Resonance Imaging in Patients with Newly Diagnosed Multiple Myeloma
487 - Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study
490 - A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma
1020 - Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
1600 - Genomic Characterization of Ibrutinib-Resistant Waldenström’s Macroglobulinemia
1603 - The Combined Treatment of Btkis with Venetoclax Exhibits an Enhanced Therapeutic Effect on Waldenström Macroglobulinemia Cells Bearing CXCR4 Mutations
1948 - Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients
1991 - Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group
3285 - Circular RNA Profiling Using High-Accuracy Long-Read Nanopore Sequencing of Multiple Myeloma Cell Lines Reveals the Wide Diversity of the Circular Transcriptome
3343 - Evaluation of the Safety and Efficacy of Denosumab in Patients with Multiple Myeloma and Severe Renal Impairment; Results from an IMWG Bone Subcommittee Study
3361 - Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group
3380 - Less Is More: Deciphering the Association between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma
4397 - Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom’s Macroglobulinemia Treated with Different Regimens in the Real-World Setting
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
4674 - Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis
4675 - Risk and Patterns of Progression Among Smoldering Myeloma Patients after the Implementation of New Criteria and Modern Imaging
4694 - Measurable Residual Disease and Peripheral Residual Disease to Assess Treatment Response in Real-World Patients with Newly Diagnosed Multiple Myeloma
4696 - Evaluating Minimal Residual Disease Negativity As a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
4715 - Sequential Whole Body Low Dose CTs in Patients with Smoldering Multiple Myeloma Identify Early Progression and May Improve Patient Outcomes
4724 - Early Treatment Response Assessment with Sequential Whole Body Magnetic Resonance Imaging in Patients with Newly Diagnosed Multiple Myeloma
Terragna, C.
Terral, W. H.
Terrazzano, G.
Terre, A.
Terrell, D. R.
1186 - Variation in Diagnostic Evaluation Patterns for Pediatric Evans Syndrome: Survey Results from the Pediatric ITP Consortium of North America (ICON)
3704 - Impact of Hospital-Acquired Venous Thromboembolism on Surviving Medical Admission: Findings from the Medical Inpatient Thrombosis and Hemostasis Study
5202 - "It Was Bootstrap All the Way": Exploring the Barriers and Facilitators to the Development of Non-Hematology Sickle Cell Disease Experts in the United States
3704 - Impact of Hospital-Acquired Venous Thromboembolism on Surviving Medical Admission: Findings from the Medical Inpatient Thrombosis and Hemostasis Study
5202 - "It Was Bootstrap All the Way": Exploring the Barriers and Facilitators to the Development of Non-Hematology Sickle Cell Disease Experts in the United States
Terriou, L.
302 - Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study
1329 - Hematological Landscape of Adult Patients with Diamond-Blackfan Anaemia Syndrome (DBAS): Results from the French DBA Cohort
1329 - Hematological Landscape of Adult Patients with Diamond-Blackfan Anaemia Syndrome (DBAS): Results from the French DBA Cohort
Terriou, L.
1321 - Efficacy and Safety of Pegcetacoplan in PNH Patients with Extra-Vascular Hemolysis Under Anti-C5: The Real-Life Experience of the National French Reference Center
3840 - Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)
3840 - Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)
Terse, V.
852 - Machine Learning Identifies Gene Mutations and Variant Allele Fractions That Refine the 2022 European Leukemianet Risk Stratification for Acute Myeloid Leukemia
1550 - Prognostic Significance of Wilms’ Tumor 1 Gene Mutations in Acute Myeloid Leukemia: Risk Stratification and Survival Outcomes
2931 - Double Trouble: Composite Mutations in Driver Genes in Acute Myeloid Leukemia (AML)
4290 - Mutational Landscape and Factors Affecting Prognosis in Acute Myeloid Leukaemia (AML) with RUNX1::RUNX1T1
4310 - Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia (AML)
1550 - Prognostic Significance of Wilms’ Tumor 1 Gene Mutations in Acute Myeloid Leukemia: Risk Stratification and Survival Outcomes
2931 - Double Trouble: Composite Mutations in Driver Genes in Acute Myeloid Leukemia (AML)
4290 - Mutational Landscape and Factors Affecting Prognosis in Acute Myeloid Leukaemia (AML) with RUNX1::RUNX1T1
4310 - Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia (AML)
Teruel, A.
Terui, Y.
Terzi Di Bergamo, L.
73 - Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway
762 - Prevalence and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Chronic Lymphocytic Leukemia and Richter Transformation
854 - A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
1367 - Mouse Model of Splenic Marginal Zone Lymphoma to Decipher the Pathogenetic Implications of NOTCH2 and KLF2 Mutations
1578 - Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma: Clinical and Molecular Correlations
2960 - Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma
2980 - Integration of [18f]FDG-PET Radiomics with Liquid Biopsy Improves Outcome Prediction in Newly Diagnosed DLBCL Patients
4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study
762 - Prevalence and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Chronic Lymphocytic Leukemia and Richter Transformation
854 - A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
1367 - Mouse Model of Splenic Marginal Zone Lymphoma to Decipher the Pathogenetic Implications of NOTCH2 and KLF2 Mutations
1578 - Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma: Clinical and Molecular Correlations
2960 - Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma
2980 - Integration of [18f]FDG-PET Radiomics with Liquid Biopsy Improves Outcome Prediction in Newly Diagnosed DLBCL Patients
4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study
Tesakov, I.
Teschemaker, A.
5105 - Real-World Bleeding Risk, Outcomes and Treatment Patterns of Patients with CLL/SLL Receiving BTKi with or without Prescription Anticoagulants or Antiplatelets
5109 - Real-World Risk of Major Bleeding Events in BTKi-Treated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
5109 - Real-World Risk of Major Bleeding Events in BTKi-Treated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Teschner, D.
708 - Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Real-World Multi-Center Study from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
3554 - Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group
4688 - Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy
3554 - Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group
4688 - Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy
Tesfaye, F.
Teshima, T.
260 - Gvhd-Induced Inflammatory Memory in Intestinal Stem Cells Enhances IFN-y-Induced Antigen Presentation and Apoptosis of Intestinal Epithelial Cells
384 - Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC
902 - Ropeginterferon Alfa-2b Induces Apoptosis and Differentiation of Leukemia Stem Cells and Separates GVL Effects from Gvhd after Allogeneic Hematopoietic Cell Transplantation
903 - Early Initiation of Calcineurin Inhibitor Induces CD8+ Transitory Exhausted-like and CD4+ Cytotoxic T Cells, Maintaining Responsiveness to PD-1 Blockade and Contributing to the Development of Chronic Gvhd after Post-Transplant Cyclophosphamide
2930 - Combination of Low White Blood Cell Count and Impaired Renal Function Is a Risk Factor for Higher Concentrations of Venetoclax and Prolonged Neutropenia in AML Patients with Venetoclax Combined Regimen: Real World Experience in the Japanese Cohort
3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
3096 - Reduced FDG Uptake in the Brain on Baseline 18FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Intravascular Large B-Cell Lymphoma and Advanced-Stage Diffuse Large B-Cell Lymphoma
- Firing Up COLD Tumor Microenvironment to Facilitate GVL
384 - Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC
902 - Ropeginterferon Alfa-2b Induces Apoptosis and Differentiation of Leukemia Stem Cells and Separates GVL Effects from Gvhd after Allogeneic Hematopoietic Cell Transplantation
903 - Early Initiation of Calcineurin Inhibitor Induces CD8+ Transitory Exhausted-like and CD4+ Cytotoxic T Cells, Maintaining Responsiveness to PD-1 Blockade and Contributing to the Development of Chronic Gvhd after Post-Transplant Cyclophosphamide
2930 - Combination of Low White Blood Cell Count and Impaired Renal Function Is a Risk Factor for Higher Concentrations of Venetoclax and Prolonged Neutropenia in AML Patients with Venetoclax Combined Regimen: Real World Experience in the Japanese Cohort
3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
3096 - Reduced FDG Uptake in the Brain on Baseline 18FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Intravascular Large B-Cell Lymphoma and Advanced-Stage Diffuse Large B-Cell Lymphoma
- Firing Up COLD Tumor Microenvironment to Facilitate GVL
Tesi, B.
Teske, R.
218 - 10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years
308 - Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial
308 - Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial
Tesone, J.
Tessier, S.
Tessoulin, B.
239 - Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group
745 - Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial
853 - Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling
1657 - 5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial
3110 - Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial
4360 - Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network
4497 - Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy
745 - Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial
853 - Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling
1657 - 5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial
3110 - Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial
4360 - Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network
4497 - Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy
Testa, E. R.
Testa, G.
Testoni, N.
Tetard, M.
Tetenborg, L.
Tetens, A. R.
Tettamanti, M.
Tettamanti, S.
Tettamanti, S.
Tettero, J. M.
Tewari, P.
Tewari, S.
Tewari, S. O.
Tews, D.
Texeira, S.
Tezal, D.
Tezuka, K.
Tfaily, M. A.
Thabane, L.
Thachil, J.
Thacker, E.
Thackray, K.
Thadi, A.
Thakar, H. L.
Thakar, M.
Thakkar, A.
Thakkar, D.
Thakkar, S.
Thakkar, Y.
Thakker, D.
Thakoerdin, S. R.
Thakore, M.
Thakur, S.
Thakurta, A.
1909 - A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data
2525 - Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis
2527 - KLF5 Is a Key Regulator of IMiD-Induced Neutropenia
3333 - Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial
2525 - Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis
2527 - KLF5 Is a Key Regulator of IMiD-Induced Neutropenia
3333 - Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial
Thalambedu, N.
Thalji, N. K.
Thamake, S.
997 - Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial
1825 - Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)
4591 - Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial
3228.1 - Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)
1825 - Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)
4591 - Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial
3228.1 - Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)
Than, H.
3529 - Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies
3678 - Modified Delphi Process to Develop Best Practice Recommendations for Myelofibrosis Management in Routine Clinical Practice in the Asia-Pacific Region (The APAC-MF Alliance)
3678 - Modified Delphi Process to Develop Best Practice Recommendations for Myelofibrosis Management in Routine Clinical Practice in the Asia-Pacific Region (The APAC-MF Alliance)
Thanarajasingam, G.
387 - Feasibility of Multi-Modal Physical Function Data Collection to Assess Treatment Tolerability in Patients with Lymphoma
580 - A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma
2299 - Incorporating Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) into Dose Review in a Phase I Clinical Trial
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
3019 - Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients
1661.3 - Trial in Progress – Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma
580 - A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma
2299 - Incorporating Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) into Dose Review in a Phase I Clinical Trial
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
3019 - Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients
1661.3 - Trial in Progress – Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma
Thandapani, P.
Thanekar, U.
Thanendrarajan, S.
254 - Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)
256 - Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
1904 - The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
1937 - Identification of Risk Factors for Myeloma Progression in African American Patients
2405 - Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience
3781 - Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort
3789 - Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma
4676 - Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
4713 - Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
4726 - Impact of Additional Chromosome 1q Copies on Multiple Myeloma Survival Outcomes
4729 - Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages
256 - Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
1904 - The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
1937 - Identification of Risk Factors for Myeloma Progression in African American Patients
2405 - Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience
3781 - Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort
3789 - Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma
4676 - Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
4713 - Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
4726 - Impact of Additional Chromosome 1q Copies on Multiple Myeloma Survival Outcomes
4729 - Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages
Thangaraj, J. L.
Thangavadivel, S.
Thangavel, S.
Thangwaritorn, P.
Thani, N.
Thanneeru, P.
Thao, L. T. P.
303 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial
1318 - Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia
1318 - Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia
Thapa, B.
Thapa, S. B.
3021 - Clinical Characteristics and Outcomes of Patients with MYD88 Positive Waldenström Macroglobulinemia: A Single Center Retrospective Analysis
3784 - Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma
4392 - Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis
4740 - Activity and Safety of Venetoclax (VEN)-Based Treatment in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM)
3784 - Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma
4392 - Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis
4740 - Activity and Safety of Venetoclax (VEN)-Based Treatment in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM)
Thapar, M.
Tharakan, S.
Tharmaseelan, H.
Tharwat, M.
Thastrup, M.
Thatavarty, A.
Thatcher, E.
Thatcher, E.
Thavarajah, T.
Thaw Dar, N. N.
Thaw, K. H.
1788 - QRISK3: A New Marker for Thrombotic Events in Essential Thrombocythemia and Polycythemia Vera at Diagnosis and during Follow up
1804 - Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort
4547 - Rapid and Sustained Recovery of Cellular Immunity in Patients with Myelofibrosis on Momelotinib Therapy
1804 - Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort
4547 - Rapid and Sustained Recovery of Cellular Immunity in Patients with Myelofibrosis on Momelotinib Therapy
Thaxton, M. L.
Thaya, L.
Thayyil, A.
The, P.
Thein, S. L.
177 - A Machine Learning-Based Workflow for Predicting Transplant Outcome in Patients with Sickle Cell Disease
800 - The Amyloidogenic Transthyretin V122I Variant Increase Severity of Cardiac Phenotype and Mortality in Sickle Cell Disease
2485 - Acquired Mutations in the Mitochondrial Genome As Prognostic Markers in Sickle Cell Disease
2490 - 8-Oxoguanine DNA Glycosylase 1 Recruits Transcription Factor STAT1 to Promote the Inflammatory Responses in Sickle Cell Disease
2491 - Mitapivat-Induced Improvements in RBC Deformability and Membrane Integrity in Patients with Sickle Cell Disease Are Sustained during Extended Therapy
2513 - Duffy Status and Hydroxyurea Dosing in Adult Patients with Sickle Cell Disease: A Potential for Iatrogenic Harm?
1143.1 - A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with Stable Sickle Cell Disease: Trial in Progress
800 - The Amyloidogenic Transthyretin V122I Variant Increase Severity of Cardiac Phenotype and Mortality in Sickle Cell Disease
2485 - Acquired Mutations in the Mitochondrial Genome As Prognostic Markers in Sickle Cell Disease
2490 - 8-Oxoguanine DNA Glycosylase 1 Recruits Transcription Factor STAT1 to Promote the Inflammatory Responses in Sickle Cell Disease
2491 - Mitapivat-Induced Improvements in RBC Deformability and Membrane Integrity in Patients with Sickle Cell Disease Are Sustained during Extended Therapy
2513 - Duffy Status and Hydroxyurea Dosing in Adult Patients with Sickle Cell Disease: A Potential for Iatrogenic Harm?
1143.1 - A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with Stable Sickle Cell Disease: Trial in Progress
Theiss, F.
Thelen, M.
Themeli, M.
Theobald, M.
152 - The Transcriptional Activators p300/Crebbp Are Context-Dependent Functional Repressors of Interferon Genes, Offering Therapeutic Promise in AML
206 - Synergistic Efficacy of Dual Menin and PRMT5 Targeting Against NPM1 mutated and KMT2A-rearranged Leukemia
722 - Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation
2536 - Deep Cellular and Molecular Characterization Reveal a Distinct Phenotype and Metabolic Signature of Human Senescent CD8+ T Cells: Implication for Cancer Cellular Therapy
3444 - Dual Inhibition of Histone and DNA Methylation in AML Enhances the Effectiveness of TCR-Based Cellular Therapy through Upregulation of Surface MHC Class I/p53 Antigen Complex
206 - Synergistic Efficacy of Dual Menin and PRMT5 Targeting Against NPM1 mutated and KMT2A-rearranged Leukemia
722 - Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation
2536 - Deep Cellular and Molecular Characterization Reveal a Distinct Phenotype and Metabolic Signature of Human Senescent CD8+ T Cells: Implication for Cancer Cellular Therapy
3444 - Dual Inhibition of Histone and DNA Methylation in AML Enhances the Effectiveness of TCR-Based Cellular Therapy through Upregulation of Surface MHC Class I/p53 Antigen Complex
Theodorakakou, F.
361 - Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study
490 - A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma
889 - Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis
1017 - Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants
1020 - Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
1927 - Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network
1934 - Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)
1948 - Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients
1979 - Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
1991 - Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group
3328 - An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response
3361 - Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group
3380 - Less Is More: Deciphering the Association between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma
4397 - Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom’s Macroglobulinemia Treated with Different Regimens in the Real-World Setting
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
4674 - Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis
4675 - Risk and Patterns of Progression Among Smoldering Myeloma Patients after the Implementation of New Criteria and Modern Imaging
4724 - Early Treatment Response Assessment with Sequential Whole Body Magnetic Resonance Imaging in Patients with Newly Diagnosed Multiple Myeloma
490 - A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma
889 - Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis
1017 - Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants
1020 - Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
1927 - Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network
1934 - Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)
1948 - Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients
1979 - Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
1991 - Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group
3328 - An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response
3361 - Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group
3380 - Less Is More: Deciphering the Association between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma
4397 - Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom’s Macroglobulinemia Treated with Different Regimens in the Real-World Setting
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
4674 - Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis
4675 - Risk and Patterns of Progression Among Smoldering Myeloma Patients after the Implementation of New Criteria and Modern Imaging
4724 - Early Treatment Response Assessment with Sequential Whole Body Magnetic Resonance Imaging in Patients with Newly Diagnosed Multiple Myeloma
Theodoropoulos, J.
Theoharaki, K.
Theologi, O.
Theoret, M. R.
1829 - Response Rate, Event-Free Survival (EFS), and Overall Survival in Higher-Risk Myelodysplastic Syndromes (MDS): U.S. Food and Drug Administration (FDA) Trial-Level and Patient-Level Analyses
1907 - Novel T-Cell Receptor Signature Linked to Plasma Cell Dyscrasias
2416 - FDA Analysis of Enrollment of Pediatric and AYA Patients in Clinical Trials By Race and Ethnicity
3806 - FDA Analysis of Race and Ethnic Enrollment of Clinical Trials for Drug Registration in Adult Patients for Leukemia and Myelodysplastic Syndrome
1907 - Novel T-Cell Receptor Signature Linked to Plasma Cell Dyscrasias
2416 - FDA Analysis of Enrollment of Pediatric and AYA Patients in Clinical Trials By Race and Ethnicity
3806 - FDA Analysis of Race and Ethnic Enrollment of Clinical Trials for Drug Registration in Adult Patients for Leukemia and Myelodysplastic Syndrome
Thepot, S.
349 - Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial
1826 - A Phase 2 Prospective Study Evaluating Low-Dose Deferasirox in Patients with Low-Risk Myelodysplastic Syndrome Resistant or Relapsing after Erythropoietin Stimulating Agents (LODEFI)
1826 - A Phase 2 Prospective Study Evaluating Low-Dose Deferasirox in Patients with Low-Risk Myelodysplastic Syndrome Resistant or Relapsing after Erythropoietin Stimulating Agents (LODEFI)
Thépot, S.
351 - Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA - Results of the Phase 1-2 Part a of the GFM Combola Study
352 - Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes
1839 - Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups
4590 - Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents
352 - Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes
1839 - Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups
4590 - Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents
Theprungsirikul, P.
Theriot, J.
Therwhanger, D.
238 - Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis
3009 - Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma
3009 - Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma
Thet, W. S.
Theunissen, K.
Theurich, S.
895 - Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
3322 - Symptomatic Progression Free Survival (SPFS): A New Endpoint for Multiple Myeloma (MM) Combining Patient-Reported Outcomes (PROs) and Progression-Free Survival (PFS)
3918 - L-Asparaginase Treatment Induces Reversible Immunoregulatory and Immunosuppressive Effects in Non-Malignant B Cells in a Model of T-Cell Dependent B Cell Activation
3322 - Symptomatic Progression Free Survival (SPFS): A New Endpoint for Multiple Myeloma (MM) Combining Patient-Reported Outcomes (PROs) and Progression-Free Survival (PFS)
3918 - L-Asparaginase Treatment Induces Reversible Immunoregulatory and Immunosuppressive Effects in Non-Malignant B Cells in a Model of T-Cell Dependent B Cell Activation
Thévenet, U.
Thévenet, U.
846 - Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group
1475 - Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group
3564 - Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group
4335 - Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group
1475 - Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group
3564 - Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group
4335 - Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group
Theves, F.
Thiagarajan, P.
31 - Genetic Determinants of Hypercoagulability in Complement and Hemostatic Systems Shape the Thrombotic Risk of Paroxysmal Nocturnal Hemoglobinuria
35 - First Results of High Throughput Pipeline for Serotypic and TCR Clonotypic Specificities in Aplastic Anemia and Large Granular Lymphocyte Leukemia Uncovering Antigenic Peptides Relevant to Disease Etiology
1254 - Budd-Chiari Syndrome: Pathogenetic Factors and Completeness of Screening for Paroxysmal Nocturnal Hemoglobinuria
1688 - Low-Count T-/NK-Large Granular Lymphocytic Leukemia: A Nosologically Distinct Disease Subtype at the Crossroads between Lymphoproliferation, Autoimmunity and Immunodeficiency
4084 - An Immunogenetic Perspective on Bone Marrow Failure Syndromes: The KIR-HLA System
4085 - Counterpoising Immune Pressure and Privilege: Paroxysmal Nocturnal Hemoglobinuria Evolutionary Dynamics
4980 - Novel Machine Learning Approaches Tailored to Protein Configuration Predict Drug Vulnerabilities in Myeloid Neoplasia
35 - First Results of High Throughput Pipeline for Serotypic and TCR Clonotypic Specificities in Aplastic Anemia and Large Granular Lymphocyte Leukemia Uncovering Antigenic Peptides Relevant to Disease Etiology
1254 - Budd-Chiari Syndrome: Pathogenetic Factors and Completeness of Screening for Paroxysmal Nocturnal Hemoglobinuria
1688 - Low-Count T-/NK-Large Granular Lymphocytic Leukemia: A Nosologically Distinct Disease Subtype at the Crossroads between Lymphoproliferation, Autoimmunity and Immunodeficiency
4084 - An Immunogenetic Perspective on Bone Marrow Failure Syndromes: The KIR-HLA System
4085 - Counterpoising Immune Pressure and Privilege: Paroxysmal Nocturnal Hemoglobinuria Evolutionary Dynamics
4980 - Novel Machine Learning Approaches Tailored to Protein Configuration Predict Drug Vulnerabilities in Myeloid Neoplasia
Thibaud, S.
357 - Combined PD-1 and Tim-3 Blockade Improves the in Vitro Anti-Myeloma Activity of T Cells of Patients on Talquetamab
3329 - Delayed Neutrophil Recovery Following BCMA-Directed CAR-T Correlates with Poor Outcomes and Is Associated with a Cytokine Signature of Persistent Inflammation and T Cell Checkpoint Activation
3329 - Delayed Neutrophil Recovery Following BCMA-Directed CAR-T Correlates with Poor Outcomes and Is Associated with a Cytokine Signature of Persistent Inflammation and T Cell Checkpoint Activation
Thibaud, S.
Thibodeau, J.
Thibult, M. L.
Thiebaut, A.
Thieblemont, C.
239 - Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group
474 - Post-Therapeutic Tumor Losses of B-Cell Receptor Components CD20/CD19, a New Challenge in the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
575 - Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa
577 - Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma
867 - Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
1596 - Predictive Power of Early, Sequential Minimal Residual Disease and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Monitoring in Young Patients with Mantle Cell Lymphoma in the Lyma Trial: A Lysa Study
3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
3110 - Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial
3115 - Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)
3124 - CAR T-Cells Treatment for Relapsed/Refractory B-Cell Lymphoma Is Effective and Safe in People Living with HIV (PLWH): A Lysa Study from the Descar-T Registry
3241 - Prognosis of the IGLV3-21R110 Mutation in a Real-Life Chronic Lymphocytic Leukemia Cohort
3256 - Preemptive Therapy with Venetoclax for High-Risk Stage a CLL Patients: First Analysis of Prevene, a Phase II Trial of the Filo Group
4467 - Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B Lysa Trials
4480 - 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma
4491 - Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy
4505 - Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial
474 - Post-Therapeutic Tumor Losses of B-Cell Receptor Components CD20/CD19, a New Challenge in the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
575 - Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa
577 - Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma
867 - Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
1596 - Predictive Power of Early, Sequential Minimal Residual Disease and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Monitoring in Young Patients with Mantle Cell Lymphoma in the Lyma Trial: A Lysa Study
3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
3110 - Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial
3115 - Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)
3124 - CAR T-Cells Treatment for Relapsed/Refractory B-Cell Lymphoma Is Effective and Safe in People Living with HIV (PLWH): A Lysa Study from the Descar-T Registry
3241 - Prognosis of the IGLV3-21R110 Mutation in a Real-Life Chronic Lymphocytic Leukemia Cohort
3256 - Preemptive Therapy with Venetoclax for High-Risk Stage a CLL Patients: First Analysis of Prevene, a Phase II Trial of the Filo Group
4467 - Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B Lysa Trials
4480 - 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma
4491 - Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy
4505 - Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial
Thieblemont, C.
1734 - Immune Biomarkers of Mechanism of Action of Epcoritamab (Epcor) Plus Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) in Frontline DLBCL
2349 - Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2349 - Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Thiede, C.
218 - 10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years
1057 - Synthetic Bone Marrow Smears Are a Privacy-Preserving Substitute for Developing Accurate Leukemia Classification Models in Hematological Microscopy
2211 - Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients
2690 - Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
1057 - Synthetic Bone Marrow Smears Are a Privacy-Preserving Substitute for Developing Accurate Leukemia Classification Models in Hematological Microscopy
2211 - Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients
2690 - Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
Thiede, C.
2948 - HLA‑DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD
1527.1 - Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML – the SAL/AMLCG Vincent Trial
1527.1 - Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML – the SAL/AMLCG Vincent Trial
Thiele Orberg, E.
Thiele-Orberg, E.
264 - Immunomodulatory Microbial Metabolites Protect Against Graft-Vs-Host Disease and Enhance Anti-Leukemia Responses in Mice and Patients Receiving Stem Cell Transplantation
4904 - Loss of Microbiota-Derived Metabolites Is Associated with Mucosal-Barrier-Injury Bloodstream Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
4904 - Loss of Microbiota-Derived Metabolites Is Associated with Mucosal-Barrier-Injury Bloodstream Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Thielecke, L.
Thielen, N.
Thienel, U.
Thillaye-Kerr, R.
Thimm, A.
Thirman, M. J.
211 - Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia
1432 - Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
1452 - Targeting Menin in T-Lineage Acute Lymphoblastic Leukemia
1432 - Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
1452 - Targeting Menin in T-Lineage Acute Lymphoblastic Leukemia
Thirumaran, R.
Thirumurthi, S.
Thiruneelakantapillai, L.
Thiruvengadam, N.
2276 - The Clinical Impact and Cost-Effectiveness of PET-Based and Ctdna-Based Evaluation at End-of-Therapy after Frontline Treatment of DLBCL
3638 - Serious Adverse Drug Reactions (sADRs) Involving Hematology and Resulting in Black Box Warnings or FDA Non-Approval: Results from the First Quarter Century of RADAR/Sonar
3638 - Serious Adverse Drug Reactions (sADRs) Involving Hematology and Resulting in Black Box Warnings or FDA Non-Approval: Results from the First Quarter Century of RADAR/Sonar
Thiruvengadam, S. K.
470 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
524 - Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma
526 - Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
1668 - Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma – International, Multi-Center Real-World Experience
1729 - Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma
2276 - The Clinical Impact and Cost-Effectiveness of PET-Based and Ctdna-Based Evaluation at End-of-Therapy after Frontline Treatment of DLBCL
3127 - Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease
3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
3638 - Serious Adverse Drug Reactions (sADRs) Involving Hematology and Resulting in Black Box Warnings or FDA Non-Approval: Results from the First Quarter Century of RADAR/Sonar
3654 - Changes in Treatment Patterns over Time Among Real-World Patients with Follicular Lymphoma at Predominantly Community Facilities in the US
1674.1 - Trial in Progress: Open-Label Phase 1 Study to Evaluate Safety of SGN-35C in Adults with Select Relapsed/Refractory Lymphomas (SGN35C-001)
1742.1 - A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
524 - Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma
526 - Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
1668 - Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma – International, Multi-Center Real-World Experience
1729 - Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma
2276 - The Clinical Impact and Cost-Effectiveness of PET-Based and Ctdna-Based Evaluation at End-of-Therapy after Frontline Treatment of DLBCL
3127 - Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease
3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
3638 - Serious Adverse Drug Reactions (sADRs) Involving Hematology and Resulting in Black Box Warnings or FDA Non-Approval: Results from the First Quarter Century of RADAR/Sonar
3654 - Changes in Treatment Patterns over Time Among Real-World Patients with Follicular Lymphoma at Predominantly Community Facilities in the US
1674.1 - Trial in Progress: Open-Label Phase 1 Study to Evaluate Safety of SGN-35C in Adults with Select Relapsed/Refractory Lymphomas (SGN35C-001)
1742.1 - A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Thivaios, G.
Thol, F. R.
844 - The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3-ITD Mutations
847 - Prognostic Impact of Subclinical FLT3-ITD Microclones in Patients with Acute Myeloid Leukemia
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1090 - Reliable Assessment of Iron Deficiency in Patients with Myeloproliferative Neoplasms through Fluorescence Spectroscopy-Based Measurement of Zinc Protoporphyrin (ZPP)
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
2951 - Prognostic Role of NGS-Based MRD Assessment in FLT3-TKD Mutated Patients with Acute Myeloid Leukemia
2956 - Intra-Tumor Heterogeneity in Core-Binding Factor Acute Myeloid Leukemia
2883.1 - A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln‑049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease
847 - Prognostic Impact of Subclinical FLT3-ITD Microclones in Patients with Acute Myeloid Leukemia
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1090 - Reliable Assessment of Iron Deficiency in Patients with Myeloproliferative Neoplasms through Fluorescence Spectroscopy-Based Measurement of Zinc Protoporphyrin (ZPP)
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
2951 - Prognostic Role of NGS-Based MRD Assessment in FLT3-TKD Mutated Patients with Acute Myeloid Leukemia
2956 - Intra-Tumor Heterogeneity in Core-Binding Factor Acute Myeloid Leukemia
2883.1 - A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln‑049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease
Tholouli, E.
Thom, C. S.
1170 - Alterations in GATA1s Chromatin Occupancy Lead to Hyperproliferative, Cytokine-Independent Megakaryopoiesis
1268 - Standardized Prophylactic Platelet Transfusion Dose for Infants Decreases Platelet Exposure without Increasing Bleeding or Transfusion Frequency
2549 - Tropomyosin 1 Has Separate Roles in Murine Platelet Function and Developmental Hematopoiesis
1268 - Standardized Prophylactic Platelet Transfusion Dose for Infants Decreases Platelet Exposure without Increasing Bleeding or Transfusion Frequency
2549 - Tropomyosin 1 Has Separate Roles in Murine Platelet Function and Developmental Hematopoiesis
Thomalla, J.
84 - Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma – Subgroup Analysis of the GMMG HD6 Phase III Trial
1963 - Quality of Life in the Multicenter, Randomized, Phase 3 GMMG-HD6 Trial Applying Elotuzumab, Lenalidomide, Bortezomib and Dexaemethason in Patients with Newly-Diagnosed Multiple Myeloma
1963 - Quality of Life in the Multicenter, Randomized, Phase 3 GMMG-HD6 Trial Applying Elotuzumab, Lenalidomide, Bortezomib and Dexaemethason in Patients with Newly-Diagnosed Multiple Myeloma
Thomas, A.
59 - A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial
2907 - Gemtuzumab Based Induction Chemotherapy Combined with Midostaurin for FLT3 Mutated Patients. Results from the Patient- Reported Outcome Measures from the NCRI AML19V2 ‘Midotarg Pilot’
3805 - Patient-Reported Outcomes in Older Acute Myeloid Leukemia Patients Fit for Intensive Treatment, Who Received Intensified Treatment (DA +/- cladribine) Following No Evidence of Response to Course 1: Results from the NCRI AML18 Trial
4191.1 - Optimising Therapy in FLT3-Mutated Acute Myeloid Leukaemia
2907 - Gemtuzumab Based Induction Chemotherapy Combined with Midostaurin for FLT3 Mutated Patients. Results from the Patient- Reported Outcome Measures from the NCRI AML19V2 ‘Midotarg Pilot’
3805 - Patient-Reported Outcomes in Older Acute Myeloid Leukemia Patients Fit for Intensive Treatment, Who Received Intensified Treatment (DA +/- cladribine) Following No Evidence of Response to Course 1: Results from the NCRI AML18 Trial
4191.1 - Optimising Therapy in FLT3-Mutated Acute Myeloid Leukaemia
Thomas, B.
Thomas, C.
Thomas, C.
398 - Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies
525 - Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
1750 - Clinical Activity of Tisagenlecleucel in Large B Cell Lymphomas According to the 5th Edition of the Who Classification
2344 - Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study
2377 - Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers
525 - Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
1750 - Clinical Activity of Tisagenlecleucel in Large B Cell Lymphomas According to the 5th Edition of the Who Classification
2344 - Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study
2377 - Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers
Thomas, C. J.
750 - Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease
763 - Proteogenomic Screens Identify Plasma Cell Specific Vulnerabilities to Halt Oncogenic Transcription in Multiple Myeloma
1722 - Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis
763 - Proteogenomic Screens Identify Plasma Cell Specific Vulnerabilities to Halt Oncogenic Transcription in Multiple Myeloma
1722 - Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis
Thomas, D.
1006 - Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine
1817 - High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine
2715 - Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity
3196 - CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity
3208 - Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
4237 - High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies
1817 - High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine
2715 - Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity
3196 - CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity
3208 - Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
4237 - High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies
Thomas, D.
1267 - Higher Rate of Red Blood Cell (RBC) Alloimmunization in RBC-Transfused Myelodysplastic Syndrome Compared to Acute Myeloid Leukemia
1304 - Impact of Chronic Inflammation and Cytotoxic Therapy on Bone Marrow Microenvironment of Patients with Autoimmune Rheumatic Diseases and Myeloid Neoplasms
4594 - TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
1304 - Impact of Chronic Inflammation and Cytotoxic Therapy on Bone Marrow Microenvironment of Patients with Autoimmune Rheumatic Diseases and Myeloid Neoplasms
4594 - TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
Thomas, E.
Thomas, F.
Thomas, G. E.
2723 - AML Cells Have Increased Mitochondrial RNA Degradation and Inhibiting This Degradation Promotes Cell Differentiation, Decreases Viability, and Increases Sensitivity to Immune-Mediated Killing
2724 - The Exportin, CSE1L, Regulates Ribosome Biogenesis and Is a Selective Dependency in Childhood and Young Adult Acute Myeloid Leukemia
2724 - The Exportin, CSE1L, Regulates Ribosome Biogenesis and Is a Selective Dependency in Childhood and Young Adult Acute Myeloid Leukemia
Thomas, I.
55 - A Randomized Comparison of CPX-351 and FLAG-Ida in Patients with High-Risk Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) and MDS-Related Gene Mutations: A Subgroup Analysis of the UK NCRI AML19 Trial
59 - A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial
407 - Profiling Baseline Health-Related Quality of Life of Patients with Newly Diagnosed Myeloid Malignancies: A Pooled Analysis of 3349 Patients with AML, APL and MDS from the International Proactive Project
844 - The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3-ITD Mutations
845 - Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements – Experience from UK NCRI AML17 and AML19
1830 - Genetic Diversity Drives Differing Morphological and Clinical Presentation and Survival in Myelodysplastic-Type CMML with a Low Absolute Monocyte Count
2907 - Gemtuzumab Based Induction Chemotherapy Combined with Midostaurin for FLT3 Mutated Patients. Results from the Patient- Reported Outcome Measures from the NCRI AML19V2 ‘Midotarg Pilot’
3805 - Patient-Reported Outcomes in Older Acute Myeloid Leukemia Patients Fit for Intensive Treatment, Who Received Intensified Treatment (DA +/- cladribine) Following No Evidence of Response to Course 1: Results from the NCRI AML18 Trial
59 - A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial
407 - Profiling Baseline Health-Related Quality of Life of Patients with Newly Diagnosed Myeloid Malignancies: A Pooled Analysis of 3349 Patients with AML, APL and MDS from the International Proactive Project
844 - The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3-ITD Mutations
845 - Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements – Experience from UK NCRI AML17 and AML19
1830 - Genetic Diversity Drives Differing Morphological and Clinical Presentation and Survival in Myelodysplastic-Type CMML with a Low Absolute Monocyte Count
2907 - Gemtuzumab Based Induction Chemotherapy Combined with Midostaurin for FLT3 Mutated Patients. Results from the Patient- Reported Outcome Measures from the NCRI AML19V2 ‘Midotarg Pilot’
3805 - Patient-Reported Outcomes in Older Acute Myeloid Leukemia Patients Fit for Intensive Treatment, Who Received Intensified Treatment (DA +/- cladribine) Following No Evidence of Response to Course 1: Results from the NCRI AML18 Trial
Thomas, M.
Thomas, M.
Thomas, III, M.
Thomas, M.
Thomas, M.
Thomas, N.
Thomas, P. G.
1288 - Dnmt3a Mutant Hematopoietic Stem Cells Produce Hyperactive T Cells with Increased Alloimmune and Anti-Leukemic Activity
2076 - CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia
2731 - Multi-Pronged Effects of Cohesin Mutations in the Myeloid Leukemia of Down Syndrome
2076 - CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia
2731 - Multi-Pronged Effects of Cohesin Mutations in the Myeloid Leukemia of Down Syndrome
Thomas, R.
Thomas, R.
Thomas, S. M.
Thomas, S.
Thomas, S. K.
767 - Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects
861 - Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM)
1021 - Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies
1584 - Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis
1654 - Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical
1922 - Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis
1923 - Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis
1971 - Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma
3024 - Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma
3272 - Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma
3344 - Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant
3764 - Association of Social Determinants of Health Status (SDOH) and Ethnicity with Survival in Multiple Myeloma Patients
4687 - Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
4737 - Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)
5154 - Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma
861 - Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM)
1021 - Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies
1584 - Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis
1654 - Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical
1922 - Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis
1923 - Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis
1971 - Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma
3024 - Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma
3272 - Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma
3344 - Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant
3764 - Association of Social Determinants of Health Status (SDOH) and Ethnicity with Survival in Multiple Myeloma Patients
4687 - Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
4737 - Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)
5154 - Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma
Thomas, S.
Thomas, T.
Thomas, W.
Thomas-Tikhonenko, A.
1033 - P2RX5-Directed CAR-T Cells for Genotype-Guided Treatment of Lymphoid and Plasma Cell Malignancies in Patients of African Ancestry
1361 - Targeting HMGA1 Epigenetic Regulators and Downstream ETV5 Pathways with Histone Deacetylase Inhibitors in Combination Therapy for Relapsed, Pediatric B-ALL
4170 - PAX5 Loss Compromises CD22 Protein Levels and Responses to Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia
1361 - Targeting HMGA1 Epigenetic Regulators and Downstream ETV5 Pathways with Histone Deacetylase Inhibitors in Combination Therapy for Relapsed, Pediatric B-ALL
4170 - PAX5 Loss Compromises CD22 Protein Levels and Responses to Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia
Thomassen, S.
2603 - Citrullination in the C-Terminus of Tissue Factor Pathway Inhibitor-Alpha Impairs the Inhibition of Factor V Activation, and the Synergy with Protein S in Factor Xa Inactivation
3987 - Tissue Factor Pathway Inhibitor Modulates Endothelial and Vascular Smooth Muscle Cell Functions By Drifting Cellular Phenotypes
3994 - Citrullination of TFPI By PAD4 Impairs Its Natural Anticoagulant Activity Towards Factors Xa, VIIa and Tissue Factor, and Reduces Binding to Its Cofactor Protein S
3987 - Tissue Factor Pathway Inhibitor Modulates Endothelial and Vascular Smooth Muscle Cell Functions By Drifting Cellular Phenotypes
3994 - Citrullination of TFPI By PAD4 Impairs Its Natural Anticoagulant Activity Towards Factors Xa, VIIa and Tissue Factor, and Reduces Binding to Its Cofactor Protein S
Thomé, C.
Thomopoulos, T.
Thompson, A.
511 - An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel
513 - Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises
519 - Clinical Management Bundle for Patients with Sickle Cell Disease: Improving Completion of Age-Specific Screening Tests and Disease-Modifying Therapy Use
603 - Innovative Model for Creation and Use of Co-Developed Pain Management Plans for Patients with Sickle Cell Disease
709 - Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
1067 - Acceptability and Feasibility of Salivary Stress Research with Adolescents and Young Adults with Sickle Cell Disease
2194 - Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent β-Thalassemia
2313 - High Concordance between Investigator-Verified Diagnosis and Manual Data Abstraction for Sickle Cell Diagnosis Type: An ASH Research Collaborative Data Hub Validation Study
2691 - Outcomes of Immunosuppressive Therapy in Children Less Than Three Years of Age with Idiopathic Severe Aplastic Anemia: A North American Collaboration
3576 - Participants with a History of Stroke in Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials
3693 - Prospective Biopsychosocial Impacts of Stress and Disease Stigma Among Adolescents and Young Adults with Sickle Cell Disease
- Representing Sickle Cell Disease Health Concepts in Real World Evidence Generation: Examples from Real World Data (RWD) Initiatives and the Importance to the Sickle Cell Disease Community
- Landscape of SCD Treatment Options and New Therapies
513 - Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises
519 - Clinical Management Bundle for Patients with Sickle Cell Disease: Improving Completion of Age-Specific Screening Tests and Disease-Modifying Therapy Use
603 - Innovative Model for Creation and Use of Co-Developed Pain Management Plans for Patients with Sickle Cell Disease
709 - Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
1067 - Acceptability and Feasibility of Salivary Stress Research with Adolescents and Young Adults with Sickle Cell Disease
2194 - Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent β-Thalassemia
2313 - High Concordance between Investigator-Verified Diagnosis and Manual Data Abstraction for Sickle Cell Diagnosis Type: An ASH Research Collaborative Data Hub Validation Study
2691 - Outcomes of Immunosuppressive Therapy in Children Less Than Three Years of Age with Idiopathic Severe Aplastic Anemia: A North American Collaboration
3576 - Participants with a History of Stroke in Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials
3693 - Prospective Biopsychosocial Impacts of Stress and Disease Stigma Among Adolescents and Young Adults with Sickle Cell Disease
- Representing Sickle Cell Disease Health Concepts in Real World Evidence Generation: Examples from Real World Data (RWD) Initiatives and the Importance to the Sickle Cell Disease Community
- Landscape of SCD Treatment Options and New Therapies
Thompson, C.
Thompson, C. A.
1710 - Characteristics and Outcomes of Incidentally Diagnosed Diffuse Large B Cell Lymphoma (DLBCL)
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
3736 - Occurrence and Predictors of Patient Reported Fertility Discussions in Non-Hodgkin Lymphoma Patients: Utilizing the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
3754 - Real-World Predictors of Financial Toxicity in Patients with Lymphoma
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
3736 - Occurrence and Predictors of Patient Reported Fertility Discussions in Non-Hodgkin Lymphoma Patients: Utilizing the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
3754 - Real-World Predictors of Financial Toxicity in Patients with Lymphoma
Thompson, E.
Thompson, E. G.
72 - Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study
900 - Biological and Clinical Significance of Endogenous and Chimeric Antigen Receptor (CAR) T Cell Immune Profiling in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
3382 - Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis
3388 - Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up
4585 - Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab
900 - Biological and Clinical Significance of Endogenous and Chimeric Antigen Receptor (CAR) T Cell Immune Profiling in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
3382 - Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis
3388 - Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up
4585 - Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab
Thompson, I. R.
Thompson, J. E.
Thompson, J. A.
Thompson, K.
Thompson, M. C.
883 - Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1
885 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study
1010 - Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)
1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
1870 - Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton’s Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study
3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
4625 - Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study
885 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study
1010 - Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)
1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
1870 - Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton’s Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study
3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
4625 - Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study
Thompson, P. A.
1700 - Real-World Outcomes of Patients with High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements Treated in the Contemporary Era
1855 - Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL
3009 - Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma
3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
4511 - Bridging Radiotherapy to Axicabtagene Ciloleucel (axi-cel) Is Associated with Favourable Outcomes for Large B-Cell Lymphoma (LBCL) in Third-Line and Beyond: An Australian Single-Centre Real-World Experience
1855 - Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL
3009 - Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma
3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
4511 - Bridging Radiotherapy to Axicabtagene Ciloleucel (axi-cel) Is Associated with Favourable Outcomes for Large B-Cell Lymphoma (LBCL) in Third-Line and Beyond: An Australian Single-Centre Real-World Experience
Thompson, S. L.
5105 - Real-World Bleeding Risk, Outcomes and Treatment Patterns of Patients with CLL/SLL Receiving BTKi with or without Prescription Anticoagulants or Antiplatelets
5109 - Real-World Risk of Major Bleeding Events in BTKi-Treated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
5109 - Real-World Risk of Major Bleeding Events in BTKi-Treated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Thompson, S.
Thompson, Z.
189 - The High Mobility Group A1 (HMGA1) Chromatin Regulator Induces Inflammatory Signals and Promotes Atherogenesis in Tet2 Mutant Clonal Hematopoiesis
756 - HMGA1 Chromatin Regulators Disrupt 3D Genome Architecture and Chromatin Looping to Repress MHC II Genes and Drive Immune Evasion during MPN Progression
1277 - High Mobility Group A1 (HMGA1) Chromatin Regulators Maintain Quiescent, Regenerative HSC By Repressing IGF1 Networks That Promote Stem Cell Aging
756 - HMGA1 Chromatin Regulators Disrupt 3D Genome Architecture and Chromatin Looping to Repress MHC II Genes and Drive Immune Evasion during MPN Progression
1277 - High Mobility Group A1 (HMGA1) Chromatin Regulators Maintain Quiescent, Regenerative HSC By Repressing IGF1 Networks That Promote Stem Cell Aging
Thompson-Peach, C.
Thoms, J. A.
Thomsen, M.
Thomson, H.
Thong, Y. L.
Thongon, N.
50 - A Single-Cell T-Cell Reference Map Delineates the Biological Landscape of CD4+ T Cells in Myelodysplastic Syndromes Under Venetoclax Therapy
153 - Pharmacological Targeting of the Heme-Regulated Inhibitor Kinase Overcomes Ineffective Erythropoiesis in Patients with Myelodysplastic Syndromes with Ringed Sideroblasts and Sickle Cell Disease
4094 - T Lymphopenia and Aged Immune System Characterize Immunodeficiency in Adult Patients with Telomere Biology Disorders
153 - Pharmacological Targeting of the Heme-Regulated Inhibitor Kinase Overcomes Ineffective Erythropoiesis in Patients with Myelodysplastic Syndromes with Ringed Sideroblasts and Sickle Cell Disease
4094 - T Lymphopenia and Aged Immune System Characterize Immunodeficiency in Adult Patients with Telomere Biology Disorders
Thorburn, A.
Thordardottir, T. H.
Thorén, F. B.
Thoren, K.
3294 - Excess Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Screened Cohort of Patients with Gaucher Disease (GD)
4669 - Increased Risk of Monoclonal Gammopathy of Undetermined Significance in US Military Service Members: A Case-Control Study of 1,589 Service Members Deployed to Either Iraq, Germany, or Not-Deployed Ex-US with or without Reported Burn Pit and Toxic Smoke Exposure
4669 - Increased Risk of Monoclonal Gammopathy of Undetermined Significance in US Military Service Members: A Case-Control Study of 1,589 Service Members Deployed to Either Iraq, Germany, or Not-Deployed Ex-US with or without Reported Burn Pit and Toxic Smoke Exposure
Thorn (nee Daniels), T.
Thornton, B.
Thornton, P.
3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial
4626 - Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study
4626 - Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study
Thornton, T.
Thorpe, M. P.
Thorsteinsdottir, I.
Thorsteinsdottir, S.
1015 - Differential Detection of Clonal Bone Marrow Plasma Cells in IgA Vs. IgG Monoclonal Gammopathy of Undetermined Significance and Its Association with Disease Progression
3306 - Implementing Revised Reference Intervals for Free Light Chains Improves Risk Stratification of Monoclonal Gammopathy of Undetermined Significance
3306 - Implementing Revised Reference Intervals for Free Light Chains Improves Risk Stratification of Monoclonal Gammopathy of Undetermined Significance
Thota, P.
Thota, S.
Thrasher, A. J.
Thrasher, A. J.
Throumpari, N.
Thunga, S.
Thurner, L.
114 - Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial
4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial
Thursky, K. A.
Tiab, M.
774 - The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma
4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
Tian, D.
Tian, F.
96 - Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
454 - Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas
565 - Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma
648 - Non-Invasive Characterization and Early Detection of Post-Transplant Lymphoproliferative Disorders
853 - Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling
1157 - Acquired Immunodeficiency Landscapes Via Integrated Noninvasive Viral & Immune Profiling in HIV-Associated Lymphoproliferative Disease
2223 - Direct Method for Estimating the Fraction of T and B/Plasma Cell-Derived DNA
454 - Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas
565 - Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma
648 - Non-Invasive Characterization and Early Detection of Post-Transplant Lymphoproliferative Disorders
853 - Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling
1157 - Acquired Immunodeficiency Landscapes Via Integrated Noninvasive Viral & Immune Profiling in HIV-Associated Lymphoproliferative Disease
2223 - Direct Method for Estimating the Fraction of T and B/Plasma Cell-Derived DNA
Tian, H.
Tian, H.
Tian, S.
Tian, S.
Tian, T.
3031 - Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study
3249 - Sustained Superiority of Zanubrutinib vs Bendamustine + Rituximab in Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN CLL): 5-Year Follow-Up of Cohort 1 from the SEQUOIA Study
3255 - Deep and Sustained Responses in Patients with CLL Treated with Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report from the Zanubrutinib Extension Study
3257.1 - CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naive CLL
3249 - Sustained Superiority of Zanubrutinib vs Bendamustine + Rituximab in Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN CLL): 5-Year Follow-Up of Cohort 1 from the SEQUOIA Study
3255 - Deep and Sustained Responses in Patients with CLL Treated with Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report from the Zanubrutinib Extension Study
3257.1 - CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naive CLL
Tian, W.
1632 - Updated Results from a Phase I Trial of Amulirafusp Alfa (IMM0306) in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma
3033 - Phase Ib/IIa Study of Amulirafusp Alfa (IMM0306) in Combination with Lenalidomide in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma
3033 - Phase Ib/IIa Study of Amulirafusp Alfa (IMM0306) in Combination with Lenalidomide in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma
Tian, X.
Tian, X.
Tian, X.
Tian, Y.
Tian, Y.
Tian, Y.
Tian, Y.
663 - Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial
3224 - Newly-Acquired and Clonally-Increased Mutations in TP53 and RAS Pathways Promote Progressive Disease and Leukemic Transformation in Patients with Myelodysplatic Neoplasms
3224 - Newly-Acquired and Clonally-Increased Mutations in TP53 and RAS Pathways Promote Progressive Disease and Leukemic Transformation in Patients with Myelodysplatic Neoplasms
Tian, Z.
Tiao, E.
Ticku, J.
Ticozzi, C.
Tiedemann, R. E.
1954 - Analysis of Chip Mutations Pre-and Post-Transplant in Multiple Myeloma (MM): Expanded Results from a Prospective Longitudinal Study
1956 - Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies
3082 - Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis
3376 - Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)
3787 - Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin
1956 - Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies
3082 - Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis
3376 - Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)
3787 - Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin
Tiedemann, R. E.
Tiefgraber, M.
Tieghi, A.
242 - Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study
245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
1754 - Clinical Implications of Plasma-Derived Extracellular Vesicles in Myeloproliferative Neoplasms: Unveiling Inflammatory Potential and Biomarkers for Cancer Treatment
245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
1754 - Clinical Implications of Plasma-Derived Extracellular Vesicles in Myeloproliferative Neoplasms: Unveiling Inflammatory Potential and Biomarkers for Cancer Treatment
Tien, H. F.
666 - Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
2951 - Prognostic Role of NGS-Based MRD Assessment in FLT3-TKD Mutated Patients with Acute Myeloid Leukemia
4579 - Incorporating TET2 Variant Allele Frequency Enhances Prognostication in CMML: Insights from 849 Patients across Multiple Institutions
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
2951 - Prognostic Role of NGS-Based MRD Assessment in FLT3-TKD Mutated Patients with Acute Myeloid Leukemia
4579 - Incorporating TET2 Variant Allele Frequency Enhances Prognostication in CMML: Insights from 849 Patients across Multiple Institutions
Tierens, A. M.
1542 - Isomarker: An Explainable Machine Learning Framework for Identification of Cell State Markers in Acute Myeloid Leukemia
1570 - Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in the Patients with CCAAT Enhancer-Binding Protein a Gene (CEBPA) Mutated Acute Myeloid Leukemia
2954 - Presence of Leukemia-Related Basophils and Mast Cells with Atypical Immunophenotype during Induction Should Not be Interpreted As Measurable Residual Disease in Children with Acute Myeloid Leukemia with RUNX1::RUNX1T1
1570 - Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in the Patients with CCAAT Enhancer-Binding Protein a Gene (CEBPA) Mutated Acute Myeloid Leukemia
2954 - Presence of Leukemia-Related Basophils and Mast Cells with Atypical Immunophenotype during Induction Should Not be Interpreted As Measurable Residual Disease in Children with Acute Myeloid Leukemia with RUNX1::RUNX1T1
Tiger, Y. K.
111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
973 - Dual HDAC and EZH2 Inhibition Primes Mosunetuzumab for the Treatment of Germinal Center-Derived B-Cell Lymphoma
1644 - Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study
2411g - Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma
3112 - Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma
3751 - Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis
5170d - Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients
3123.1 - Trial in Progress: A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-Cop to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T- Cell Lymphoma - Crescendo
973 - Dual HDAC and EZH2 Inhibition Primes Mosunetuzumab for the Treatment of Germinal Center-Derived B-Cell Lymphoma
1644 - Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study
2411g - Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma
3112 - Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma
3751 - Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis
5170d - Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients
3123.1 - Trial in Progress: A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-Cop to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T- Cell Lymphoma - Crescendo
Tijani, L.
Tijaro Ovalle, N.
Tikare, N.
Tikhonova, A. N.
Tilakawardane, D.
Tilburg, J.
Tilburt, J.
Tilch, M. K.
3042.2 - Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy – MCL Elderly III
4422.3 - Trials in Progress: Carman - an International, Randomized Phase II Study Evaluating Early Treatment Intensification in Patients with High Risk Mantle Cell Lymphoma Using CAR-T-Cell Treatment after an Abbreviated Induction Therapy with Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) As Compared to Standard of Care Induction and Maintenance (Arm B)
4422.3 - Trials in Progress: Carman - an International, Randomized Phase II Study Evaluating Early Treatment Intensification in Patients with High Risk Mantle Cell Lymphoma Using CAR-T-Cell Treatment after an Abbreviated Induction Therapy with Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) As Compared to Standard of Care Induction and Maintenance (Arm B)
Tilgner, M.
Till, B. G.
783 - Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma: A Single-Center Retrospective Analysis
1616 - EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab
1666 - Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma
1667 - Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma
1684 - Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas
3043 - Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up
3051 - High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD
3069 - Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia
4395 - EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study
4431 - Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting
4832 - Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials
5116 - Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma
1661.2 - A Pilot Trial of Low Dose-Mosunetuzumab for Low-Tumor Burden Indolent B-Cell Lymphoma: Trial in Progress
4634.2 - Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial
1616 - EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab
1666 - Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma
1667 - Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma
1684 - Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas
3043 - Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up
3051 - High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD
3069 - Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia
4395 - EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study
4431 - Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting
4832 - Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials
5116 - Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma
1661.2 - A Pilot Trial of Low Dose-Mosunetuzumab for Low-Tumor Burden Indolent B-Cell Lymphoma: Trial in Progress
4634.2 - Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial
Tilly, H.
469 - Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes
575 - Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa
577 - Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma
649 - Senior-IPI: An Easily Applicable and Meaningful Prognostic Index for First-Line LBCL Patients Older Than 80 Years Treated with Age-Adapted Immunochemotherapy
2964 - Aberrant Isotype Class Switch Recombination Reactivation Leads to a Genome Wide Genomic Instability in Follicular Lymphoma
4353 - Clonal Dominance in Follicular Lymphoma: A Predictor of Poor Prognosis and Histological Transformation
4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study
4467 - Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B Lysa Trials
575 - Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa
577 - Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma
649 - Senior-IPI: An Easily Applicable and Meaningful Prognostic Index for First-Line LBCL Patients Older Than 80 Years Treated with Age-Adapted Immunochemotherapy
2964 - Aberrant Isotype Class Switch Recombination Reactivation Leads to a Genome Wide Genomic Instability in Follicular Lymphoma
4353 - Clonal Dominance in Follicular Lymphoma: A Predictor of Poor Prognosis and Histological Transformation
4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study
4467 - Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B Lysa Trials
Tilmont, R.
Timblin, K. M.
Timm, M. M.
1858 - Artificial Intelligence-Enhancement of Flow Cytometry Data Accelerates the Identification of Minimal Residual Chronic Lymphocytic Leukemia
1945 - Development of a Three-Gene-Based Proliferation Score (3GPS) to Predict Proliferation Index in Newly Diagnosed Multiple Myeloma
4226 - Artificial Intelligence-Enhancement of Flow Cytometry Data Accelerates the Identification of Minimal Residual B Lymphoblastic Leukemia
1945 - Development of a Three-Gene-Based Proliferation Score (3GPS) to Predict Proliferation Index in Newly Diagnosed Multiple Myeloma
4226 - Artificial Intelligence-Enhancement of Flow Cytometry Data Accelerates the Identification of Minimal Residual B Lymphoblastic Leukemia
Timmerman, J.
Timmers, C.
Timmers, G. J.
Timmins, H.
Timofeeva, N.
Timonian, M.
488 - Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma
1017 - Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants
1895 - Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in 365 Patients with MGUS and SMM Demonstrates Complex Progressive Changes in Immune Cell Functionality with a Distinct Footprint on Tumor Cell Biology and Disease Control
1928 - Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy
1017 - Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants
1895 - Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in 365 Patients with MGUS and SMM Demonstrates Complex Progressive Changes in Immune Cell Functionality with a Distinct Footprint on Tumor Cell Biology and Disease Control
1928 - Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy
Tinajero, J.
Ting, S.
303 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial
1318 - Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia
2941 - Lipidomic Analysis of Flt3-ITD AML Cells Treated with Intensive Chemotherapy and Independent of Concomitant Sorafenib Display a Profile of Increased Susceptibility to Ferroptosis
1318 - Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia
2941 - Lipidomic Analysis of Flt3-ITD AML Cells Treated with Intensive Chemotherapy and Independent of Concomitant Sorafenib Display a Profile of Increased Susceptibility to Ferroptosis
Tinmouth, A. T.
Tinsley-Vance, S. M.
Tiong, I. S.
51 - Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission
223 - Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A-rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial
653 - DNA Damage Repair Pathway Variants Are Frequent in Patients Undergoing CAR-T Cell Therapy for Lymphoma and Associated with Increased Risk of Myeloid Neoplasia Post Cytotoxic Therapy
223 - Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A-rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial
653 - DNA Damage Repair Pathway Variants Are Frequent in Patients Undergoing CAR-T Cell Therapy for Lymphoma and Associated with Increased Risk of Myeloid Neoplasia Post Cytotoxic Therapy
Tiong, J.
Tipgomut, C.
Tippett, G. D.
219 - A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update
2883 - Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials
4271 - Interim Results of the Phase II Study Investigating CPX-351 in Combination with Ivosidenib for Patients with IDH1-Mutated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
2883 - Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials
4271 - Interim Results of the Phase II Study Investigating CPX-351 in Combination with Ivosidenib for Patients with IDH1-Mutated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Tipping, A.
Tiribelli, M.
242 - Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study
245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
1772 - Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 – 60 Years: A “Campus CML” Study
2893 - Venetoclax and Azacitidine for Relapse Prevention in NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial
3155 - CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study
3158 - ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial
4535 - Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network
245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
1772 - Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 – 60 Years: A “Campus CML” Study
2893 - Venetoclax and Azacitidine for Relapse Prevention in NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial
3155 - CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study
3158 - ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial
4535 - Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network
Tirone, B.
57 - Venetoclax Combined with "7+3" Induction Chemotherapy Induces High MRD-Negative Response Rates in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy across Ages
4265.5 - A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML
4265.5 - A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML
Tirtakusuma, R.
Tischer, J.
2179 - Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies – a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group
2193 - Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
4944 - Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
2193 - Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
4944 - Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
Tischmacher, A.
Tisdale, J.
411 - MLL1 Complex Is a Critical Regulator of Fetal Hemoglobin Repression
511 - An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel
516 - CD117 Antibody Conditioning and Multiplex Base Editing Enable Rapid and Robust Fetal Hemoglobin Reactivation in a Rhesus Autologous Transplantation Model
1141 - Adding CD117 Antibody to Alemtuzumab, Low Dose Total Body Irradiation (TBI), and Sirolimus for Matched Related Donor (MRD) Hematopoietic Cell Transplant (HCT) in Sickle Cell Disease (SCD): Initial Results
2100.1 - Motixafortide for Hematopoietic Stem and Progenitor Cell Mobilization and Collection in Sickle Cell Disease
- Clinical/Translational Science
- Moderator Introduction (Classical Hematology Perspective)
511 - An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel
516 - CD117 Antibody Conditioning and Multiplex Base Editing Enable Rapid and Robust Fetal Hemoglobin Reactivation in a Rhesus Autologous Transplantation Model
1141 - Adding CD117 Antibody to Alemtuzumab, Low Dose Total Body Irradiation (TBI), and Sirolimus for Matched Related Donor (MRD) Hematopoietic Cell Transplant (HCT) in Sickle Cell Disease (SCD): Initial Results
2100.1 - Motixafortide for Hematopoietic Stem and Progenitor Cell Mobilization and Collection in Sickle Cell Disease
- Clinical/Translational Science
- Moderator Introduction (Classical Hematology Perspective)
Tisi, M. C.
1577 - TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial
3131 - Outcomes of CAR T-Cells Therapy in High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas: A Weighted Comparison Analysis from CAR-T SIE Study
4362 - Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)
4786 - High Ferritin and C-Reactive Protein Levels Result in Poor Clinical Outcome in R/R Large B-Cell Lymphoma Patients Despite Significant Anti-CD19 CAR-T Cell In Vivo Expansion
4797 - Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study
3131 - Outcomes of CAR T-Cells Therapy in High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas: A Weighted Comparison Analysis from CAR-T SIE Study
4362 - Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)
4786 - High Ferritin and C-Reactive Protein Levels Result in Poor Clinical Outcome in R/R Large B-Cell Lymphoma Patients Despite Significant Anti-CD19 CAR-T Cell In Vivo Expansion
4797 - Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study
Tissino, E.
Titeux, M.
Tittley, S.
Titus, E.
Titus, J.
Tiu, G. C.
Tiwari, P. K.
Tizazu, B.
Tjioe, K. C.
Tjoa, K.
Tjota, M.
To, I.
989 - A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2373 - Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data
2373 - Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data
Tobalina García, A.
Tobiasson, M.
Tobin, J. W.
Tobin, W. O.
Tobon, K.
1672 - Real World Experience with Sequential Brentuximab Vedotin Plus AVD Chemotherapy As Frontline Therapy for Older Patients with Classical Hodgkin Lymphoma: A Multicenter Retrospective Study
2415 - Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience
2820 - Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting
3784 - Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma
5168 - Effect of Talquetamab on Responses in Patients with Relapsed and Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies
2415 - Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience
2820 - Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting
3784 - Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma
5168 - Effect of Talquetamab on Responses in Patients with Relapsed and Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies
Toda, Y.
Todd, J.
Todd, K.
Todisco, E.
113 - Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia
835 - Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
1541 - Genomic Landscape and Clonal Hematopoiesis Dynamics in Patients with Ovarian Cancer during PARP Inhibitors Treatment: Preliminary Results of a Prospective Longitudinal Study
2849 - CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study
2863 - Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)
5188 - Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results
835 - Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
1541 - Genomic Landscape and Clonal Hematopoiesis Dynamics in Patients with Ovarian Cancer during PARP Inhibitors Treatment: Preliminary Results of a Prospective Longitudinal Study
2849 - CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study
2863 - Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)
5188 - Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results
Todisco, G.
104 - Clinical Relevance of the Integrative Analysis of Gut Microbiome and Metabolomics in Myeloid Neoplasms: Correlations with Genomic Profiles, Treatment Response/Complications and Clinical Outcome
105 - Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)
665 - Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
2221 - A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
3137 - Unveiling MED12L: A Potential Novel Orchestrator of Platelet Dysfunction in Myeloproliferative Myeloid Neoplasms
3194 - Single-Cell Multi-Omics Reveals Anticipated Erythroid Differentiation and Transcriptional Regulation in Differentiation Trajectories of SF3B1 - JAK2/MPL Mutated Cells in MDS/MPN-RS-T
3198 - Large-Scale Transcriptome Analysis Supports Genomic Taxonomy and Predicts Response to Hypomethylating Agents in Myelodysplastic Neoplasms
3597 - The “David Vs Goliath” Study: Application of Large Language Models (LLM) for Automatic Medical Information Retrieval from Multiple Data Sources to Accelerate Clinical and Translational Research in Hematology
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
4052 - Clonal Hematopoiesis and the Risk of Dementia: The Monzino 80-Plus Population-Based Study
4981 - Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
105 - Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)
665 - Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
2221 - A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
3137 - Unveiling MED12L: A Potential Novel Orchestrator of Platelet Dysfunction in Myeloproliferative Myeloid Neoplasms
3194 - Single-Cell Multi-Omics Reveals Anticipated Erythroid Differentiation and Transcriptional Regulation in Differentiation Trajectories of SF3B1 - JAK2/MPL Mutated Cells in MDS/MPN-RS-T
3198 - Large-Scale Transcriptome Analysis Supports Genomic Taxonomy and Predicts Response to Hypomethylating Agents in Myelodysplastic Neoplasms
3597 - The “David Vs Goliath” Study: Application of Large Language Models (LLM) for Automatic Medical Information Retrieval from Multiple Data Sources to Accelerate Clinical and Translational Research in Hematology
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
4052 - Clonal Hematopoiesis and the Risk of Dementia: The Monzino 80-Plus Population-Based Study
4981 - Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
Todoroff, K.
Todorova, I.
Toenges, R.
488 - Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma
1019 - A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
1894 - Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development
1019 - A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
1894 - Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development
Toenges, R.
Tofacchi, E.
Toffalori, C.
Tofovic, S.
Tognon, C.
Toh, S.
Tohidi-Esfahani, I.
1654 - Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical
4412 - Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)
4412 - Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)
Toho, M.
366 - Soluble B-Cell Maturation Antigen Levels for Disease Monitoring in Oligo- and Non-Secretory Relapsed Multiple Myeloma
3035 - Serum BCMA Is a Better Reflector of Tumor Volume Than IgM in the Induction Period of Waldenström Macroglobulinemia
3042 - Simultaneous Assessment of Total Metabolic Tumor Volume and Intratumoral CD4+ T-Cell Infiltration Identifies Early Progression of Follicular Lymphoma on Watch-and-Wait Approach
3313 - Soluble BCMA As a Surrogate Biomarker for Tumor Burden in Multiple Myeloma: Correlations with Various Biomarkers and Treatment Responses
4682 - Different Patterns of Antigen Expression in Bone Marrow and Circulating Tumor Plasma Cells in Patients with MGUS and Smoldering Multiple Myeloma
3035 - Serum BCMA Is a Better Reflector of Tumor Volume Than IgM in the Induction Period of Waldenström Macroglobulinemia
3042 - Simultaneous Assessment of Total Metabolic Tumor Volume and Intratumoral CD4+ T-Cell Infiltration Identifies Early Progression of Follicular Lymphoma on Watch-and-Wait Approach
3313 - Soluble BCMA As a Surrogate Biomarker for Tumor Burden in Multiple Myeloma: Correlations with Various Biomarkers and Treatment Responses
4682 - Different Patterns of Antigen Expression in Bone Marrow and Circulating Tumor Plasma Cells in Patients with MGUS and Smoldering Multiple Myeloma
Toivanen, L.
Tokessy, L.
Tokiya, R.
Tokunaga, M.
Tol, S.
2454 - Lu/BCAM Expression Defines Functionally Distinct Red Blood Cells
2483 - Alterations in the Immune Phenotype of Adaptive Immune Cells in Sickle Cell Disease: A Conventional and Computational Flow Cytometry Analysis
3527 - Dynamics of Immune Reconstitution in Adults with Sickle Cell Disease Undergoing Nonmyeloablative Matched Sibling Donor Stem Cell Transplantation: A Conventional and Computational Analysis
2483 - Alterations in the Immune Phenotype of Adaptive Immune Cells in Sickle Cell Disease: A Conventional and Computational Flow Cytometry Analysis
3527 - Dynamics of Immune Reconstitution in Adults with Sickle Cell Disease Undergoing Nonmyeloablative Matched Sibling Donor Stem Cell Transplantation: A Conventional and Computational Analysis
Tolbert, J.
594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
3357 - Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study
3357 - Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study
Tole, M. C.
Tole, S.
Tolksdorf, E.
Tolley, R.
Tolosano, E.
Tolotta, J.
Tolstorukov, M. Y.
Tolu, S. S.
336 - Combination JAK Inhibition and Immune Checkpoint Blockade for the Treatment of 9p Amplified Lymphomas
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
573 - Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort
973 - Dual HDAC and EZH2 Inhibition Primes Mosunetuzumab for the Treatment of Germinal Center-Derived B-Cell Lymphoma
3077 - Diagnostic Utility of the 18f-FDG PET/CT Scan in Solid Organ Transplant Patients with EBV Reactivation at Risk for Post-Transplant Lymphoproliferative Disorder
3112 - Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma
5042 - Association between Food Insecurity, Financial Toxicity, and Healthcare Utilization in Patients with Lymphoma
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
573 - Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort
973 - Dual HDAC and EZH2 Inhibition Primes Mosunetuzumab for the Treatment of Germinal Center-Derived B-Cell Lymphoma
3077 - Diagnostic Utility of the 18f-FDG PET/CT Scan in Solid Organ Transplant Patients with EBV Reactivation at Risk for Post-Transplant Lymphoproliferative Disorder
3112 - Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma
5042 - Association between Food Insecurity, Financial Toxicity, and Healthcare Utilization in Patients with Lymphoma
Toma, M.
Tomasello, R.
Tomasoni, C.
Tomassetti, S.
Tomassetti, S.
Tomasso, A.
Tomasson, M. H.
Tomasulo, E.
Tomé, A. L.
Tomelleri, A.
Tomelleri, A.
Tomida, S.
Tominaga, R.
Tomita, A.
Tomita, A.
Tomita, M.
Tomizawa, D.
Tomizawa-Murasawa, M.
Tomkins, O. M.
Tomkinson, B. E.
Tomlinson, B. K.
927 - Predictive Modeling of Hematopoietic Stem Cell Transplant Outcomes: Discovering the Role of Immunogenetic Features through Machine Learning Models
1382 - Decitabine Activity Against TP53-Mutated Myeloid Neoplasms Is Enhanced By Combination with a Non-Cytotoxic p53/BAX-Independent Inhibitor of Pyrimidine Synthesis
1840 - PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study
2115 - A Retrospective Study of C5b-9 and MASP2 Deposition in Skin Microvasculature As a Prognostic and Diagnostic Tool for Transplant-Associated Thrombotic Microangiopathy
2131 - A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation
1382 - Decitabine Activity Against TP53-Mutated Myeloid Neoplasms Is Enhanced By Combination with a Non-Cytotoxic p53/BAX-Independent Inhibitor of Pyrimidine Synthesis
1840 - PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study
2115 - A Retrospective Study of C5b-9 and MASP2 Deposition in Skin Microvasculature As a Prognostic and Diagnostic Tool for Transplant-Associated Thrombotic Microangiopathy
2131 - A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation
Tomlinson, G. A.
544 - Growth and Puberty in African Children with Sickle Cell Anemia Treated with Hydroxyurea
545 - Hydroxyurea Treatment Reduces Infection Rates in African Children with Sickle Cell Anemia
2495 - Effects of Splenomegaly in Children with Sickle Cell Anemia Treated with Hydroxyurea: Secondary Analysis of the Sphere Trial
545 - Hydroxyurea Treatment Reduces Infection Rates in African Children with Sickle Cell Anemia
2495 - Effects of Splenomegaly in Children with Sickle Cell Anemia Treated with Hydroxyurea: Secondary Analysis of the Sphere Trial
Tomoka, T.
3005 - High Tumor Mutational Burden Associates with Increased CD8 T-Cell Presence, Decreased Tumor Heterogeneity, and Increased AICDA Expression in an HIV-Inclusive Cohort of Diffuse Large B-Cell Lymphoma
4344 - Immunogenomic Profiles of EBV-Associated Classic Hodgkin Lymphoma in an HIV-Inclusive Cohort
4344 - Immunogenomic Profiles of EBV-Associated Classic Hodgkin Lymphoma in an HIV-Inclusive Cohort
Tomuleasa, C.
Tondini, C.
Toner, K.
Tong, B.
Tong, C.
Tong, H.
663 - Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial
836 - Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial
1526 - Efficacy and Safety of Venetoclax Added to Arsenics Plus All-Trans-Retinoic Acid Combination Salvage Regimen for Patients with Relapsed/Refractory Acute Promyelocytic Leukemia
1630 - The Efficacy and Safety of Obinutuzumab with Zanubrutinib As First-Line Treatment in Older Patients with Mantle Cell Lymphoma
1733 - The ZR2-Minichop Study: Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin, and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
2701 - A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor–Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis
4450 - Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study
4487 - Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma
4494 - Zanubrutinib in Combination with R-CHOP for Previously Untreated Mcd Type of Diffuse Large B-Cell Lymphoma (DLBCL)
4570 - HMGB3 As a Cargo Protein for XPO1: Implications for Myelodysplastic Syndromes Prognosis and Treatment
4575 - Single-Cell Transcriptomic Analysis Reveals Distinct Hematopoietic Landscapes and Immune Dysregulation in Der(1;7)(q10;p10) Myelodysplastic Syndromes
4685 - Pro-Inflammatory Monocytes As Key Effector Cells in Peripheral Circulatory Inflammatory Storms Driven By IFN-γ and IL-6 Pathways in Imcd
836 - Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial
1526 - Efficacy and Safety of Venetoclax Added to Arsenics Plus All-Trans-Retinoic Acid Combination Salvage Regimen for Patients with Relapsed/Refractory Acute Promyelocytic Leukemia
1630 - The Efficacy and Safety of Obinutuzumab with Zanubrutinib As First-Line Treatment in Older Patients with Mantle Cell Lymphoma
1733 - The ZR2-Minichop Study: Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin, and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
2701 - A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor–Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis
4450 - Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study
4487 - Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma
4494 - Zanubrutinib in Combination with R-CHOP for Previously Untreated Mcd Type of Diffuse Large B-Cell Lymphoma (DLBCL)
4570 - HMGB3 As a Cargo Protein for XPO1: Implications for Myelodysplastic Syndromes Prognosis and Treatment
4575 - Single-Cell Transcriptomic Analysis Reveals Distinct Hematopoietic Landscapes and Immune Dysregulation in Der(1;7)(q10;p10) Myelodysplastic Syndromes
4685 - Pro-Inflammatory Monocytes As Key Effector Cells in Peripheral Circulatory Inflammatory Storms Driven By IFN-γ and IL-6 Pathways in Imcd
Tong, J.
Tong, K.
Tong, K. W.
1399 - Inhibition of Threonine Tyrosine Kinase Suppressed TP53-mutated Acute Myeloid Leukaemia Via Synergism with Venetoclax and Activation of the Cgas-Sting Pathway
1510 - Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) As an Effective Treatment Remodels Proteostasis and Triggers Inflammatory Response in FLT3-ITD AML
2763 - HPK1 Inhibition and Venetoclax Combination Suppressed AML By Enhancing Cytotoxic T-Cell Response to Leukaemia
1510 - Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) As an Effective Treatment Remodels Proteostasis and Triggers Inflammatory Response in FLT3-ITD AML
2763 - HPK1 Inhibition and Venetoclax Combination Suppressed AML By Enhancing Cytotoxic T-Cell Response to Leukaemia
Tong, M.
Tong, W.
1753 - Pitpβ Loss Ameliorates Jak2 V617F-Induced Myeloproliferative Neoplasms (MPN) in Mice
2730 - CBL Loss or Mutations Reduces MHCII Expression through Downregulating ERG in Myeloid Malignancies
4574 - CBL Loss or Mutations Upregulates AXL to Promote Cytokine-Independent Growth in Myeloid Malignancies: AXL Upregulation Promotes Cytokine-Independent Growth in CBL-Mutant CMML
- Targeting Casitas B-lineage Lymphoma (CBL) Mutant Myeloid Malignancies
2730 - CBL Loss or Mutations Reduces MHCII Expression through Downregulating ERG in Myeloid Malignancies
4574 - CBL Loss or Mutations Upregulates AXL to Promote Cytokine-Independent Growth in Myeloid Malignancies: AXL Upregulation Promotes Cytokine-Independent Growth in CBL-Mutant CMML
- Targeting Casitas B-lineage Lymphoma (CBL) Mutant Myeloid Malignancies
Tong, W.
Tong, X.
Tong, X.
1401 - The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients
4276 - Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial
4276 - Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial
Tong, Y.
Tong, Y.
Tonnelet, D.
Tono, C.
Tonon, G.
Toomey, N.
Toop, C.
1267 - Higher Rate of Red Blood Cell (RBC) Alloimmunization in RBC-Transfused Myelodysplastic Syndrome Compared to Acute Myeloid Leukemia
3208 - Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
4594 - TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
3208 - Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
4594 - TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
Toor, A. A.
Tooze, R.
Topçu, E.
41 - The Pathogenesis of Therapy-Related Myeloid Neoplasms from TP53-Mutant Clonal Hematopoiesis
193 - Somatic TP53 Mutations Rescue the Hematopoietic Stem and Progenitor Cell Defect at the Expense of Increased Risk for Myeloid Malignancies in ERCC6L2-Associated Inherited Bone Marrow Failure Syndrome
193 - Somatic TP53 Mutations Rescue the Hematopoietic Stem and Progenitor Cell Defect at the Expense of Increased Risk for Myeloid Malignancies in ERCC6L2-Associated Inherited Bone Marrow Failure Syndrome
Topf, J.
Topp, M. S.
866 - Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study
2007 - Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis
3080 - Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab
3118 - Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies
3792d - Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement
4388 - Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
4688 - Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy
4705 - Classic Anti-Myeloma Treatments Alter Circulating Immune Cell Subsets with Potential Implications for T Cell Immunotherapies in Multiple Myeloma
2007 - Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis
3080 - Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab
3118 - Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies
3792d - Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement
4388 - Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
4688 - Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy
4705 - Classic Anti-Myeloma Treatments Alter Circulating Immune Cell Subsets with Potential Implications for T Cell Immunotherapies in Multiple Myeloma
Toprak, A. C.
Torbenson, V.
Tordecilla, J.
Toren, A.
Toren, A.
Toriello, M.
Torka, P.
398 - Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies
569 - Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin
652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
1707 - High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease
2336 - Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
2344 - Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study
3647 - A Healthcare Utilization Model Comparing Time Toxicity between Glofitamab and Epcoritamab
4346 - Molecular Features Are Associated with Disease Stage in Diffuse Large B-Cell Lymphoma and Reveal Heterogeneity in Patient Outcomes
4429 - Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis
4451 - Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases
5101 - Impact of the Diagnosis-to-Treatment Interval (DTI) on Outcomes in Older Adults with Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Real-World Setting
- International Graduate Hematology
569 - Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin
652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
1707 - High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease
2336 - Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
2344 - Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study
3647 - A Healthcare Utilization Model Comparing Time Toxicity between Glofitamab and Epcoritamab
4346 - Molecular Features Are Associated with Disease Stage in Diffuse Large B-Cell Lymphoma and Reveal Heterogeneity in Patient Outcomes
4429 - Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis
4451 - Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases
5101 - Impact of the Diagnosis-to-Treatment Interval (DTI) on Outcomes in Older Adults with Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Real-World Setting
- International Graduate Hematology
Torka, P.
340 - Single-Agent Mosunetuzumab Produces High Complete Response Rates in Patients with Newly Diagnosed Follicular Lymphoma: Primary Analysis of the Mithic-FL1 Trial
1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
2290 - Representation of Older Adults in FDA and EMA Registrational Trials for Acute Myeloid Leukemia (AML)
3053 - Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma
3743 - End-of-Life Care Patterns in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Real-World Setting
4434 - Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
4474 - A Prospective Geriatric Assessment (GA) Study Predicting Toxicities in Older Adults (OA) with Non-Hodgkin Lymphoma (NHL): Timed up and Go Test (TUG) Time Emerges As a Functional Vital Sign
4485 - Sequential R-CHOP/(R)-ICE and Dose-Adjusted EPOCH-R Are Both Appropriate Frontline Treatments for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Retrospective Analysis
1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
2290 - Representation of Older Adults in FDA and EMA Registrational Trials for Acute Myeloid Leukemia (AML)
3053 - Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma
3743 - End-of-Life Care Patterns in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Real-World Setting
4434 - Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
4474 - A Prospective Geriatric Assessment (GA) Study Predicting Toxicities in Older Adults (OA) with Non-Hodgkin Lymphoma (NHL): Timed up and Go Test (TUG) Time Emerges As a Functional Vital Sign
4485 - Sequential R-CHOP/(R)-ICE and Dose-Adjusted EPOCH-R Are Both Appropriate Frontline Treatments for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Retrospective Analysis
Torkelson, A.
Tormo Garcia, C.
Tormo, M.
1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
3214 - The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
3214 - The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
Tormo, M.
319 - Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study
320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry
1440 - Single-Agent Subcutaneous Blinatumomab for Advanced B-Cell Acute Lymphoblastic Leukemia: Long-Term Follow-up from a Phase 1b Dose Expansion Cohort
1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
1838 - Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
3205 - Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia
3207 - Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial
4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML
320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry
1440 - Single-Agent Subcutaneous Blinatumomab for Advanced B-Cell Acute Lymphoblastic Leukemia: Long-Term Follow-up from a Phase 1b Dose Expansion Cohort
1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
1838 - Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
3205 - Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia
3207 - Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial
4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML
Tornese, M.
Törngren, M.
Torno, L.
Toros, H.
Torrado Chedas, T.
Torrado, T.
598 - HCT-Adapted ELN 2022 Risk Classification: Validation of a Very Poor Risk Group (Adverse-Plus) in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)
2108 - Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)
2108 - Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)
Torre, E.
104 - Clinical Relevance of the Integrative Analysis of Gut Microbiome and Metabolomics in Myeloid Neoplasms: Correlations with Genomic Profiles, Treatment Response/Complications and Clinical Outcome
4547 - Rapid and Sustained Recovery of Cellular Immunity in Patients with Myelofibrosis on Momelotinib Therapy
4547 - Rapid and Sustained Recovery of Cellular Immunity in Patients with Myelofibrosis on Momelotinib Therapy
Torre, L. M.
Torregrosa Diaz, J. M.
Torrejón Martínez, M. J.
Torrent, A.
962 - Prognostic Impact of the Genetic Risk at Baseline Associated to the MRD Clearance in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Preliminary Results of Pethema LAL19 Trial
1437 - Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial
2844 - Dissecting the Role of Acquired Regions of Homozygosity Detected By Microarray Along the Genome of a Large Cohort of Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia
1437 - Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial
2844 - Dissecting the Role of Acquired Regions of Homozygosity Detected By Microarray Along the Genome of a Large Cohort of Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia
Torres, B.
Torres, J.
Torres Jiménez, W.
Torres, L.
962 - Prognostic Impact of the Genetic Risk at Baseline Associated to the MRD Clearance in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Preliminary Results of Pethema LAL19 Trial
1437 - Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial
4328 - Single-Cell Multiomics Data-Driven Measurable Residual Disease (MRD) Assessment Using Multidimensional Flow Cytometry (MFC) in Acute Myeloid Leukemia (AML)
1437 - Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial
4328 - Single-Cell Multiomics Data-Driven Measurable Residual Disease (MRD) Assessment Using Multidimensional Flow Cytometry (MFC) in Acute Myeloid Leukemia (AML)
Torres, L.
Torres Mantilla, H. A.
Torres Seber, R. O.
Torres Tienza, A.
Torres Viera, M. A.
983 - Refining Prognostication in Peripheral T Cell Lymphoma (PTCL): A Risk-Adapted Prognostic Model for Patients with Limited-Stage PTCL
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
1718 - Using Polatuzumab Plus Chemotherapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Study from the Grupo De Estudio De Linfoproliferativos De Latinoamerica (GELL)
2370 - The Impact of Social Determinants and Diagnostic Inequities in Hodgkin Lymphoma Outcomes: A Comparative Analysis of South America and the United States
3064 - Central Nervous System Involvement in Aggressive ATLL: Can We Predict the Risk in a Devastating Complication? Epidemiology and Clinical Features from Latin America. a Collaborative Study from Grupo De Estudio Latino-Americano De Linfoproliferativo (GELL) & T-Cell Brazil Project (TCBP)
3718 - Uncovering the Epidemiology, Therapy Patterns and Outcomes of MALT Lymphoma in Latin America: A Multinational Retrospective Cohort Study
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
1718 - Using Polatuzumab Plus Chemotherapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Study from the Grupo De Estudio De Linfoproliferativos De Latinoamerica (GELL)
2370 - The Impact of Social Determinants and Diagnostic Inequities in Hodgkin Lymphoma Outcomes: A Comparative Analysis of South America and the United States
3064 - Central Nervous System Involvement in Aggressive ATLL: Can We Predict the Risk in a Devastating Complication? Epidemiology and Clinical Features from Latin America. a Collaborative Study from Grupo De Estudio Latino-Americano De Linfoproliferativo (GELL) & T-Cell Brazil Project (TCBP)
3718 - Uncovering the Epidemiology, Therapy Patterns and Outcomes of MALT Lymphoma in Latin America: A Multinational Retrospective Cohort Study
Torres-Cabala, C. P.
Torres-Diz, M.
Torres-Esquius, S.
2708 - Genomic Instability in Early-Onset Myelodysplastic Syndrome Patients Harboring Rare Germline Variants in NHEJ DNA Repair Genes
2709 - Association of Clonal Hematopoiesis and Dysgranulopoiesis with Germline ETV6 Carriers without Hematological Malignancies
- Performance and Clinical Utility of Germline Genetic Testing Criteria for Predisposition to Myeloid Neoplasms in Adults
2709 - Association of Clonal Hematopoiesis and Dysgranulopoiesis with Germline ETV6 Carriers without Hematological Malignancies
- Performance and Clinical Utility of Germline Genetic Testing Criteria for Predisposition to Myeloid Neoplasms in Adults
Torres-Tienza, A.
Torresan Delamain, M.
Torricelli, S.
Toscani, D.
4656 - Single Cell Transcriptomics on Bone Marrow Biopsies Unveils Peculiar Bone Microenvironment Cell Subtypes and Highlights Alterations Correlated with High-Risk Features in Precursor Monoclonal Gammopathies and Multiple Myeloma Patients
4660 - Bovine Herpes Virus Type 1 Oncolytic Therapy Elicits Direct Cytotoxic Effects and Immune Microenvironment Reshaping in Multiple Myeloma
4660 - Bovine Herpes Virus Type 1 Oncolytic Therapy Elicits Direct Cytotoxic Effects and Immune Microenvironment Reshaping in Multiple Myeloma
Tosi, D.
Toska, S.
Toskic, D.
Tosolini, A.
Tossey, J.
Tosto, F. A.
750 - Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease
1722 - Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis
1722 - Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis
Totev, T. I.
Toth, A.
Tothova, Z.
Totogashvili, N.
Touloumenidou, T.
Touma, Z.
Toumeh, N.
2869 - Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hotspots: A Retrospective Study of 82 Patients
3308 - Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients
3736 - Occurrence and Predictors of Patient Reported Fertility Discussions in Non-Hodgkin Lymphoma Patients: Utilizing the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
3308 - Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients
3736 - Occurrence and Predictors of Patient Reported Fertility Discussions in Non-Hodgkin Lymphoma Patients: Utilizing the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
Toumi, R.
Tourdot, B.
Tournilhac, O.
584 - Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group
600 - Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia – a Study on Behalf of the Chronic Malignancies Working Party of the EBMT
979 - Prospective, Multicentric, Phase II Randomized Controlled Trial Comparing the Efficacy and Toxicity of Methotrexate to Cyclophosphamide in Large Granular Lymphocyte Leukemia: A French National Study (NCT01976182)
1608 - Modeling NK-Cell Lymphoma in Mice Reveals Cell-of-Origin, Microenvironment, and Therapeutic Targets
3010 - Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Waldenström’s Macroglobulinemia. Report from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (LWP EBMT)
600 - Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia – a Study on Behalf of the Chronic Malignancies Working Party of the EBMT
979 - Prospective, Multicentric, Phase II Randomized Controlled Trial Comparing the Efficacy and Toxicity of Methotrexate to Cyclophosphamide in Large Granular Lymphocyte Leukemia: A French National Study (NCT01976182)
1608 - Modeling NK-Cell Lymphoma in Mice Reveals Cell-of-Origin, Microenvironment, and Therapeutic Targets
3010 - Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Waldenström’s Macroglobulinemia. Report from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (LWP EBMT)
Tourtellotte, W.
Touw, I. P.
Touzart, A.
745 - Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial
2793 - APR-246 Overcomes Resistance to Asparaginase in Lymphoid Malignancies By Targeting Metabolic Cell Vulnerabilities
2793 - APR-246 Overcomes Resistance to Asparaginase in Lymphoid Malignancies By Targeting Metabolic Cell Vulnerabilities
Touzeau, C.
495 - Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm‑2 Studies
594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
774 - The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma
3282 - Voltage-Dependent Anion Channel 2 Controls Mitochondrial Priming through BAK Stabilization in Multiple Myeloma
3355 - Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)
3370 - First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)
4653 - Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies
4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
4765 - Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)
594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
774 - The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma
3282 - Voltage-Dependent Anion Channel 2 Controls Mitochondrial Priming through BAK Stabilization in Multiple Myeloma
3355 - Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)
3370 - First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)
4653 - Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies
4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
4765 - Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)
Tovar, N.
Tovar, N.
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
359 - Enhanced Antitumoral Efficacy of ARI0002h CAR-T with CD28-TMD in Normal and Low BCMA Expressing Myeloma Cells
3321 - Real-World Treatment Sequencing, Attrition Rates, and Survival Outcomes in Multiple Myeloma: A Retrospective Study over Four Decades
3452 - Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT
359 - Enhanced Antitumoral Efficacy of ARI0002h CAR-T with CD28-TMD in Normal and Low BCMA Expressing Myeloma Cells
3321 - Real-World Treatment Sequencing, Attrition Rates, and Survival Outcomes in Multiple Myeloma: A Retrospective Study over Four Decades
3452 - Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT
Tower, R. J.
Towle, K.
590 - Bone Marrow Spatial Signatures Predict Survival Outcomes and Toxicities after CAR-T Therapy in Patients with Relapsed/Refractory Multiple Myeloma
1019 - A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
1894 - Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development
1903 - Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages
1019 - A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
1894 - Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development
1903 - Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages
Townes, T. M.
Townsend, L. S.
2791 - Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma
3067 - Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients
3067 - Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients
Townsend, N. W.
Townsend, W.
990 - Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072
2342 - Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK
3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications
5132 - Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study
2342 - Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK
3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications
5132 - Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study
Townsley, D.
Toyama, T.
Toye, A. M.
Toze, C. L.
2919 - Survival Outcomes for Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML-MRC) in a Real-World, Retrospective Cohort Receiving Intensive Chemotherapy
5095 - Richter Transformation (RT) in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Comparison of Two Eras
5095 - Richter Transformation (RT) in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Comparison of Two Eras
Tozzi, L.
Trab, T.
Trabolsi, A.
337 - Loncastuximab Tesirine with Rituximab Induces Robust and Durable Complete Metabolic Responses in High-Risk Relapsed/Refractory Follicular Lymphoma
983 - Refining Prognostication in Peripheral T Cell Lymphoma (PTCL): A Risk-Adapted Prognostic Model for Patients with Limited-Stage PTCL
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
2981 - Gene Expression-Based Classifier Reclassifies Burkitt Lymphoma, HGBL NOS, DLBCL NOS, and Double/Triple Hit Lymphomas into Subtypes with More Uniform Mutational and Microenvironment Landscapes and Treatment Response
3751 - Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis
983 - Refining Prognostication in Peripheral T Cell Lymphoma (PTCL): A Risk-Adapted Prognostic Model for Patients with Limited-Stage PTCL
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
2981 - Gene Expression-Based Classifier Reclassifies Burkitt Lymphoma, HGBL NOS, DLBCL NOS, and Double/Triple Hit Lymphomas into Subtypes with More Uniform Mutational and Microenvironment Landscapes and Treatment Response
3751 - Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis
Trachtenberg, S.
Tracy, S.
1645 - Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II
1646 - Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma
4407 - Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study
1646 - Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma
4407 - Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study
Tracy, S.
523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
4215 - Divergent CD4+ T-Cell Fates Govern Relapse and Remission in B-Cell Acute Lymphoblastic Leukemia
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
4215 - Divergent CD4+ T-Cell Fates Govern Relapse and Remission in B-Cell Acute Lymphoblastic Leukemia
Traer, E.
211 - Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia
662 - Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN)
1498 - Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients
1564 - Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial
2292 - Impact of Social Determinants of Health on Access to Blood and Marrow Transplantation for Acute Myeloid Leukemia
2859 - NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia
2887 - Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4312 - PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
4314 - Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML
4324 - Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
4325 - IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy
662 - Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN)
1498 - Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients
1564 - Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial
2292 - Impact of Social Determinants of Health on Access to Blood and Marrow Transplantation for Acute Myeloid Leukemia
2859 - NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia
2887 - Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4312 - PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
4314 - Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML
4324 - Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
4325 - IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy
Traets, M. J.
290 - Oxygen Gradient Ektacytometry Is Associated with Markers of Hemolysis and Inflammation in a Large Sickle Cell Disease Cohort within the GenoMed4ALL Project
1112 - Iron Deficiency in HbSC Disease Is Associated with Less Sickle Cell Disease-Related Complications – a Rationale for Repetitive Phlebotomy As Disease Modifying Therapy
1138 - Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease
1112 - Iron Deficiency in HbSC Disease Is Associated with Less Sickle Cell Disease-Related Complications – a Rationale for Repetitive Phlebotomy As Disease Modifying Therapy
1138 - Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease
Traina, F.
Traina, J. A.
Trainor, P.
Trambusti, I.
Tramontano, A. C.
Tran, A.
Tran, D. V.
Tran, D. V.
Tran, D. X.
Tran, E.
Tran, H. T.
586 - Mutations in BCOR, CCND2, NRAS and XPO1 Predict Clinical Outcomes upon MRD-Guided Venetoclax Plus Ibrutinib in Relapsed and Refractory Chronic Lymphocytic Leukemia
888 - Quality of Life in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus Venetoclax
888 - Quality of Life in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus Venetoclax
Tran, H.
128 - Reduced Doses of Factor Concentrates and Bypassing Agents to Treat Breakthrough Bleeds in Patients with Hemophilia A and B on Fitusiran Antithrombin-Based Dosing Regimen: ATLAS-OLE
710 - A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3
710 - A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3
Tran, M.
Tran, M.
Tran, T. H.
Tran, T. H.
307 - Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001
311 - Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001
311 - Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001
Tran, T.
Tran, T. N.
Tran, V. L.
725 - Aberrant Stemness Transcription Signature Unveils a Mechanism of Chemotherapy Resistance through Blunting p53-Mediated Response in Acute Myeloid Leukemia
1325 - Building a Clinical Genetic GATA2 Variant Curation System with Activity Metrics
4091 - GATA2 Genetic Variant-Induced Pathogenesis: Loss-of-Function and Gain-of-Function Mechanisms
1325 - Building a Clinical Genetic GATA2 Variant Curation System with Activity Metrics
4091 - GATA2 Genetic Variant-Induced Pathogenesis: Loss-of-Function and Gain-of-Function Mechanisms
Tranberg, A.
Trancucci, D.
Trappe, R. U.
859 - Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First – Line Treatment for Waldenström’s Macroglobulinemia: Results of the Multicenter Phase II trial (ECWM-2) of the European Consortium for Waldenström’s Macroglobulinemia
4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial
4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial
Trappolini, S.
Trask, P.
1726 - Primary Results of the Health-Related Quality of Life (HRQoL) and Tolerability Assessments from the Phase I/II NP30179 Study of Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2299 - Incorporating Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) into Dose Review in a Phase I Clinical Trial
2299 - Incorporating Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) into Dose Review in a Phase I Clinical Trial
Trastulli, F.
Trautmann-Grill, K.
364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
555 - Sustained Improvement of Survival in Patients Receiving Emicizumab Prophylaxis Instead of Immunosuppression during Early Management of Acquired Hemophilia a (AHA)
710 - A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
4428 - Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial
555 - Sustained Improvement of Survival in Patients Receiving Emicizumab Prophylaxis Instead of Immunosuppression during Early Management of Acquired Hemophilia a (AHA)
710 - A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
4428 - Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial
Travaglino, E.
Traverse-Glehen, A.
853 - Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling
975 - Structural and Functional Analysis of the Clonotypic B Cell Receptor Immunoglobulin in Splenic Marginal Zone Lymphoma: Ontogenetic and Therapeutic Implications
4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study
4479 - Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa
975 - Structural and Functional Analysis of the Clonotypic B Cell Receptor Immunoglobulin in Splenic Marginal Zone Lymphoma: Ontogenetic and Therapeutic Implications
4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study
4479 - Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa
Travis, P. M.
Trawinska, M. M.
Traxler, E. A.
Tray, K.
Treaba, D. O.
Treadwell, M.
Trefny, M.
Treger, T. D.
Tregnago, C.
Treiber, H.
4308 - Rapid, Reliable, and Comprehensive Identification of MDS-Defining Cytogenetic Changes By a FISH-Panel Containing Six Probes in a Real-World Population of Patients with Suspected AML
4495 - Combining Rituximab, Dexamethasone, Etoposide, Ifosfamide and Carboplatin (R-DeVIC) in Relapsed or Refractory Central Nervous System Lymphoma – a Retrospective Clinical Study
4495 - Combining Rituximab, Dexamethasone, Etoposide, Ifosfamide and Carboplatin (R-DeVIC) in Relapsed or Refractory Central Nervous System Lymphoma – a Retrospective Clinical Study
Treiber, J.
Treitman, R.
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
982 - Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
4392 - Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis
982 - Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
4392 - Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis
Trejos Carvajal, D. M.
Trelles-Martínez, R.
Tremblay, D.
16 - Anticoagulation Management of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A Global Abdominal/Splanchnic Thrombosis Retrospective Observational Study in 486 MPN Patients (GASTRO-MPN)
243 - TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms
2798 - Relative Influence of Socioeconomic and Biological Determinants of Outcomes in Adult Acute Lymphoblastic Leukemia
4230 - Predictors of Survival in Core Binding Factor Acute Myeloid Leukemia: An Analysis of the National Cancer Database
4512 - Role of HMGA2 Overexpression Caused By Specific Genetic HMGA2 Aberrations in Disease Progression in Calreticulin-Mutated Myelofibrosis Patients
5182 - Estimating the Prevalence of Possible Undiagnosed Chronic Myelomonocytic Leukemia in the General Population: An Nhanes Analysis
243 - TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms
2798 - Relative Influence of Socioeconomic and Biological Determinants of Outcomes in Adult Acute Lymphoblastic Leukemia
4230 - Predictors of Survival in Core Binding Factor Acute Myeloid Leukemia: An Analysis of the National Cancer Database
4512 - Role of HMGA2 Overexpression Caused By Specific Genetic HMGA2 Aberrations in Disease Progression in Calreticulin-Mutated Myelofibrosis Patients
5182 - Estimating the Prevalence of Possible Undiagnosed Chronic Myelomonocytic Leukemia in the General Population: An Nhanes Analysis
Tremblay, D.
Tremble, L.
Trenker, C.
Trentin, L.
1523 - Disease Course and Treatment Patterns of Acute Myeloid Leukemia with FLT3 Mutations and Myeloid Sarcoma Reveal High Efficacy of Gilteritinib: A Multicentric Retrospective Study
1854 - Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic Leukemia
4132 - Activating STAT3 Mutations Drive CD38 Expression in T-Large Granular Lymphocytic Leukemia
4619 - Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study
1854 - Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic Leukemia
4132 - Activating STAT3 Mutations Drive CD38 Expression in T-Large Granular Lymphocytic Leukemia
4619 - Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study
Treon, S. P.
743 - Single-Cell RNA Analysis of Bone Marrow Mononuclear Cells Reveals Abnormal Activation of T Cells and Monocytes, and Identifies CD35 As a Novel Biomarker and Therapeutic Target in Waldenstrom Macroglobulinemia
834 - Development and Characterization of Novel Dual HCK/BTK Bifunctional Protacs That Potently Inhibit Kinase Function and Demonstrate Robust in Vitro and In Vivo Degradation of Targets for the Treatment of MYD88-Mutated B-Cell Malignancies
860 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study
1647 - Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
2968 - Multi-Omic Analysis Identifies Deletions in Chr17p and High ROR1 Expression, but Not TP53 Mutations As Predictors of Overall Survival in Patients with Untreated Waldenstrom’s Macroglobulinemia (WM)
2972 - Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström’s Macroglobulinemia and Represent Novel Therapeutic Targets.
2986 - Analysis of Alternative Splicing in Waldenstrom’s Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates
3011 - A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis
4338 - Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom’s Macroglobulinemia Undergoing Ibrutinib Monotherapy
4358 - Expanded Genome-Wide Association Study (GWAS) Identifies Nine Novel Germline Risk Loci for Waldenström Macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL)
4359 - Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors
4404 - A Phase II Trial of Loncastuximab Tesirine in Patients with Previously Treated Waldenström Macroglobulinemia
1661.1 - BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia
834 - Development and Characterization of Novel Dual HCK/BTK Bifunctional Protacs That Potently Inhibit Kinase Function and Demonstrate Robust in Vitro and In Vivo Degradation of Targets for the Treatment of MYD88-Mutated B-Cell Malignancies
860 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study
1647 - Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
2968 - Multi-Omic Analysis Identifies Deletions in Chr17p and High ROR1 Expression, but Not TP53 Mutations As Predictors of Overall Survival in Patients with Untreated Waldenstrom’s Macroglobulinemia (WM)
2972 - Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström’s Macroglobulinemia and Represent Novel Therapeutic Targets.
2986 - Analysis of Alternative Splicing in Waldenstrom’s Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates
3011 - A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis
4338 - Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom’s Macroglobulinemia Undergoing Ibrutinib Monotherapy
4358 - Expanded Genome-Wide Association Study (GWAS) Identifies Nine Novel Germline Risk Loci for Waldenström Macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL)
4359 - Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors
4404 - A Phase II Trial of Loncastuximab Tesirine in Patients with Previously Treated Waldenström Macroglobulinemia
1661.1 - BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia
Trepeta, N.
74 - Eradication of the CLECL1+ CLL Subset That Is Prone to Carrying Novel Genomic Mutations and Promoting a Pro-Tumor Microenvironment By a Series of New Monoclonal Antibodies Reactive with Distinct Target Epitopes
1853 - Infiltration of Malignant B Cells Suppresses and Re-Organizes Lymph Node Fibroblasts in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
1853 - Infiltration of Malignant B Cells Suppresses and Re-Organizes Lymph Node Fibroblasts in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
Trere, D.
Triantafyllou, T.
Triche, Jr., T. J.
Tricot, G.
1885 - Single Nuclei Multiomic Profiling of Transcriptional and Chromatin Accessibility of Tumor Cells Underlines Extensive Cis-Regulatory Interaction during Multiple Myeloma Progression
1904 - The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
1937 - Identification of Risk Factors for Myeloma Progression in African American Patients
4729 - Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages
1904 - The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
1937 - Identification of Risk Factors for Myeloma Progression in African American Patients
4729 - Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages
Triggianese, P.
Trigo, F.
Trigo Miranda, F.
Triguero, A.
241 - Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia
2005 - Efficacy of Carvykti in Cartitude-4 Versus Other Conventional Treatment Regimens for Lenalidomide-Refractory Multiple Myeloma Patients Using Inverse Probability of Treatment Weighting
3452 - Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT
2005 - Efficacy of Carvykti in Cartitude-4 Versus Other Conventional Treatment Regimens for Lenalidomide-Refractory Multiple Myeloma Patients Using Inverse Probability of Treatment Weighting
3452 - Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT
Trikannad, A. K.
256 - Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
3074 - Cutaneous Involvement By Peripheral T-Cell Lymphoma: Incidence, Characteristics, Treatment Trends, and Outcomes in the United States (2000-2021)
4713 - Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
3074 - Cutaneous Involvement By Peripheral T-Cell Lymphoma: Incidence, Characteristics, Treatment Trends, and Outcomes in the United States (2000-2021)
4713 - Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
Trikha, R.
Trimarco, V.
Trimnell, C.
Trinchero, A.
Trinh, M. K.
Trinh, M. N.
Trinkaus, M.
Trinkaus, M.
Tripathi, P.
Tripathy, N.
Triplett, B. M.
383 - Memory T-Cell Add Back and Prophylactic blinatumomab Post Tcrαβ Depleted Haploidentical Transplantation Results in Promising Outcomes in Pediatric Patients with High-Risk Acute Leukemia
1331 - Outcomes of Germline Genetic Testing in Children with Hematologic Malignancies Undergoing Allogeneic Transplantation
2076 - CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia
4956 - Rheological Comparison of Red Cells from Individuals with SCD Treated with Gene Therapy, Haploidentical Transplantation or Hydroxyurea
5067 - Kidney Outcomes after Hematopoietic Cell Transplantation in Children and Young Adults with Sickle Cell Disease
1331 - Outcomes of Germline Genetic Testing in Children with Hematologic Malignancies Undergoing Allogeneic Transplantation
2076 - CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia
4956 - Rheological Comparison of Red Cells from Individuals with SCD Treated with Gene Therapy, Haploidentical Transplantation or Hydroxyurea
5067 - Kidney Outcomes after Hematopoietic Cell Transplantation in Children and Young Adults with Sickle Cell Disease
Tripodi, J.
243 - TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms
4512 - Role of HMGA2 Overexpression Caused By Specific Genetic HMGA2 Aberrations in Disease Progression in Calreticulin-Mutated Myelofibrosis Patients
4520 - High-Resolution Chromosomal Microarrays Reveals Exon-Level Deletion in Chromosome 12q14.3 in Patients with Myeloproliferative Neoplasms
4512 - Role of HMGA2 Overexpression Caused By Specific Genetic HMGA2 Aberrations in Disease Progression in Calreticulin-Mutated Myelofibrosis Patients
4520 - High-Resolution Chromosomal Microarrays Reveals Exon-Level Deletion in Chromosome 12q14.3 in Patients with Myeloproliferative Neoplasms
Tripodo, C.
Trippa, L.
1017 - Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants
1027 - Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma
1928 - Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
3360 - Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
1027 - Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma
1928 - Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
3360 - Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Trisal, P.
Trisolini, S. M.
Triulzi, D. J.
Trivedi, C.
Trivedi, C.
Trivedi, S.
Trivedi, V.
Triviño, J. C.
Trkulja, K. L.
Trněný, M.
469 - Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes
749 - Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
865 - Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study
974 - A Murine Phase 2 Proof-of-Concept Study of Polatuzumab Vedotin in Combination with Venetoclax in Experimental Therapy of BCL2-Positive Aggressive Lymphomas
1631 - Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study
3012 - Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?
3027 - Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
749 - Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
865 - Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study
974 - A Murine Phase 2 Proof-of-Concept Study of Polatuzumab Vedotin in Combination with Venetoclax in Experimental Therapy of BCL2-Positive Aggressive Lymphomas
1631 - Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study
3012 - Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?
3027 - Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Trneny, M.
237 - Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project
240 - Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
2973 - Comprehensive Genomic Analysis of Non-Relapsed and Late-Relapsed Mantle Cell Lymphoma Patients Compared to Refractory and Early-Relapsed Patients Treated By Standard Immunochemotherapy
2979 - Vitreous Body Cell Free DNA Sequencing As a Reliable Method for Vitreoretinal Lymphoma Diagnostics
4422.3 - Trials in Progress: Carman - an International, Randomized Phase II Study Evaluating Early Treatment Intensification in Patients with High Risk Mantle Cell Lymphoma Using CAR-T-Cell Treatment after an Abbreviated Induction Therapy with Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) As Compared to Standard of Care Induction and Maintenance (Arm B)
240 - Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
2973 - Comprehensive Genomic Analysis of Non-Relapsed and Late-Relapsed Mantle Cell Lymphoma Patients Compared to Refractory and Early-Relapsed Patients Treated By Standard Immunochemotherapy
2979 - Vitreous Body Cell Free DNA Sequencing As a Reliable Method for Vitreoretinal Lymphoma Diagnostics
4422.3 - Trials in Progress: Carman - an International, Randomized Phase II Study Evaluating Early Treatment Intensification in Patients with High Risk Mantle Cell Lymphoma Using CAR-T-Cell Treatment after an Abbreviated Induction Therapy with Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) As Compared to Standard of Care Induction and Maintenance (Arm B)
Trneny, M.
1697 - The Survival Improvement of Transplant-Eligible Primary CNS Lymphoma Patients within Last 15 Years
1711 - PCNSL Patients Treated with the Matrix Regimen in the Real World Have Similar Outcome to Those in the IELSG 32 Trial
1713 - BMI and Its Changes As a Predictor of Survival in DLBCL Patients
3081 - Validation of the CNS-IPI-C Prognostic Model in Patients with Systemic DLBCL in the Real World
1711 - PCNSL Patients Treated with the Matrix Regimen in the Real World Have Similar Outcome to Those in the IELSG 32 Trial
1713 - BMI and Its Changes As a Predictor of Survival in DLBCL Patients
3081 - Validation of the CNS-IPI-C Prognostic Model in Patients with Systemic DLBCL in the Real World
Trociukas, I.
Troester, S.
Trogrlic, D.
Trombetta, E.
Trombetta, R.
Tron, A.
Troske, D.
Trotier, D.
Trotman, J.
860 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study
861 - Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM)
885 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study
1654 - Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical
3007 - Frontline R-CHOP and BR Have Similar Outcomes By SUVmax in Follicular Lymphoma
3019 - Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients
3029 - Comparative Efficacy of Zanubrutinib Plus Obinutuzumab Versus Last Prior Treatment in Relapsed/Refractory Follicular Lymphoma: Growth Modulation Index Analysis from ROSEWOOD Study
4412 - Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)
- In Pursuit of a Functional Cure for Follicular Lymphoma
861 - Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM)
885 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study
1654 - Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical
3007 - Frontline R-CHOP and BR Have Similar Outcomes By SUVmax in Follicular Lymphoma
3019 - Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients
3029 - Comparative Efficacy of Zanubrutinib Plus Obinutuzumab Versus Last Prior Treatment in Relapsed/Refractory Follicular Lymphoma: Growth Modulation Index Analysis from ROSEWOOD Study
4412 - Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)
- In Pursuit of a Functional Cure for Follicular Lymphoma
Trottier, A.
1876 - Identification of Novel Protein Biomarkers in Bone Marrow Interstitial Fluid Links Coagulation Cascade Proteins to Survival Outcomes in Multiple Myeloma
4583 - Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment
4598 - Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents
4583 - Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment
4598 - Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents
Trottier, J.
Trovati Maciel, T.
36 - Vexas Syndrome Is a New Cause of p53-Mediated Erythroblastopenia
171 - IMA001 Is a Novel Therapeutic Molecule That Reduces Sickling and Hemolytic Anemia Markers in a Sickle Cell Disease Mouse Model
621 - Rap-536, a Murine Luspatercept Analog Ameliorates Anemia and Vaso-Occlusion in Experimental Model of Sickle Cell Disease
1103 - IMA001 Is a Novel Therapeutic Molecule That Improves Hematological Parameters during Vaso-Occlusion in Sickle Cell Disease In Vivo
2486 - Inhibition of the Complement Alternative Pathway Attenuates Hemolysis and Preserves Renal Function in a Mouse Model of Sickle Cell Disease
3870 - Complement Activation and Its Implication in the Pathophysiology of Hemolytic Anemia and Aging in Mouse Models of Sickle Cell Disease and Beta-Thalassemia
171 - IMA001 Is a Novel Therapeutic Molecule That Reduces Sickling and Hemolytic Anemia Markers in a Sickle Cell Disease Mouse Model
621 - Rap-536, a Murine Luspatercept Analog Ameliorates Anemia and Vaso-Occlusion in Experimental Model of Sickle Cell Disease
1103 - IMA001 Is a Novel Therapeutic Molecule That Improves Hematological Parameters during Vaso-Occlusion in Sickle Cell Disease In Vivo
2486 - Inhibition of the Complement Alternative Pathway Attenuates Hemolysis and Preserves Renal Function in a Mouse Model of Sickle Cell Disease
3870 - Complement Activation and Its Implication in the Pathophysiology of Hemolytic Anemia and Aging in Mouse Models of Sickle Cell Disease and Beta-Thalassemia
Trowbridge, J. J.
Troy, J. D.
Troy-Barnes, E.
2537 - Immunoglobulin Replacement Therapy (IgRT) for the Treatment of Haematological Malignancy Associated Secondary Immunodeficiency (HM-SID) – a Large UK Tertiary Centre Experience
3895 - Observational Data on Parvovirus B19 Cases in Patients with Red Cell Disorders in the United Kingdom from 2023-2024
3895 - Observational Data on Parvovirus B19 Cases in Patients with Red Cell Disorders in the United Kingdom from 2023-2024
Troyer, J.
Trsova, I.
Trudeau, K.
Trudel, S.
1021 - Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies
1954 - Analysis of Chip Mutations Pre-and Post-Transplant in Multiple Myeloma (MM): Expanded Results from a Prospective Longitudinal Study
1956 - Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies
1982 - Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM)
3261 - Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide
3338 - Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma
3370 - First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)
3787 - Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin
4690 - Handgrip Strength – Finetuning an Objective Measure of Frailty in Transplant-Eligible Patients with Multiple Myeloma
1954 - Analysis of Chip Mutations Pre-and Post-Transplant in Multiple Myeloma (MM): Expanded Results from a Prospective Longitudinal Study
1956 - Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies
1982 - Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM)
3261 - Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide
3338 - Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma
3370 - First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)
3787 - Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin
4690 - Handgrip Strength – Finetuning an Objective Measure of Frailty in Transplant-Eligible Patients with Multiple Myeloma
Trudel, S.
3376 - Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)
4731 - Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide
4731 - Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide
Trudu, M.
Trueman, D.
Truger, M.
899 - Secondary Cytogenetic and Molecular Genetic Abnormalities in Newly Diagnosed Multiple Myeloma Patients
1899 - Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies
4688 - Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy
1899 - Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies
4688 - Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy
Trujillo Rivera, E. A.
Trujillo-Ocampo, A.
Trumpp, A.
Trunk, A. D.
2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
3488 - Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
3488 - Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
Truong, R.
2336 - Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
4474 - A Prospective Geriatric Assessment (GA) Study Predicting Toxicities in Older Adults (OA) with Non-Hodgkin Lymphoma (NHL): Timed up and Go Test (TUG) Time Emerges As a Functional Vital Sign
4474 - A Prospective Geriatric Assessment (GA) Study Predicting Toxicities in Older Adults (OA) with Non-Hodgkin Lymphoma (NHL): Timed up and Go Test (TUG) Time Emerges As a Functional Vital Sign
Truong, T.
Truppel-Hartmann, A.
Trusiak, S.
Trutzer, I. M.
Truxall, J.
Tsaftaridis, P.
Tsagiopoulou, M.
Tsai, C. C.
Tsai, C. K.
Tsai, D. E.
Tsai, D.
Tsai, E.
Tsai, H. K.
Tsai, H. C.
Tsai, H. L.
3173 - High Molecular Risk Mutations (HMR) Drive Progression of CALR-mutated Myeloproliferative Neoplasm (MPN)
3551 - Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy
3551 - Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy
Tsai, N. C.
1043 - Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)
4935 - Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)
4935 - Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)
Tsai, S. Q.
Tsai, S. B.
523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
2423 - Association of Neighborhood Crime with AML Molecular Subtypes and Survival
3794 - Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
2423 - Association of Neighborhood Crime with AML Molecular Subtypes and Survival
3794 - Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
Tsai, W. C.
Tsai, X. C.
Tsakiroglou, P.
Tsakmaklis, N.
743 - Single-Cell RNA Analysis of Bone Marrow Mononuclear Cells Reveals Abnormal Activation of T Cells and Monocytes, and Identifies CD35 As a Novel Biomarker and Therapeutic Target in Waldenstrom Macroglobulinemia
834 - Development and Characterization of Novel Dual HCK/BTK Bifunctional Protacs That Potently Inhibit Kinase Function and Demonstrate Robust in Vitro and In Vivo Degradation of Targets for the Treatment of MYD88-Mutated B-Cell Malignancies
1647 - Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
2968 - Multi-Omic Analysis Identifies Deletions in Chr17p and High ROR1 Expression, but Not TP53 Mutations As Predictors of Overall Survival in Patients with Untreated Waldenstrom’s Macroglobulinemia (WM)
2972 - Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström’s Macroglobulinemia and Represent Novel Therapeutic Targets.
2986 - Analysis of Alternative Splicing in Waldenstrom’s Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates
3011 - A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis
4338 - Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom’s Macroglobulinemia Undergoing Ibrutinib Monotherapy
4359 - Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors
834 - Development and Characterization of Novel Dual HCK/BTK Bifunctional Protacs That Potently Inhibit Kinase Function and Demonstrate Robust in Vitro and In Vivo Degradation of Targets for the Treatment of MYD88-Mutated B-Cell Malignancies
1647 - Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
2968 - Multi-Omic Analysis Identifies Deletions in Chr17p and High ROR1 Expression, but Not TP53 Mutations As Predictors of Overall Survival in Patients with Untreated Waldenstrom’s Macroglobulinemia (WM)
2972 - Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström’s Macroglobulinemia and Represent Novel Therapeutic Targets.
2986 - Analysis of Alternative Splicing in Waldenstrom’s Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates
3011 - A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis
4338 - Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom’s Macroglobulinemia Undergoing Ibrutinib Monotherapy
4359 - Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors
Tsaknakis, G.
Tsang, E.
Tsang, M.
1652 - Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma
1856 - Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
3252 - Utilizing AI-Enabled EKG Algorithms to Identify Atrial Fibrillation Risk in Patients with CLL Receiving BTK Inhibitors
1856 - Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
3252 - Utilizing AI-Enabled EKG Algorithms to Identify Atrial Fibrillation Risk in Patients with CLL Receiving BTK Inhibitors
Tsang, R.
1695 - Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy
3744 - Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada
4469 - Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy
3744 - Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada
4469 - Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy
Tsao, V.
Tschantz, W. R.
Tse, E.
Tse, R. L. S.
Tseng, E.
Tseng, L. J.
Tseng, Y. D.
1666 - Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma
1667 - Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma
3051 - High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD
4880 - Differential Impact of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning on Supragingival Plaque Microbiota and Oral Mucositis after Allogeneic Transplantation
1667 - Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma
3051 - High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD
4880 - Differential Impact of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning on Supragingival Plaque Microbiota and Oral Mucositis after Allogeneic Transplantation
Tshilolo, L.
Tsilimidos, G.
Tsirigos, A.
Tsirigos, A.
Tsitsilonis, O.
361 - Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study
490 - A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma
1020 - Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
1083 - High Incidence of Thalassemia Traits Among Myelodysplastic Syndrome Patients May Mask Macrocytic Anemia but Not the Enhanced Proteasome Proteolytic Activity
1934 - Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)
490 - A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma
1020 - Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
1083 - High Incidence of Thalassemia Traits Among Myelodysplastic Syndrome Patients May Mask Macrocytic Anemia but Not the Enhanced Proteasome Proteolytic Activity
1934 - Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)
Tsiverioti, C.
Tsombal, A.
Tsuchiya, T.
Tsui, H.
Tsui, S. P.
1510 - Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) As an Effective Treatment Remodels Proteostasis and Triggers Inflammatory Response in FLT3-ITD AML
1569 - Measurable Residual Disease Detection on Day 30 Post Haematopoietic Stem Cell Transplantation Predicts Clinical Outcome in Acute Myeloid Leukemia
1569 - Measurable Residual Disease Detection on Day 30 Post Haematopoietic Stem Cell Transplantation Predicts Clinical Outcome in Acute Myeloid Leukemia
Tsuji, J.
1895 - Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in 365 Patients with MGUS and SMM Demonstrates Complex Progressive Changes in Immune Cell Functionality with a Distinct Footprint on Tumor Cell Biology and Disease Control
1903 - Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression
1928 - Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
3233 - The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages
1903 - Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression
1928 - Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
3233 - The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages
Tsuji, N.
Tsuji, T.
Tsujimura, T.
Tsukada, N.
Tsukamoto, K.
Tsukamoto, S.
260 - Gvhd-Induced Inflammatory Memory in Intestinal Stem Cells Enhances IFN-y-Induced Antigen Presentation and Apoptosis of Intestinal Epithelial Cells
902 - Ropeginterferon Alfa-2b Induces Apoptosis and Differentiation of Leukemia Stem Cells and Separates GVL Effects from Gvhd after Allogeneic Hematopoietic Cell Transplantation
903 - Early Initiation of Calcineurin Inhibitor Induces CD8+ Transitory Exhausted-like and CD4+ Cytotoxic T Cells, Maintaining Responsiveness to PD-1 Blockade and Contributing to the Development of Chronic Gvhd after Post-Transplant Cyclophosphamide
902 - Ropeginterferon Alfa-2b Induces Apoptosis and Differentiation of Leukemia Stem Cells and Separates GVL Effects from Gvhd after Allogeneic Hematopoietic Cell Transplantation
903 - Early Initiation of Calcineurin Inhibitor Induces CD8+ Transitory Exhausted-like and CD4+ Cytotoxic T Cells, Maintaining Responsiveness to PD-1 Blockade and Contributing to the Development of Chronic Gvhd after Post-Transplant Cyclophosphamide
Tsukamoto, S.
Tsukamoto, T.
Tsukasaki, K.
Tsumoto, K.
Tsumura, Y.
Tsuneyama, K.
Tsurkan, L.
Tsuruhara, M.
Tsurumi, H.
Tsyganok, T.
Tsykunova, G.
Tu, L.
97 - JAK/Rock Inhibitor Rovadicitinib for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease:Updated Results of Multicenter, Phase 1b/2a Trial
1504 - TQB3455 Plus Azacitidine in Patients with Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Phase 1 Trial
1504 - TQB3455 Plus Azacitidine in Patients with Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Phase 1 Trial
Tu, M.
1305 - Deciphering Transcriptome Alterations in Bone Marrow Hematopoiesis at Single-Cell Resolution in Prolonged Thrombocytopenia after Umbilical Cord Blood Transplantation
3504 - Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment after Allogeneic Stem Cell Transplantation: A Prospective, Single-Arm Clinical Trail
3504 - Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment after Allogeneic Stem Cell Transplantation: A Prospective, Single-Arm Clinical Trail
Tu, S.
1050 - Updated Results from a Phase Ⅱ Clinical Trial:Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia
3469 - Comparison of the Efficacy and Adverse Effects of Recipient-Derived Versus Donor-Derived CAR-T Cell Therapy for Post-Transplant Relapse in B-ALL
4405 - Zilovertamab Vedotin Monotherapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort a of the Multicenter, Open-Label, Phase 2 Waveline-006 Study
4457 - Retrospective Analysis of 118 Cases of Primary Central Nervous System Lymphoma
3469 - Comparison of the Efficacy and Adverse Effects of Recipient-Derived Versus Donor-Derived CAR-T Cell Therapy for Post-Transplant Relapse in B-ALL
4405 - Zilovertamab Vedotin Monotherapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort a of the Multicenter, Open-Label, Phase 2 Waveline-006 Study
4457 - Retrospective Analysis of 118 Cases of Primary Central Nervous System Lymphoma
Tuan, Y. H.
Tuazon, S. A.
887 - Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study
4633 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004
4832 - Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials
4633 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004
4832 - Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials
Tubman, V. N.
Tucci, A.
82 - Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score
453 - B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements
2464 - Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results
2863 - Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)
3016 - Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Marginal Zone Lymphoma: Results from the Phase 2 Bellwave-003 Study
3070 - Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
4449 - A Phase II Clinical Study Exploring the Safety and Efficacy of the Oral PI3Kδ Inhibitor, Linperlisib, in Relapsed Refractory T Cell Lymphoma
4473 - Impact of MYC Alterations in De Novo and Transformed Large B-Cell Lymphoma: An Italian Single Center Experience
3042.2 - Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy – MCL Elderly III
453 - B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements
2464 - Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results
2863 - Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)
3016 - Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Marginal Zone Lymphoma: Results from the Phase 2 Bellwave-003 Study
3070 - Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
4449 - A Phase II Clinical Study Exploring the Safety and Efficacy of the Oral PI3Kδ Inhibitor, Linperlisib, in Relapsed Refractory T Cell Lymphoma
4473 - Impact of MYC Alterations in De Novo and Transformed Large B-Cell Lymphoma: An Italian Single Center Experience
3042.2 - Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy – MCL Elderly III
Tucci, J.
Tuchman, S.
Tuchmann-Durand, C.
Tucker, A.
Tucker, D.
1628 - Dynamics of Complete Responses in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Odronextamab in the ELM-2 Study
1650 - Evaluation of Baseline CAR-Hematotox Scores to Predict Increased Severe Infection Risk in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Odronextamab
3076 - Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20×CD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications
1650 - Evaluation of Baseline CAR-Hematotox Scores to Predict Increased Severe Infection Risk in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Odronextamab
3076 - Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20×CD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications
Tucker, K.
Tucker, T.
212 - Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
Tueur, G.
Tufa, D.
Tufano-Sugarman, A.
Tuffnell, J.
305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
4894 - Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT
4939 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
4949 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria – a Study on Behalf of Cmwp and Saawp of the EBMT
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
4894 - Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT
4939 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
4949 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria – a Study on Behalf of Cmwp and Saawp of the EBMT
Tuğcu, D.
Tuhin, I. J.
Tun, A. M.
3008 - Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study
3112 - Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma
3112 - Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma
Tun, H. W.
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
580 - A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma
1637 - Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study
3418 - Chimeric Antigen Receptor T-Cell Therapy Associated Cerebral Glucose Hypometabolism (CART-CGHM): A Novel Cerebral Metabolic Complication
580 - A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma
1637 - Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study
3418 - Chimeric Antigen Receptor T-Cell Therapy Associated Cerebral Glucose Hypometabolism (CART-CGHM): A Novel Cerebral Metabolic Complication
Tuncel, D. A.
Tuncel, J.
3474 - Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells
4801 - Next-Generation Off-the-Shelf CAR T-Cell Therapy Developed to Eliminate a Broad Spectrum of Pathogenic Cells in Hematological Diseases in the Absence of Conditioning Chemotherapy
4801 - Next-Generation Off-the-Shelf CAR T-Cell Therapy Developed to Eliminate a Broad Spectrum of Pathogenic Cells in Hematological Diseases in the Absence of Conditioning Chemotherapy
Tuncer, H. H.
Tung, E. L.
Tung, Y. T.
Tunuguntla, R.
69 - CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up
679 - Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL
2064 - CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma
679 - Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL
2064 - CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma
Tuo, Y.
Tur, L.
Tur-Rodriguez, K.
Turakhia, M.
Turecek, P.
Turgut, M.
362 - Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial
3025 - Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study
3025 - Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study
Turi, M.
Turk, E.
Turk-MacLeod, R.
Turkalj, S.
Turki, A. T.
790 - Independent, International Validation and Refinement of a Machine Learning Algorithm to Classify Acute Leukemia Using Routine Laboratory Features
901 - Memory CD4+ T Cells Recognize Divergent HLA-DP Immunopeptidomes and Contribute to Leukemia Control after Allogeneic HCT
- Leveraging Large Scale Data and AI for Red Blood Cell Quality Assessment and Precision Transfusion Medicine
901 - Memory CD4+ T Cells Recognize Divergent HLA-DP Immunopeptidomes and Contribute to Leukemia Control after Allogeneic HCT
- Leveraging Large Scale Data and AI for Red Blood Cell Quality Assessment and Precision Transfusion Medicine
Turkina, A.
3151 - Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP‑CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses
4539 - Results of the Molecular Response Evaluation and TKI Dose Adjustment in Chronic Myeloid Leukemia Patients in Prospective Study of Reduction and Discontinuation Treatment of TKI (READIT)
4539 - Results of the Molecular Response Evaluation and TKI Dose Adjustment in Chronic Myeloid Leukemia Patients in Prospective Study of Reduction and Discontinuation Treatment of TKI (READIT)
Turlure, P.
731 - Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials
2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study
3167 - Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination – a FIM Study
3483 - Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
4909 - Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study
3167 - Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination – a FIM Study
3483 - Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
4909 - Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
Turner, B.
Turner, S.
Turnquist, H.
Turnwald, A.
Turpin, R.
Turpin, S.
Turrentine, K.
Turrini, M.
1523 - Disease Course and Treatment Patterns of Acute Myeloid Leukemia with FLT3 Mutations and Myeloid Sarcoma Reveal High Efficacy of Gilteritinib: A Multicentric Retrospective Study
2863 - Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)
3800 - Myelodysplastic Neoplasms Patients’ and Caregivers’ Unmet Needs and Their Impact on Their Quality of Life and Symptoms
5188 - Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results
2863 - Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)
3800 - Myelodysplastic Neoplasms Patients’ and Caregivers’ Unmet Needs and Their Impact on Their Quality of Life and Symptoms
5188 - Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results
Turriziani, C.
Turtle, C. J.
71 - Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)
2028 - Prediction of Therapeutic Potential of CD19 CAR-T Cells for LBCL By Histone Mark Analyses of Core Epigenetic Programming
2068 - NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)
3422 - TNFα Apoptotic Signaling By Antigen-Engaged CAR T-Cells Mediates Clearance of Target Antigen-Negative Acute Myeloid Leukemia
4832 - Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials
2028 - Prediction of Therapeutic Potential of CD19 CAR-T Cells for LBCL By Histone Mark Analyses of Core Epigenetic Programming
2068 - NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)
3422 - TNFα Apoptotic Signaling By Antigen-Engaged CAR T-Cells Mediates Clearance of Target Antigen-Negative Acute Myeloid Leukemia
4832 - Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials
Turunen, B.
Tuscano, J. M.
Tuscano, J. M.
Tuskova, L.
974 - A Murine Phase 2 Proof-of-Concept Study of Polatuzumab Vedotin in Combination with Venetoclax in Experimental Therapy of BCL2-Positive Aggressive Lymphomas
2973 - Comprehensive Genomic Analysis of Non-Relapsed and Late-Relapsed Mantle Cell Lymphoma Patients Compared to Refractory and Early-Relapsed Patients Treated By Standard Immunochemotherapy
3012 - Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?
2973 - Comprehensive Genomic Analysis of Non-Relapsed and Late-Relapsed Mantle Cell Lymphoma Patients Compared to Refractory and Early-Relapsed Patients Treated By Standard Immunochemotherapy
3012 - Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?
Tuz Zahra, F.
1130 - Trends and Disparities in Sickle Cell Disease-Related Mortality in the United States from 1999 to 2020: Insights from the CDC Wonder Database
2415 - Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience
4270 - Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
5103 - Trends and Disparities in Acute Lymphoblastic Leukemia-Related Mortality in the United States from 1999 to 2020: Insights from the CDC Wonder Database
5190 - Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas
2415 - Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience
4270 - Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
5103 - Trends and Disparities in Acute Lymphoblastic Leukemia-Related Mortality in the United States from 1999 to 2020: Insights from the CDC Wonder Database
5190 - Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas
Tvito, A.
Twardowski, N.
1965 - Comparative Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter Study
3801 - Molecular Features of Acute Myeloid Leukemia in Hispanics: An Analysis from the Marrow Consortium
3801 - Molecular Features of Acute Myeloid Leukemia in Hispanics: An Analysis from the Marrow Consortium
Tweeten, B.
Tyagi, A.
Tyburski, E.
Tycko, B.
1888 - Repurposing DNA Methyltranferase Inhibitors As Epigenetic Priming Agents for T Cell Directed Therapies in Multiple Myeloma
4654 - Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients
4654 - Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients
Tyekucheva, S.
583 - Complex Karyotype, but Not Isolated TP53 mutation, Predicts Overall Survival in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy
587 - Low Variant Allele Frequency (VAF) TP53 Mutation (mut) Is Not a Poor Prognostic Marker in CLL Patients Treated with Targeted Therapy
1865 - Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
1874 - A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
4617 - Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL
4628 - A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome (RS)
587 - Low Variant Allele Frequency (VAF) TP53 Mutation (mut) Is Not a Poor Prognostic Marker in CLL Patients Treated with Targeted Therapy
1865 - Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
1874 - A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
4617 - Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL
4628 - A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome (RS)
Tyner, J. W.
62 - Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML
271 - Mapping the Drug Combination Landscape for AML: An Integrative Ex Vivo Functional and Computational Approach
1498 - Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients
1566 - Combination with Palbociclib Overcomes Venetoclax Resistance Mechanisms and Outperforms Single Agent Efficacy in Acute Myeloid Leukemia
2749 - Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML
2753 - Elucidating Transcriptional Heterogeneity in Venetoclax Resistant AMLs
2859 - NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia
2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
4312 - PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
4314 - Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML
4815 - Characterizing the Role of Interferon-γ Signaling in Natural Killer Cell Dysfunction in Venetoclax-Resistant Acute Myeloid Leukemia
271 - Mapping the Drug Combination Landscape for AML: An Integrative Ex Vivo Functional and Computational Approach
1498 - Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients
1566 - Combination with Palbociclib Overcomes Venetoclax Resistance Mechanisms and Outperforms Single Agent Efficacy in Acute Myeloid Leukemia
2749 - Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML
2753 - Elucidating Transcriptional Heterogeneity in Venetoclax Resistant AMLs
2859 - NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia
2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
4312 - PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
4314 - Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML
4815 - Characterizing the Role of Interferon-γ Signaling in Natural Killer Cell Dysfunction in Venetoclax-Resistant Acute Myeloid Leukemia
Tyrrell, L.
Tyshevich, A.
2981 - Gene Expression-Based Classifier Reclassifies Burkitt Lymphoma, HGBL NOS, DLBCL NOS, and Double/Triple Hit Lymphomas into Subtypes with More Uniform Mutational and Microenvironment Landscapes and Treatment Response
3038 - Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma
3038 - Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma
Tyznar, D.
Tzachanis, D.
Tzankov, A.
Tzankov, A.
73 - Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway
854 - A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
1367 - Mouse Model of Splenic Marginal Zone Lymphoma to Decipher the Pathogenetic Implications of NOTCH2 and KLF2 Mutations
854 - A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
1367 - Mouse Model of Splenic Marginal Zone Lymphoma to Decipher the Pathogenetic Implications of NOTCH2 and KLF2 Mutations
Tzankov, A.
Tzeng, E.